<html lang="en" class="pb-page js" data-request-id="9523b28971f9626e-SJC"><head data-pb-dropzone="head"><style type="text/css" nonce="9523b28971f9626e-SJC">@font-face {font-family: "Source Sans Pro";src: url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.ttf) format("truetype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.woff) format("woff"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.otf) format("opentype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.eot) format("embedded-opentype");}.truste_cursor_pointer {cursor: pointer;}.truste_border_none {border: none;}.truste_accessible_link {font-family: "Source Sans Pro", sans-serif;color: #1D4ED8;font-size: 14px;font-weight: 600;text-decoration: underline;}.truste_accessible_link:hover {color: #1D4ED8;text-decoration: none !important;}.truste_accessible_link:focus-visible {outline: none;border-radius: 4px;box-shadow: 0 0 0 1px #FFFFFF, 0 0 0 4px #3699F1;}</style>
            

<meta charset="UTF-8">






    
        
            
        
    
        
            
        
    
        
            
        
    
        
            
        
    
        
    
        
    
        
            
                
                
<title>Glycemia Reduction in Type 2 Diabetes — Glycemic Outcomes | New England Journal of Medicine</title>





                
            
        
    







    
        
            
        
    
        
            
        
    
        
            
                
                



                
            
        
    
        
            
        
    
        
    
        
    
        
            
        
    











    








    

    
    

    
    
    
    
        
            
                <link rel="stylesheet" type="text/css" href="/wro/1125813~article-metrics.css">
            
            
            
        
    

    
    
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_nejm_1-994b0160d1eb33dc79517ef0295aab1b.ico" type="image/x-icon">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_16-4aa032aa775940f725817b7ff42f0e2c.png" type="image/png" sizes="16x16">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_32-0a94fa44823476ffa0bb15bdb320fb34.png" type="image/png" sizes="32x32">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_152-d6c3522864a8e483996b7e9c132c901a.png" sizes="152x152">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_180-f2538afc53a365d4cd3f10ab73c56aad.png" sizes="180x180">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_167-8e888012bbdd31a00c3e54bc5b8ca5b6.png" sizes="167x167">
        
    

    
    
            <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-5b89b331018866a4a965.css" media="all">
        <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/print-5b89b331018866a4a965.css" media="print">
           <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css" media="all" id="article-style-sheet">
    
        <script src="https://ssl-cdn.janraincapture.com/widget_data/flow.js:7h8bznq6j7bvyvzqcrwvyp8dfb:en-US:20240514181256512029:standard" type="text/javascript"></script><script src="https://cssjs.nejm.org/akamai/capture:login" type="text/javascript"></script><script src="https://ssl-widget-cdn.rpxnow.com/translations/login/en-US" type="text/javascript"></script><script type="text/javascript" id="janrainAuthWidget" src="https://cssjs.nejm.org/akamai/mms-prod.js"></script><script nonce="9523b28971f9626e-SJC">
        try {
            document.documentElement.classList.add('js');
        } catch (e) {
        }
    </script>
     
    

















    
        
            
                
                
                
                    
                    <!-- TrustArc Scripts -->
<script async="async" src="https://consent.trustarc.com/notice?domain=nejm.com&amp;c=teconsent&amp;js=nj&amp;noticeType=bb&amp;gtm=1&amp;text=true&amp;pcookie" crossorigin="" id="truste_0.34091051707333064"></script>
<script src="https://consent.trustarc.com/autoblockasset/core.min.js?domain=nejm.com"></script>
<script src="https://consent.trustarc.com/autoblockoptout?domain=nejm.com"></script>
<!-- /TrustArc Scripts -->
<!-- BlueConic Scripts -->
<script src="https://bc.nejm.org/script.js"></script>
    <!-- /BlueConic Scripts -->
<!-- Printing Meta Tags -->
    <meta name="topics" content="Diabetes|Clinical Medicine General|Cardiology General">
<meta name="articleCategory" content="Research">
<meta name="articleType" content="Original Article">
<meta name="Specialties" content="Cardiology|Clinical Medicine|Endocrinology"><script type="text/javascript">var mmsData = {"access":{"isFreeCountry":"n"},"ad":{"category":"article"},"imageChallenge":{"id":null},"article":{"doi":"10.1056/NEJMoa2200433","title":"Glycemia Reduction in Type 2 Diabetes — Glycemic Outcomes","category":"Research","type":"Original Article","topics":"Diabetes|Clinical Medicine General|Cardiology General","specialties":"Cardiology|Clinical Medicine|Endocrinology","seriesTitle":"","viewType":"Full","age":"2Years-1990","issueDate":"2022-09-22T00:00Z","isFree":"y","broadTopics":"","perspectiveTopics":"","granularTopics":"","methodologicalArea":"","isOnlineFirst":"n","isCurrentIssue":"n","metaTags":"\u003cmeta name\u003d\"topics\" content\u003d\"Diabetes|Clinical Medicine General|Cardiology General\"/\u003e\n\u003cmeta name\u003d\"articleCategory\" content\u003d\"Research\"/\u003e\n\u003cmeta name\u003d\"articleType\" content\u003d\"Original Article\"/\u003e\n\u003cmeta name\u003d\"Specialties\" content\u003d\"Cardiology|Clinical Medicine|Endocrinology\"/\u003e"},"page":{"activity":"showFullText","url":"www.nejm.org/doi/full/10.1056/NEJMoa2200433","viewType":"desktop","journal":"NEJM"},"user":{"ucid":null,"audienceSegment":null,"specialtyGroupCode":null,"meterCountRemaining":null,"totalMeterCount":null},"object":[{"type":"Quick Take","title":"Glycemia Reduction Approaches in Type 2 Diabetes","doi":"10.1056/NEJMdo006679","issueDate":"2022-09-22T00:00Z","age":"6Months-1990","isFree":"n","topics":"Diabetes|Cardiology General|Clinical Medicine General","viewType":"Full","specialties":"Endocrinology|Cardiology|Clinical Medicine"},{"type":"Research Summary","title":"Glycemia Reduction in Type 2 Diabetes — Glycemic Outcomes","doi":"10.1056/NEJMdo006680","issueDate":"2022-09-22T00:00Z","age":"6Months-1990","isFree":"n","topics":"Diabetes|Cardiology General|Clinical Medicine General","viewType":"Full","specialties":"Endocrinology|Cardiology|Clinical Medicine"}]};</script>
    <script type="text/javascript">var mmsDataAdd = {"user":{"customerType":"null","accessInstitutionID":"null"}};</script>
    <!-- Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- placeholder id=null, description=Adobe-Target-Prehiding-Snippet --><!--
  Adobe Target - Prehiding Snippet
  v2.0.0
-->
<script nonce="9523b28971f9626e-SJC">
function tgtNoFlicker(e,n,t,o,i,c,l,r){function d(){return n.getElementsByTagName("head")[0]}function a(e,t){if(e){var o=n.getElementById(t);o&&e.removeChild(o)}}function f(e,o){!function(e,t,o){if(e){var i=n.createElement("style");i.id=t,i.innerHTML=o,e.appendChild(i)}}(d(),t,e),setTimeout(function(){a(d(),t)},o)}var m;n.location.href.indexOf(c)>-1?f(l,r):f(o,i),n.location.href.indexOf("mboxDisable")>-1?(a(d(),t),console.log("[TARGET] - Disabled, removing prehiding style")):(m=function(e){e&&(a(d(),t),console.log("[TARGET] - Blocked, removing prehiding style"))},fetch("//cdn.tt.omtrdc.net/cdn/target-vec.js",{method:"HEAD",mode:"no-cors"}).then(e=>m(!1)).catch(e=>m(!0)))}

tgtNoFlicker(window, document, 'at-body-style', 'div[data-location-name="Anonymous Module"], div[data-location-name="Anonymous Banner"], main > div.page-body > div > div > div > div.col-md-2-3.o-col.o-col--primary > div[class*="u-hide"], main > div.page-body > div > div > div > div.col-md-1-3.o-col.o-col--secondary > aside, header > h1#mainContent, a.m-article__link[href*="/10.1056/NEJMoa2116747"] > span.m-article__blurb > p, li.g-nejm-group__user-tool-secondary {opacity: 0 !important}', 3000);

tgtNoFlicker(window, document, 'at-mbox-style', '.N-ad-global-top-right, #N-ad-myNEJM-contextual-top, .N-ad-recentArticles, #N-ad-article-rightRail-1, #N-ad-siteWide-rightRail-1, #N-ad-imageChallenge-rightRail-2 {opacity: 0 !important}', 3000);


</script><!-- /Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- Launch Header Embed Code -->
    <script src="//assets.adobedtm.com/launch-ENcd6450fae3ae4870becbe6a2b01ab2e1.min.js" async="" type="ta-blocked" data-ta-blocked="1"></script>
    <!-- /Launch Header Embed Code -->

                    
                
            
        
    
        
            
                
                
                
                    
                    <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="New England Journal of Medicine"><meta name="dc.Title" content="Glycemia Reduction in Type 2 Diabetes — Glycemic Outcomes"><meta name="dc.Creator" content="The GRADE Study Research Group"><meta name="dc.Description" content="The comparative effectiveness of glucose-lowering medications for use with metformin to maintain target glycated hemoglobin levels in persons with type 2 diabetes is uncertain.In this trial involvi..."><meta name="Description" content="The comparative effectiveness of glucose-lowering medications for use with metformin to maintain target glycated hemoglobin levels in persons with type 2 diabetes is uncertain.In this trial involvi..."><meta name="dc.Publisher" content="Massachusetts Medical Society"><meta name="dc.Date" scheme="WTN8601" content="2022-09-22"><meta name="dc.Type" content="research-article"><meta name="dc.Format" content="text/HTML"><meta name="dc.Identifier" scheme="doi" content="10.1056/NEJMoa2200433"><meta name="dc.Identifier" scheme="publisher-id" content="NJ202209223871205"><meta name="dc.Language" content="EN"><meta name="dc.Relation" content="10.1056/NEJMoa2200436"><meta name="dc.Relation" content="10.1056/NEJMe2210531"><meta name="dc.Coverage" content="world"><meta name="dc.Rights" content="Copyright © 2022 Massachusetts Medical Society. All rights reserved.">




<link rel="meta" type="application/atom+xml" href="https://doi.org/10.1056%2FNEJMoa2200433">
<link rel="meta" type="application/rdf+json" href="https://doi.org/10.1056%2FNEJMoa2200433">
<link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1056%2FNEJMoa2200433">


                    
                
            
        
    
        
            
                
                
                
                
                
            
        
    
        
            
                
                
                
                    
                    





<meta name="robots" content="noarchive">





    





    
    
        
        <meta name="twitter:title" content="Glycemia Reduction in Type 2 Diabetes — Glycemic Outcomes | NEJM">
        <meta property="og:title" content="Glycemia Reduction in Type 2 Diabetes — Glycemic Outcomes | NEJM">
    


    <meta property="og:type" content="article">


    
    
        <meta property="og:url" content="https://www.nejm.org/doi/full/10.1056/NEJMoa2200433">
    
    


    
    
        <meta property="og:image" content="https://www.nejm.org/cms/asset/e7658d51-44ad-4465-b469-597495771f3b/nejmoa2200433_f1.jpg">
        <meta name="twitter:image" content="https://www.nejm.org/cms/asset/e7658d51-44ad-4465-b469-597495771f3b/nejmoa2200433_f1.jpg">
    



    <meta property="og:site_name" content="The New England Journal of Medicine">


    
    
        
        <meta property="og:description" content="The comparative effectiveness of glucose-lowering medications for use with metformin
to maintain target glycated hemoglobin levels in persons with type 2 diabetes is uncertain.
In this trial involv...">
        <meta name="twitter:description" content="The comparative effectiveness of glucose-lowering medications for use with metformin
to maintain target glycated hemoglobin levels in persons with type 2 diabetes is uncertain.
In this trial involv...">
    


    
    
        <meta property="og:image:width" content="2640">
    


    
    
        <meta property="og:image:height" content="2248">
    


    <meta name="twitter:card" content="summary">


    <meta name="twitter:site" content="@NEJM">


<meta name="viewport" content="width=device-width,initial-scale=1"><script src="https://consent.trustarc.com/asset/notice.js/v/v1.7-402" async="async" crossorigin="" importance="high" nonce="9523b28971f9626e-SJC"></script><meta name="publication_doi" content="10.1056/NEJMoa2200433">


    















                    
                
            
        
    
        
    
        
    
        
            
                
                
                
                
                
            
        
    




<meta name="format-detection" content="telephone=no">

<meta http-equiv="X-UA-Compatible" content="IE=edge">
    




    
        
        
        <link rel="canonical" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2200433">
    
    







<meta name="pbContext" content=";article:article:doi\:10.1056/NEJMoa2200433;requestedJournal:journal:nejm;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:doi\:10.1056/nejm_2022.387.issue-12;wgroup:string:MMS NextGen Website Group;pageGroup:string:Publication Pages;subPage:string:Full Text;website:website:mms-site;journal:journal:nejms">
        <script id="altmetric-embed-js" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-288192a491f0ad9cc434f05ea175659426f5ab0cfd6befb3f3592f96bb90b0d1.js"></script><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-933-8e181dff8b36ea01dc4c.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-34-6ea546d794fb7a1cea52.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-743-ddd329e1530654ec0846.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-305-9eee37798fdfe5196307.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-388-bb098c62445f518c0b46.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-556-8e58ca05fb5497e541ef.css"><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/0-dfd243c732a07d3608f6.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/7-10d355ba95f7ec1fddf2.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/11-04bf2a0da30146b4a5d0.js"></script><style type="text/css" id="bc_async_1750343144419">div[id='bc_home_trend'] {opacity:0.0;filter:alpha(opacity=0);}
</style><script src="https://static.addtoany.com/menu/modules/core.pt5ow5lr.js" type="module"></script><style type="text/css">.a2a_hide{display:none}.a2a_logo_color{background-color:#0166ff}.a2a_menu,.a2a_menu *{-moz-box-sizing:content-box;-webkit-box-sizing:content-box;box-sizing:content-box;float:none;margin:0;padding:0;position:static;height:auto;width:auto}.a2a_menu{border-radius:6px;display:none;direction:ltr;background:#FFF;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;color:#000;line-height:12px;border:1px solid #CCC;vertical-align:baseline;overflow:hidden}.a2a_mini{min-width:200px;position:absolute;width:300px;z-index:9999997}.a2a_overlay{display:none;background:#616c7deb;backdrop-filter:blur(4px);-webkit-backdrop-filter:blur(4px);position:fixed;top:0;right:0;left:0;bottom:0;z-index:9999998;-webkit-tap-highlight-color:transparent;transition:opacity .14s,backdrop-filter .14s}.a2a_full{background:#FFF;border:1px solid #FFF;box-shadow:#2a2a2a1a 0 0 20px 10px;height:auto;height:calc(320px);top:15%;left:50%;margin-left:-320px;position:fixed;text-align:center;width:640px;z-index:9999999;transition:transform .14s,opacity .14s}.a2a_full_footer,.a2a_full_header,.a2a_full_services{border:0;margin:0;padding:12px;box-sizing:border-box}.a2a_full_header{padding-bottom:8px}.a2a_full_services{height:280px;overflow-y:scroll;padding:0 12px;-webkit-overflow-scrolling:touch}.a2a_full_services .a2a_i{display:inline-block;float:none;width:181px;width:calc(33.334% - 18px)}div.a2a_full_footer{font-size:12px;text-align:center;padding:8px 14px}div.a2a_full_footer a,div.a2a_full_footer a:visited{display:inline;font-size:12px;line-height:14px;padding:8px 14px}div.a2a_full_footer a:focus,div.a2a_full_footer a:hover{background:0 0;border:0;color:#0166FF}div.a2a_full_footer a span.a2a_s_a2a,div.a2a_full_footer a span.a2a_w_a2a{background-size:14px;border-radius:3px;display:inline-block;height:14px;line-height:14px;margin:0 3px 0 0;vertical-align:top;width:14px}.a2a_modal{height:0;left:50%;margin-left:-320px;position:fixed;text-align:center;top:15%;width:640px;z-index:9999999;transition:transform .14s,opacity .14s;-webkit-tap-highlight-color:transparent}.a2a_modal_body{background:0 0;border:0;font:24px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;position:relative;height:auto;width:auto}.a2a_thanks{color:#fff;height:auto;margin-top:20px;width:auto}.a2a_thanks>div:first-child{margin:0 0 40px 0}.a2a_thanks div *{height:inherit}#a2a_copy_link{background:#FFF;border:1px solid #FFF;cursor:pointer;margin-top:15%}label.a2a_s_link#a2a_copy_link_icon,label.a2a_w_link#a2a_copy_link_icon{background-size:48px;border-radius:0;display:inline-block;height:48px;left:0;line-height:48px;margin:0 3px 0 0;position:absolute;vertical-align:top;width:48px}#a2a_modal input#a2a_copy_link_text{background-color:transparent;border:0;color:#2A2A2A;cursor:pointer;font:inherit;height:48px;left:62px;max-width:initial;min-height:auto;padding:0;position:relative;width:564px;width:calc(100% - 76px)}#a2a_copy_link_copied{background-color:#0166ff;color:#fff;display:none;font:inherit;font-size:16px;margin-top:1px;padding:3px 8px}@media (forced-colors:active){.a2a_color_buttons a,.a2a_svg{forced-color-adjust:none}}@media (prefers-color-scheme:dark){.a2a_menu a,.a2a_menu a.a2a_i,.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more,i.a2a_i{border-color:#2a2a2a!important;color:#fff!important}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover,.a2a_menu_find_container{border-color:#444!important;background-color:#444!important}.a2a_menu:not(.a2a_thanks){background-color:#2a2a2a;border-color:#2a2a2a}.a2a_menu_find{color:#fff!important}.a2a_menu label.a2a_s_find svg{background-color:transparent!important}.a2a_menu label.a2a_s_find svg path{fill:#fff!important}.a2a_full{box-shadow:#00000066 0 0 20px 10px}.a2a_overlay{background-color:#373737eb}}@media print{.a2a_floating_style,.a2a_menu,.a2a_overlay{visibility:hidden}}@keyframes a2aFadeIn{from{opacity:0}to{opacity:1}}.a2a_starting{opacity:0}.a2a_starting.a2a_full,.a2a_starting.a2a_modal{transform:scale(.8)}@media (max-width:639px){.a2a_full{border-radius:0;top:15%;left:0;margin-left:auto;width:100%}.a2a_modal{left:0;margin-left:10px;width:calc(100% - 20px)}}@media (min-width:318px) and (max-width:437px){.a2a_full .a2a_full_services .a2a_i{width:calc(50% - 18px)}}@media (max-width:317px){.a2a_full .a2a_full_services .a2a_i{width:calc(100% - 18px)}}@media (max-height:436px){.a2a_full{bottom:40px;height:auto;top:40px}}@media (max-height:550px){.a2a_modal{top:30px}}@media (max-height:360px){.a2a_modal{top:20px}.a2a_thanks>div:first-child{margin-bottom:20px}}.a2a_menu a{color:#0166FF;text-decoration:none;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;line-height:14px;height:auto;width:auto;outline:0}.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more{color:#0166FF}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover{color:#2A2A2A;border-color:#EEE;border-style:solid;background-color:#EEE;text-decoration:none}.a2a_menu label.a2a_s_find{background-size:24px;height:24px;left:8px;pointer-events:auto;position:absolute;top:7px;width:24px}.a2a_menu label.a2a_s_find svg{background-color:#FFF}.a2a_menu label.a2a_s_find svg path{fill:#CCC}#a2a_menu_container{display:inline-block}.a2a_menu_find_container{border:1px solid #CCC;border-radius:6px;padding:2px 24px 2px 0;position:relative;text-align:left}.a2a_cols_container .a2a_col1{overflow-x:hidden;overflow-y:auto;-webkit-overflow-scrolling:touch}#a2a_modal input,#a2a_modal input[type=text],.a2a_menu input,.a2a_menu input[type=text]{display:block;background-image:none;box-shadow:none;line-height:100%;margin:0;outline:0;overflow:hidden;padding:0;-moz-box-shadow:none;-webkit-box-shadow:none;-webkit-appearance:none}#a2afeed_find_container input,#a2afeed_find_container input[type=text],#a2apage_find_container input,#a2apage_find_container input[type=text]{background-color:transparent;border:0;box-sizing:content-box;color:#2A2A2A;float:none;font:inherit;font-size:16px;height:28px;line-height:20px;left:38px;outline:0;margin:0;max-width:initial;min-height:initial;padding:2px 0;position:relative;width:99%}.a2a_clear{clear:both}.a2a_svg{background-repeat:no-repeat;display:block;overflow:hidden;height:32px;line-height:32px;padding:0;pointer-events:none;width:32px}.a2a_svg svg{background-repeat:no-repeat;background-position:50% 50%;border:none;display:block;left:0;margin:0 auto;overflow:hidden;padding:0;position:relative;top:0;width:auto;height:auto}a.a2a_i,i.a2a_i{display:block;float:left;border:1px solid #FFF;line-height:24px;padding:6px 8px;text-align:left;white-space:nowrap;overflow:hidden;text-overflow:ellipsis;width:132px}a.a2a_i span,a.a2a_more span{display:inline-block;overflow:hidden;vertical-align:top}a.a2a_i .a2a_svg{margin:0 6px 0 0}a.a2a_i .a2a_svg,a.a2a_more .a2a_svg{background-size:24px;height:24px;line-height:24px;width:24px}a.a2a_sss:hover{border-left:1px solid #CCC}a.a2a_more{border-bottom:1px solid #FFF;border-left:0;border-right:0;line-height:24px;margin:6px 0 0;padding:6px;-webkit-touch-callout:none}a.a2a_more span{height:24px;margin:0 6px 0 0}.a2a_kit .a2a_svg{background-repeat:repeat}.a2a_default_style a:empty,.a2a_flex_style a:empty,.a2a_floating_style a:empty,.a2a_overlay_style a:empty{display:none}.a2a_color_buttons a,.a2a_floating_style a{text-decoration:none}.a2a_default_style:not(.a2a_flex_style) a{float:left;line-height:16px;padding:0 2px}.a2a_default_style a:hover .a2a_svg,.a2a_floating_style a:hover .a2a_svg,.a2a_overlay_style a:hover .a2a_svg svg{opacity:.7}.a2a_overlay_style.a2a_default_style a:hover .a2a_svg{opacity:1}.a2a_default_style .a2a_count,.a2a_default_style .a2a_svg,.a2a_floating_style .a2a_svg,.a2a_menu .a2a_svg,.a2a_vertical_style .a2a_count,.a2a_vertical_style .a2a_svg{border-radius:4px}.a2a_default_style .a2a_counter img,.a2a_default_style .a2a_dd,.a2a_default_style .a2a_svg{float:left}.a2a_default_style .a2a_img_text{margin-right:4px}.a2a_default_style .a2a_divider{border-left:1px solid #000;display:inline;float:left;height:16px;line-height:16px;margin:0 5px}.a2a_kit a{cursor:pointer;transition:none}.a2a_floating_style{background-color:#fff;border-radius:6px;position:fixed;z-index:9999995}.a2a_overlay_style{z-index:2147483647}.a2a_floating_style,.a2a_overlay_style{animation:a2aFadeIn .2s ease-in;padding:4px}.a2a_vertical_style:not(.a2a_flex_style) a{clear:left;display:block;overflow:hidden;padding:4px}.a2a_floating_style.a2a_default_style{bottom:0}.a2a_floating_style.a2a_default_style a,.a2a_overlay_style.a2a_default_style a{padding:4px}.a2a_count{background-color:#fff;border:1px solid #ccc;box-sizing:border-box;color:#2a2a2a;display:block;float:left;font:12px Arial,Helvetica,sans-serif;height:16px;margin-left:4px;position:relative;text-align:center;width:50px}.a2a_count:after,.a2a_count:before{border:solid transparent;border-width:4px 4px 4px 0;content:"";height:0;left:0;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:50%;width:0}.a2a_count:before{border-right-color:#ccc}.a2a_count:after{border-right-color:#fff;margin-left:-3px}.a2a_count span{animation:a2aFadeIn .14s ease-in}.a2a_vertical_style .a2a_counter img{display:block}.a2a_vertical_style .a2a_count{float:none;margin-left:0;margin-top:6px}.a2a_vertical_style .a2a_count:after,.a2a_vertical_style .a2a_count:before{border:solid transparent;border-width:0 4px 4px 4px;content:"";height:0;left:50%;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:0;width:0}.a2a_vertical_style .a2a_count:before{border-bottom-color:#ccc}.a2a_vertical_style .a2a_count:after{border-bottom-color:#fff;margin-top:-3px}.a2a_color_buttons .a2a_count,.a2a_color_buttons .a2a_count:after,.a2a_color_buttons .a2a_count:before,.a2a_color_buttons.a2a_vertical_style .a2a_count:after,.a2a_color_buttons.a2a_vertical_style .a2a_count:before{background-color:transparent;border:none;color:#fff;float:none;width:auto}.a2a_color_buttons.a2a_vertical_style .a2a_count{margin-top:0}.a2a_flex_style{display:flex;align-items:flex-start;gap:0}.a2a_default_style.a2a_flex_style{left:0;right:0;width:100%}.a2a_vertical_style.a2a_flex_style{flex-direction:column;top:0;bottom:0}.a2a_flex_style a{display:flex;justify-content:center;flex:1;padding:4px}.a2a_flex_style.a2a_vertical_style a{flex-direction:column}.a2a_floating_style.a2a_color_buttons,.a2a_floating_style.a2a_flex_style{border-radius:0;padding:0}.a2a_floating_style.a2a_default_style.a2a_flex_style{bottom:0}.a2a_kit.a2a_flex_style .a2a_counter img,.a2a_kit.a2a_flex_style .a2a_dd,.a2a_kit.a2a_flex_style .a2a_svg{float:none}.a2a_nowrap{white-space:nowrap}.a2a_note{margin:0 auto;padding:9px;font-size:12px;text-align:center}.a2a_note .a2a_note_note{margin:0;color:#2A2A2A}.a2a_wide a{display:block;margin-top:3px;border-top:1px solid #EEE;text-align:center}.a2a_label{position:absolute!important;clip-path:polygon(0px 0px,0px 0px,0px 0px);-webkit-clip-path:polygon(0px 0px,0px 0px,0px 0px);overflow:hidden;height:1px;width:1px}.a2a_kit,.a2a_menu,.a2a_modal,.a2a_overlay{-ms-touch-action:manipulation;touch-action:manipulation;outline:0}.a2a_dd{-webkit-user-drag:none}.a2a_dd img{border:0}.a2a_button_facebook_like iframe{max-width:none}</style><link rel="preconnect" href="https://use.typekit.net"><meta http-equiv="P3P" content="CP=&quot;NOI DSP ADM OUR IND OTC&quot;"><link rel="stylesheet" href="https://quilt-cdn.janrain.com/HEAD/providers.css" type="text/css"><link id="altmetric-embed-css" rel="stylesheet" type="text/css" href="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed-59614f5c46b49b21eeef3bb28c4fb38d1e7069e8d014752fcb66e84942556802.css"></head>
    

    



    
        
        
        
            <body class="pb-ui website-mms-site loaded">
            






    
    
        





    
    
        
        
    
    
    







<input type="hidden" id="isRoMode" name="isRoMode" value="false">

        <div id="pb-page-content" data-ng-non-bindable="">
                
            <div data-pb-dropzone="main" data-pb-dropzone-name="Main">
                
                    
                        



        
        <header data-sticky="false" class="ng-header js_stickyAd"><a href="#mainContent" class="ng-skipToMainContent">Skip to main content</a><div class="ng-header_topAd"><div class="ng-header_topAd-content d-flex justify-content-center align-items-center">



        
        <div id="DTM_Position_Topbanner" class="ad">
 <!--emptycomment-->
</div>
</div></div><div class="ng-header_journal-navbar"><div class="ng-header_journal-navbar-content"><div class="container-fluid"><div class="row"><div class="ng-header_journal-navbar_left col-lg-8 col-sm-12 pr-lg-0 d-flex align-items-center"><div data-location="nejm_group_product_nav" class="ng-header_journalNavMenu">



        
        <nav data-location="nejm_group_product_nav" role="navigation" class="ng-journalNavMenu">
<ul class="ng-journalNavMenu_list">
<li class="ng-journalNavMenu_list-item"><a href="/" class="ng-journalNavMenu_mainLink active" aria-current="page" aria-label="The New England Journal of Medicine selected item"><span class="ng-journalNavMenu_mainLink-text d-lg-block d-none">The New England Journal of Medicine</span><span class="ng-journalNavMenu_mainLink-text d-lg-none d-block">NEJM</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://evidence.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Evidence</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://ai.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> AI</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://catalyst.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Catalyst</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://www.jwatch.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Journal Watch</span></a></li>
</ul>
</nav>

</div></div><div class="ng-header_journal-navbar_right col-lg-4 pl-lg-0 d-none d-xl-flex align-items-center justify-content-end"><div class="ng-header_loginBar d-xl-flex align-items-lg-center">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2200433" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div></div><div class="ng-header_instBanner d-none d-lg-block"></div><div class="ng-header_logoBar"><div class="container-fluid"><div class="row"><div data-location="logo" class="ng-header_logoBar_left col-lg-4 col-6 d-flex align-items-center justify-content-start"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-logo-166667e91992a5212bc723b03e45d39f.svg" alt="The New England Journal of Medicine homepage" width="366" height="58" class="ng-header_logo-image"></a></div><div class="ng-header_logoBar_right ng-header_navBar col-lg-8 col-sm-12 p-lg-0 align-items-center justify-content-end"><div class="ng-header_navBar-content"><div class="container-fluid"><div class="row"><div class="ng-header_instBanner-md col-12 d-block d-lg-none"></div><div class="ng-header_loginBar-md col-12 d-block d-xl-none">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2200433" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div><div class="ng-header_navBar_left col-lg-8 col-sm-12 d-flex align-items-center"><div class="ng-header_stickyLogo mr-32"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-small-logo-070df7a3f4d8cfa2e71c3c45bb4b172f.svg" alt="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-image"></a></div><div class="ng-header_mainMenu">









    
    
        <div data-widget-def="menuWidget" data-widget-id="97fb3983-db63-4b0b-97dd-d9bb7929fce1" data-location="main_nav">
        



        
        <nav class="ng-menu"><ul class="ng-menu_list ng-simple-menu"><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/toc/nejm/current" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">current issue</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/toc/nejm/current" class="ng-simple-menu_list-link">VIEW CURRENT ISSUE</a></li><li class="ng-simple-menu_list-item"><a href="/toc/nejm/recently-published" class="ng-simple-menu_list-link">BROWSE RECENTLY PUBLISHED</a></li><li class="ng-simple-menu_list-item"><a href="/loi/nejm" class="ng-simple-menu_list-link">BROWSE ALL ISSUES</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/medical-specialties" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">SPECIALTIES</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/browse/specialty/cardiology" class="ng-simple-menu_list-link">Cardiology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/clinical-medicine" class="ng-simple-menu_list-link">Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/endocrinology" class="ng-simple-menu_list-link">Endocrinology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/gastroenterology" class="ng-simple-menu_list-link">Gastroenterology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/hematology-oncology" class="ng-simple-menu_list-link">Hematology/Oncology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/infectious-disease" class="ng-simple-menu_list-link">Infectious Disease</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/nephrology" class="ng-simple-menu_list-link">Nephrology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/neurology-neurosurgery" class="ng-simple-menu_list-link">Neurology/Neurosurgery</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/obstetrics-gynecology" class="ng-simple-menu_list-link">Obstetrics/Gynecology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pediatrics" class="ng-simple-menu_list-link">Pediatrics</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pulmonary-critical-care" class="ng-simple-menu_list-link">Pulmonary/Critical Care</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/surgery" class="ng-simple-menu_list-link">Surgery</a></li><li class="ng-simple-menu_list-item"><a href="/medical-specialties" class="ng-simple-menu_list-link">View All Specialties</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/topics" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">TOPICS</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/ai-in-medicine" class="ng-simple-menu_list-link">AI in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/climate-change" class="ng-simple-menu_list-link">Climate Change</a></li><li class="ng-simple-menu_list-item"><a href="/coronavirus" class="ng-simple-menu_list-link">Coronavirus</a></li><li class="ng-simple-menu_list-item"><a href="/equity" class="ng-simple-menu_list-link">Efforts toward Equity</a></li><li class="ng-simple-menu_list-item"><a href="/firearm-injury-prevention" class="ng-simple-menu_list-link">Firearm Injury Prevention</a></li><li class="ng-simple-menu_list-item"><a href="/nam" class="ng-simple-menu_list-link">From the National Academy of Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/fundamentals-of-medical-ethics" class="ng-simple-menu_list-link">Fundamentals of Medical Ethics</a></li><li class="ng-simple-menu_list-item"><a href="/gray-matters" class="ng-simple-menu_list-link">Gray Matters</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/health-policy" class="ng-simple-menu_list-link">Health Policy</a></li><li class="ng-simple-menu_list-item"><a href="/medicine-and-society" class="ng-simple-menu_list-link">Medicine and Society</a></li><li class="ng-simple-menu_list-item"><a href="/nutrition-in-medicine" class="ng-simple-menu_list-link">Nutrition in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/outbreaks" class="ng-simple-menu_list-link">Outbreaks Center</a></li><li class="ng-simple-menu_list-item"><a href="/race-and-medicine" class="ng-simple-menu_list-link">Race and Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/recognizing-historical-injustices" class="ng-simple-menu_list-link">Recognizing Historical Injustices and the Journal</a></li><li class="ng-simple-menu_list-item"><a href="/tobacco-use-reduction" class="ng-simple-menu_list-link">Tobacco Use Reduction</a></li><li class="ng-simple-menu_list-item"><a href="/topics" class="ng-simple-menu_list-link">View All Topics</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/multimedia" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">MULTIMEDIA</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/rss-feed" class="ng-simple-menu_list-link">Podcasts</a></li><li class="ng-simple-menu_list-item"><a href="/double-take" class="ng-simple-menu_list-link">Double Takes</a></li><li class="ng-simple-menu_list-item"><a href="https://illustrated-glossary.nejm.org/" class="ng-simple-menu_list-link">Illustrated Glossary</a></li><li class="ng-simple-menu_list-item"><a href="/image-challenge" class="ng-simple-menu_list-link">Image Challenge</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/images-in-clinical-medicine" class="ng-simple-menu_list-link">Images in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/interactive-medical-case" class="ng-simple-menu_list-link">Interactive Medical Cases</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/research-summary" class="ng-simple-menu_list-link">Research Summaries</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia/quick-take-video" class="ng-simple-menu_list-link">Quick Takes</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/videos-in-clinical-medicine" class="ng-simple-menu_list-link">Videos in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia" class="ng-simple-menu_list-link">View All Multimedia</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/learning" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">LEARNING/CME</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/continuing-medical-education" class="ng-simple-menu_list-link">Weekly CME</a></li><li class="ng-simple-menu_list-item"><a href="/cme-ce/obesity" class="ng-simple-menu_list-link">Obesity CME/CE</a></li><li class="ng-simple-menu_list-item"><a href="/learning" class="ng-simple-menu_list-link">VIEW ALL LEARNING/CME</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item"><a href="/author-center/home" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">AUTHOR CENTER</span></a></li></ul></nav>

        </div>
    

</div><button aria-label="Search" class="ng-header_searchBtn searchBtnNav d-block ml-24"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button></div><div class="ng-header_loginBar ng-header_loginBar-sticky col-4">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2200433" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div><div class="ng-header_logoBar_right-lg col-lg-8 col-6 d-flex align-items-center justify-content-end d-xl-none"><button aria-label="Search" class="ng-header_searchBtn d-flex justify-content-end"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><div class="ng-header_openCloseBtns d-flex align-items-center justify-content-end"><button aria-label="Open" class="ng-header_openBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#burger"></use></svg></span></button><button aria-label="Close" class="ng-header_closeBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></button></div></div><div class="ng-header_quickSearch col-12"><div class="ng-header_quickSearch-content">



        
        <div class="ng-quick-search js-ng-quick-search"><form action="/search" method="get" class="ng-quick-search_form js-form"><div class="ng-quick-search_inputArea js-inputArea"><input type="search" name="q" placeholder="Enter keyword, author, title or citation" autocomplete="off" value="" required="required" class="ng-quick-search_allField ng-large-text-input js-allField js-allField-def-tmpl ui-autocomplete-input"><button type="submit" aria-label="Search Button" class="ng-quick-search_iconBtn d-xl-none d-block js-submitBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><ul id="ui-id-1" tabindex="0" class="ui-menu ui-widget ui-widget-content ui-autocomplete ui-front" style="display: none;"></ul></div><div class="ng-quick-search_btnsArea d-none d-xl-flex align-items-center justify-content-end"><a href="/search/advanced" class="ng-quick-search_advSearchLink ng-btn_link js-advancedSearchLink">Advanced Search</a><button type="submit" class="ng-quick-search_textBtn ng-btn_secondary ng-btn_iconRight js-submitBtn"><span class="ng-btn_text">SEARCH</span><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-right"></use></svg></span></button></div></form></div>
</div></div></div></div></div></header><div class="ng-header_overlay"></div><div class="ng-header_after">









    
    
        <div data-widget-def="literatumAd" data-widget-id="4931ddbd-d46e-4597-b4fd-92549e9847ca" id="ad-global-banner-FULLx64-1">
        



        
        



    

    

    
        
    



        </div>
    

</div>

                    
                        



        
        <div>









    
    
        <main data-widget-def="axelPublicationContent" data-widget-id="fcdb5261-d6a2-4a9c-81d5-3a3e2304e9c1" id="mainContent">
        



        
        <div class="article-tools__savePopup"><div class="ng-save"><input type="hidden" value="/action/getSavedTags" class="getKeywordsServiceUrl"><input type="hidden" value="/action/mmsSaveItemsService?itemType=article" class="saveServiceUrl"><input type="hidden" value="article" class="saveType"><input type="hidden" value="10.1056/NEJMoa2200433" class="inputDoi"><input type="hidden" value="The GRADE Study Research Group" class="inputAuthor"><input type="hidden" value="N Engl J Med 2022;387:1063-1074" class="inputCitation"><input type="hidden" value="09-21-2022" class="inputEPubDate"><input type="hidden" value="September 2022" class="inputCoverDate"><input type="hidden" value="Original Article" class="inputContentType"><input type="hidden" value="Glycemia Reduction in Type 2 Diabetes — Glycemic Outcomes" class="inputArticleTitle"><input type="hidden" value="/browse/nejm-article-type/original-article" class="inputContentTypeUrl"><button type="button" id="saveArticleShowPopupBtn" aria-hidden="true" tabindex="-1" class="ng-save-btn ng-btn_secondary isLoggedOut">Save</button></div></div><div class="article-tools__articleAlertPopup"><div id="articleAlertModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="articleAlertModalTitle" class="ng-modal_title modal-title">Create an E-mail Alert for This Article</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><div class="ng-do-media_popup"><div id="doPopup" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><link id="build-style-article" rel="stylesheet" type="text/css" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css"><article xmlns="http://www.w3.org/1999/xhtml" data-design="pill" data-has="right-rail" data-type="research-article" vocab="http://schema.org/" typeof="ScholarlyArticle" lang="en" dir="ltr"><header data-extent="frontmatter" data-location="header_article"><div class="core-container"><div data-article-access="free" data-article-access-type="free" class="meta-panel"><div class="meta-panel__left-content"><div class="meta-panel__type"><a href="/browse/nejm-article-type/original-article">Original Article</a></div></div><div class="meta-panel__right-content"><div class="meta-panel__share">









    
    
        <div data-widget-def="UX3share" data-widget-id="eee5f139-16f2-48f8-97ea-1b114367da16" data-location="share_tools_article">
        



        
        <!-- Go to https://www.addtoany.com/buttons/customize/ to customize your tools --><script type="text/javascript" defer="defer" src="https://static.addtoany.com/menu/page.js" nonce="9523b28971f9626e-SJC"></script><div class="share"><div class="share__block share__inline-links"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="d-flex list-unstyled a2a a2a_kit a2a_default_style mb-0 a2a_kit_size_32" style="line-height: 32px;"><li class="a2a_listitem_custom"><a role="link" title="Facebook" data-interactiontype="social" class="share__link a2a_button_facebook" target="_blank" rel="nofollow noopener" href="/#facebook"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-facebook"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="X (formerly Twitter)" data-interactiontype="social" class="share__link a2a_button_twitter" target="_blank" rel="nofollow noopener" href="/#twitter"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-twitter"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Linked In" data-interactiontype="social" class="share__link a2a_button_linkedin" target="_blank" rel="nofollow noopener" href="/#linkedin"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-linkedin"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Email" data-interactiontype="content_email_click" class="share__link a2a_button_email" target="_blank" rel="nofollow noopener" href="/#email"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-email"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Bluesky" data-interactiontype="social" class="share__link a2a_button_bluesky" target="_blank" rel="nofollow noopener" href="/#bluesky"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-bluesky"></use></svg></span></a></li></ul></div></div>

        </div>
    

</div></div></div><h1 property="name">Glycemia Reduction in Type 2 Diabetes — Glycemic Outcomes</h1><div class="core-relations my-3"></div><div class="contributors"><span class="authors"><span class="heading">Author</span>: <span role="list"><span property="author" typeof="Person" role="listitem">The GRADE Study Research Group<sup class="xref"><a href="#fn1" role="doc-noteref">*</a></sup></span></span></span><a href="#tab-contributors" class="to-authors-affiliations" data-id="article-authors-viewall">Author Info &amp; Affiliations</a></div><div class="core-self-citation"><div class="core-date-published">Published <span property="datePublished">September 21, 2022</span></div><div property="isPartOf" typeof="Periodical"><span property="name">N Engl J Med</span> 2022<span property="isPartOf" typeof="PublicationVolume">;<span property="volumeNumber">387</span></span>:<span property="pageStart">1063</span>-<span property="pageEnd">1074</span></div><div class="doi">DOI: 10.1056/NEJMoa2200433</div><div class="core-enumeration"><a href="/toc/nejm/387/12"><span property="isPartOf" typeof="PublicationVolume">VOL. <span property="volumeNumber">387</span></span> <span property="isPartOf" typeof="PublicationIssue">NO. <span property="issueNumber">12</span></span></a></div><div><a href="#tab-information">Copyright © 2022</a></div></div><div class="info-panel"><div class="info-panel__left-content"><div class="info-panel__metrics info-panel__item"></div></div><div data-location="tools_article" class="info-panel__right-content"><div class="info-panel__article_tools info-panel__item">



        
        <div data-permission="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3D%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D387%26issueNum%3D12%26contentID%3D10.1056%252FNEJMoa2200433%26title%3DGlycemia%2BReduction%2Bin%2BType%2B2%2BDiabetes%2B%25E2%2580%2594%2BGlycemic%2BOutcomes%26publicationDate%3D09%252F22%252F2022" class="article-tools"><button id="articleToolsAlertBtn" data-url="/action/addCitationAlert?doi=10.1056%2FNEJMoa2200433" data-toggle="" data-target="#articleAlertModal" aria-label="Sign in or create account to add an article alert" data-interactiontype="article_alert" class="article-tools__citation btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to add an article alert"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#alerts"></use></svg></span></span></button><button id="articleToolsSaveBtn" data-toggle="modal" data-target="#saveArticle" aria-label="Sign in or create account to save this article" data-interactiontype="article_tools_save_click" class="article-tools__favorite btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to save this article"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#bookmarkFilled"></use></svg></span></span></button><a href="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3D%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D387%26issueNum%3D12%26contentID%3D10.1056%252FNEJMoa2200433%26title%3DGlycemia%2BReduction%2Bin%2BType%2B2%2BDiabetes%2B%25E2%2580%2594%2BGlycemic%2BOutcomes%26publicationDate%3D09%252F22%252F2022" target="_blank" title="" data-toggle="tooltip" aria-label="Permissions" data-interactiontype="article_tools_permissions_click" class="article-tools__permissions btn btn--slim" data-original-title="Permissions"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#permissions"></use></svg></span></a><a href="/about-nejm/reprints" title="" data-toggle="tooltip" aria-label="Reprints" data-interactiontype="article_tools_reprints_click" class="article-tools__reprints btn btn--slim" data-original-title="Reprints"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#reprints"></use></svg></span></a><a href="/cms/asset/d854bf7c-605d-4072-bd10-15623a1dcf4e/nejmoa2200433.pptx" target="_blank" title="" data-toggle="tooltip" aria-label="Download Slides" data-interactiontype="article_tools_slide_set_download" data-multimedia-type="Article Slideset" data-multimedia-filename="nejmoa2200433.pptx" class="article-tools__downloadSlides btn btn--slim" data-original-title="Download Slides"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#download"></use></svg></span></a><div class="article-tools__permissionsPopup"><div id="permissionsModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="permissionsModalTitle" class="ng-modal_title modal-title">Permissions</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body">For permission requests, please contact NEJM Reprints at <a href="mailto:reprints@nejm.org">reprints@nejm.org</a></div></div></div></div></div></div>
</div><div class="info-panel__citations info-panel__item"><a href="#tab-citations" class="btn btn--slim" aria-label="View Citations" data-toggle="tooltip" data-original-title="View Citations" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><i aria-hidden="true" class="icon-format_quote"></i></a></div><div class="info-panel__formats info-panel__item"><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2200433" class="btn btn--pdf btn--slim" aria-label="View PDF" data-toggle="tooltip" data-original-title="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2200433" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2200433.pdf"><i aria-hidden="true" class="icon-PDF"></i></a></div></div></div></div></header><div data-core-nav="header" data-extent="frontmatter"><div class="core-nav-wrapper core-container" aria-label="Article navigation"><div class="core-sections-menu"><button data-id="article-toolbar-showhide" aria-controls="article_sections_menu" aria-expanded="false" aria-label="Toggle section navigation menu" style="margin-top: 0px;"><i class="icon-list" aria-hidden="true"></i><span>Contents</span></button><nav id="article_sections_menu" aria-label="Contents" data-core-nav="article" style="margin-top: 0px;"><ul><li><a href="#summary-abstract" aria-current="true">Abstract</a></li><li><a href="#sec-1" aria-current="false">Methods</a></li><li><a href="#sec-2" aria-current="false">Results</a></li><li><a href="#sec-3" aria-current="false">Discussion</a></li><li class="bordered"><a href="#backnotes" aria-current="false">Notes</a></li><li><a href="#supplementary-materials" aria-current="false">Supplementary Material</a></li><li><a href="#bibliography" aria-current="false">References</a></li></ul></nav></div><nav id="article_collateral_menu"><ul data-core-nav="collateral" class="collateral-pill" style="margin-top: 0px;"><li><a href="#core-collateral-info" data-id="article-nav-menubar-info" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Information &amp; Authors"><i aria-hidden="true" class="icon-info"></i><span class="sr-only">Information &amp; Authors</span></a></li><li><a href="#core-collateral-metrics" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Metrics &amp; Citations"><i aria-hidden="true" class="icon-timeline"></i><span class="sr-only">Metrics &amp; Citations</span></a></li><li><a href="#core-collateral-fulltext-options" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="View Options"><i aria-hidden="true" class="icon-eye"></i><span class="sr-only">View Options</span></a></li><li><a href="#core-collateral-references" data-id="article-nav-menubar-references" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="References"><i aria-hidden="true" class="icon-references"></i><span class="sr-only">References</span></a></li><li><a href="#core-collateral-media" data-id="article-nav-menubar-media" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Media"><i aria-hidden="true" class="icon-photo"></i><span class="sr-only">Media</span></a></li><li><a href="#core-collateral-tables" data-id="article-nav-menubar-tables" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Tables"><i aria-hidden="true" class="icon-tables"></i><span class="sr-only">Tables</span></a></li><li><a href="#core-collateral-share" data-id="article-nav-menubar-share" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Share"><i aria-hidden="true" class="icon-share"></i><span class="sr-only">Share</span></a></li></ul></nav></div></div><div data-core-wrapper="content"><div id="abstracts" data-extent="frontmatter" data-location="articleTab_article"><div class="core-container"><section id="summary-abstract" property="abstract" typeof="Text" role="doc-abstract"><h2 property="name">Abstract</h2><section id="abs-sec-1"><h3>Background</h3><div role="paragraph">The comparative effectiveness of glucose-lowering medications for use with metformin to maintain target glycated hemoglobin levels in persons with type 2 diabetes is uncertain.</div></section><section id="abs-sec-2"><h3>Methods</h3><div role="paragraph">In this trial involving participants with type 2 diabetes of less than 10 years’ duration who were receiving metformin and had glycated hemoglobin levels of 6.8 to 8.5%, we compared the effectiveness of four commonly used glucose-lowering medications. We randomly assigned participants to receive insulin glargine U-100 (hereafter, glargine), the sulfonylurea glimepiride, the glucagon-like peptide-1 receptor agonist liraglutide, or sitagliptin, a dipeptidyl peptidase 4 inhibitor. The primary metabolic outcome was a glycated hemoglobin level, measured quarterly, of 7.0% or higher that was subsequently confirmed, and the secondary metabolic outcome was a confirmed glycated hemoglobin level greater than 7.5%.<div data-style-type="float-right"><div class="core-digital-object nejm-research-summary">
    <div class="ng-do-media" data-location="inlineArticlePreview">
        <div class="ng-do-media_item">
            <div class="ng-do-media_item-left">
                <a href="/do/10.1056/NEJMdo006680/full/" class="ng-do-media_item-img-link">
                    <img src="/cms/asset/a1fd5700-1f99-4030-8807-921562db1bf3/nejmdo006680_thumb.jpg" class="ng-do-media_item-img">
                </a>
            </div>
            <div class="ng-do-media_item-right">
                <div class="ng-do-media_item-type">
                    <a href="/browse/nejm-media-type/research-summary" class="ng-do-media_item-type-link">Research Summary</a>
                </div>
                <h6 class="ng-do-media_item-title">
                    <a href="/do/10.1056/NEJMdo006680/full/" class="ng-do-media_item-title-link">Glycemia Reduction in Type 2 Diabetes — Glycemic Outcomes</a>
                </h6>
            </div>
        </div>
    </div>
    <div class="ng-page_separator mt-32"></div>
</div></div></div></section><section id="abs-sec-3"><h3>Results</h3><div role="paragraph">A total of 5047 participants (19.8% Black and 18.6% Hispanic or Latinx) who had received metformin for type 2 diabetes were followed for a mean of 5.0 years. The cumulative incidence of a glycated hemoglobin level of 7.0% or higher (the primary metabolic outcome) differed significantly among the four groups (P&lt;0.001 for a global test of differences across groups); the rates with glargine (26.5 per 100 participant-years) and liraglutide (26.1) were similar and lower than those with glimepiride (30.4) and sitagliptin (38.1). The differences among the groups with respect to a glycated hemoglobin level greater than 7.5% (the secondary outcome) paralleled those of the primary outcome. There were no material differences with respect to the primary outcome across prespecified subgroups defined according to sex, age, or race or ethnic group; however, among participants with higher baseline glycated hemoglobin levels there appeared to be an even greater benefit with glargine, liraglutide, and glimepiride than with sitagliptin. Severe hypoglycemia was rare but significantly more frequent with glimepiride (in 2.2% of the participants) than with glargine (1.3%), liraglutide (1.0%), or sitagliptin (0.7%). Participants who received liraglutide reported more frequent gastrointestinal side effects and lost more weight than those in the other treatment groups.</div></section><section id="abs-sec-4"><h3>Conclusions</h3><div role="paragraph">All four medications, when added to metformin, decreased glycated hemoglobin levels. However, glargine and liraglutide were significantly, albeit modestly, more effective in achieving and maintaining target glycated hemoglobin levels. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases and others; GRADE ClinicalTrials.gov number, <a href="http://clinicaltrials.gov/show/NCT01794143" target="_blank">NCT01794143</a>.)</div></section></section><div class="core-digital-object quick-take">
<div class="ng-do-media" style="border-top: 1px solid #e5e5e5; padding-top: 1.5rem;" data-location="inlineArticlePreview">
    <div class="ng-do-media_item">
        <div class="ng-do-media_item-left">
            <a href="/do/10.1056/NEJMdo006679/full/" class="ng-do-media_item-img-link">
                <img src="/cms/asset/9e9f5c8a-314c-4135-bd28-84ac06917b59/media/NEJMdo006679_300x200.jpg" class="ng-do-media_item-img">
                <span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#tooltip-video"></use></svg></span>
            </a>
        </div>
        <div class="ng-do-media_item-right">
            <div class="ng-do-media_item-type">
                <a href="/browse/nejm-media-type/quick-take" class="ng-do-media_item-type-link">Quick Take</a>
            </div>
            <h6 class="ng-do-media_item-title">
                <a href="/do/10.1056/NEJMdo006679/full/" class="ng-do-media_item-title-link">Glycemia Reduction Approaches in Type 2 Diabetes</a>
            </h6>
            <div class="ng-do-media_item-duration">2m 0s</div>
        </div>
    </div>
</div>
</div></div></div><section id="bodymatter" data-extent="bodymatter" property="articleBody" typeof="Text" data-location="articleTab_article"><div class="core-container"><div role="paragraph">Type 2 diabetes affects more than 30 million adults in the United States and more than 500 million worldwide, with an annual incidence in the United States of approximately 1.5 million cases.<sup><a href="#core-r1" role="doc-biblioref" data-xml-rid="r1 r2" id="body-ref-r2" href-manipulated="true">1,2</a></sup> Its major human and economic costs are caused primarily by the development of diabetes-specific complications, including retinopathy, nephropathy, and neuropathy, and a risk of cardiovascular disease that is two to five times as high as that among persons without diabetes.<sup><a href="#core-r3" role="doc-biblioref" data-xml-rid="r3" id="body-ref-r3" href-manipulated="true" aria-label="Reference 3">3</a></sup> The long-term diabetes-specific complications have been ameliorated by interventions that decrease chronic glycemia, as measured by glycated hemoglobin levels.<sup><a href="#core-r4" role="doc-biblioref" data-xml-rid="r4 r5" id="body-ref-r5" href-manipulated="true">4,5</a></sup> A target glycated hemoglobin level of less than 7.0% (&lt;53.0 mmol per mole) has been established by consensus for most persons with type 2 diabetes, with the goal of decreasing morbidity.<sup><a href="#core-r6" role="doc-biblioref" data-xml-rid="r6" id="body-ref-r6" href-manipulated="true" aria-label="Reference 6">6</a></sup></div><div role="paragraph">Virtually all recommendations for the management of glycemia in persons with type 2 diabetes have included metformin as the first medication to be used, with a second medication added when needed to achieve or maintain a glycated hemoglobin level of less than 7.0%.<sup><a href="#core-r7" role="doc-biblioref" data-xml-rid="r7 r8" id="body-ref-r8" href-manipulated="true">7,8</a></sup> Unfortunately, there are few long-term comparator studies to guide the choice of a second glucose-lowering medication. The purpose of the Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness (GRADE) Study was to examine the relative effectiveness of agents from four of the most commonly used classes of glucose-lowering medications, when added to metformin, in achieving and maintaining target glycated hemoglobin levels in persons with recent-onset type 2 diabetes.<sup><a href="#core-r9" role="doc-biblioref" data-xml-rid="r9" id="body-ref-r9-1" href-manipulated="true" aria-label="Reference 9">9</a></sup> Here, we report the major glycemic outcomes of this trial. In our accompanying article in this issue of the <i>Journal</i>, we report the effects of the randomly assigned interventions on prespecified secondary outcomes (microvascular complications and cardiovascular events and their risk factors).<sup><a href="#core-r10" role="doc-biblioref" data-xml-rid="r10" id="body-ref-r10" href-manipulated="true" aria-label="Reference 10">10</a></sup></div><section id="sec-1" data-type="methods"><h2>Methods</h2><section id="sec-1-1"><h3>Trial Design and Oversight</h3><div role="paragraph">This multicenter, parallel-group, comparative-effectiveness clinical trial was sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health and designed by a subgroup of the investigators with NIDDK participation.<sup><a href="#core-r9" role="doc-biblioref" data-xml-rid="r9" id="body-ref-r9-2" href-manipulated="true" aria-label="Reference 9">9</a></sup> Randomization was conducted with the use of a centralized Web-based system and stratified according to trial site. The participants and clinic staff were aware of the treatment assignments; however, the investigators at the laboratories and reading centers and the members of the adjudication committee were unaware of the treatment assignments and the identity of each participant.</div><div role="paragraph">All the data were collected and analyzed by the trial research group. The authors vouch for the accuracy and completeness of the data and for the fidelity of the trial to the <a href="#ap1">protocol</a>, available with the <a href="#ap2">Supplementary Appendix</a> with the full text of this article at NEJM.org. The authors wrote the manuscript and made the decision to submit it for publication. No confidentiality restrictions were imposed by the sponsors.</div><div role="paragraph">The manufacturers contributed the trial medications under clinical-trial agreements with the NIDDK but had no role in the design, conduct, or analysis of the trial. An independent data and safety monitoring board appointed by the NIDDK oversaw the conduct of the trial. All participating centers obtained approval from local institutional review boards.</div></section><section id="sec-1-2"><h3>Participants</h3><div role="paragraph">Participants with type 2 diabetes were recruited at 36 clinical centers (Section S1 in the <a href="#ap2">Supplementary Appendix</a>) with the goal of composing a cohort that was broadly representative of the population with type 2 diabetes in the United States according to race and ethnic group. Eligible participants had type 2 diabetes that had been diagnosed at or after the age of 30 years, with the exception of American Indians or Alaska Natives, in whom the age at diagnosis was at least 20 years.<sup><a href="#core-r9" role="doc-biblioref" data-xml-rid="r9" id="body-ref-r9-3" href-manipulated="true" aria-label="Reference 9">9</a></sup> At initial screening, the known duration of diabetes was less than 10 years, and the participants had received at least 500 mg of metformin per day without the use of other glucose-lowering medications for the previous 6 months and were willing to use injection therapy. During a run-in period of 6 to 14 weeks before randomization, the metformin dose was increased to at least 1000 mg per day, with a target maximal dose (one that could be taken without unacceptable side effects) of 2000 mg per day. Eligible participants had a glycated hemoglobin level of 6.8 to 8.5% (50.8 to 69.4 mmol per mole) at the end of the run-in period.</div></section><section id="sec-1-3"><h3>Treatments</h3><div role="paragraph">The four medications selected for the current trial had to be approved by the Food and Drug Administration (FDA) and had to be in common use in combination with metformin at the time of the trial launch in 2013. Immediate-release or extended-release formulations of metformin (Bristol Myers Squibb) were supplied to all the participants. The randomly assigned treatment doses were adjusted on the basis of their labeling.</div><div role="paragraph">The treatments included the following: insulin glargine U-100 (hereafter, glargine) (Sanofi), administered daily at an initial dose of up to 20 U and adjusted according to glucose levels monitored by the participant and to avoid hypoglycemia; the sulfonylurea glimepiride (Sanofi), increased from 1 to 2 mg to a maximum of 8 mg per day, administered in divided doses and adjusted according to glucose levels monitored by the participant and to avoid hypoglycemia; the glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide (Novo Nordisk) initiated at a dose of 0.6 mg, with escalation to a maximum dose of 1.8 mg daily, depending on gastrointestinal side effects; and the dipeptidyl peptidase 4 inhibitor sitagliptin (Merck) at a dose of 100 mg, with the dose adjusted according to kidney function.</div><div role="paragraph">The assigned treatment was continued until the participant had a confirmed glycated hemoglobin level greater than 7.5% (&gt;58.5 mmol per mole) (the secondary metabolic outcome) (Fig. S1 in the <a href="#ap2">Supplementary Appendix</a>). At that time, glargine was added to the three assigned noninsulin treatments. In participants assigned to receive glargine who had a secondary outcome event and those in the other three treatment groups who had a tertiary outcome event, described below, treatment was intensified by adding prandial rapid-acting insulin aspart to the glargine regimen, and the randomly assigned medications, with the exception of glargine, were discontinued.</div><div role="paragraph">Thiazolidinediones were not included in the trial because of safety concerns present at the time of trial planning; these concerns included bone loss, fluid retention, and a risk of bladder cancer with pioglitazone.<sup><a href="#core-r11" role="doc-biblioref" data-xml-rid="r11" id="body-ref-r11" href-manipulated="true" aria-label="Reference 11">11</a></sup> Sodium–glucose cotransporter 2 (SGLT2) inhibitors were not included because they had not been approved by the FDA in the United States during the planning and launch of this trial, and there was no clinical experience with them.</div><div role="paragraph">During the trial, consensus recommendations on the preferential use of GLP-1 receptor agonists and SGLT2 inhibitors in persons with prevalent cardiovascular disease or kidney disease were issued by the American Diabetes Association and the European Association for the Study of Diabetes.<sup><a href="#core-r12" role="doc-biblioref" data-xml-rid="r12 r13" id="body-ref-r13" href-manipulated="true">12,13</a></sup> These recommendations were communicated to participants with cardiovascular disease or kidney disease and to their health care providers. Any glucose-lowering medications other than those included as part of the trial were prescribed by the participants’ own health care providers.</div></section><section id="sec-1-4"><h3>Outcomes and Assessments</h3><div role="paragraph">The participants were evaluated quarterly. The primary outcome was primary metabolic failure of the randomly assigned treatment, defined as confirmation (usually at the next quarterly visit) of a glycated hemoglobin level of 7.0% or higher.<sup><a href="#core-r9" role="doc-biblioref" data-xml-rid="r9" id="body-ref-r9-4" href-manipulated="true" aria-label="Reference 9">9</a></sup> A participant could first have a primary-outcome event at 6 months, with confirmation at 9 months, unless the glycated hemoglobin level was greater than 9.0% (&gt;74.9 mmol per mole), in which case the outcome event could occur at 3 months with confirmation at 3 to 6 weeks thereafter. The secondary metabolic outcome was a confirmed glycated hemoglobin level greater than 7.5% after the primary outcome. The protocol stipulated initiation of glargine in the three noninsulin treatment groups and intensification of insulin therapy in the original glargine treatment group after a secondary-outcome event.<sup><a href="#core-r9" role="doc-biblioref" data-xml-rid="r9" id="body-ref-r9-5" href-manipulated="true" aria-label="Reference 9">9</a></sup> The tertiary metabolic outcome was a confirmed glycated hemoglobin level greater than 7.5% after the secondary outcome, regardless of whether glargine was initiated in the three noninsulin treatment groups and insulin therapy was intensified in the original glargine treatment group. All laboratory measurements were performed in the GRADE Central Biochemical Laboratory (Section S3).</div><div role="paragraph">In the comparisons of the four treatments, other important trial outcomes included the following: serious adverse events; targeted adverse events (severe hypoglycemia warranting treatment, as well as pancreatitis and pancreatic and other cancers, with the exception of nonmelanoma skin cancer) adjudicated by committee<sup><a href="#core-r9" role="doc-biblioref" data-xml-rid="r9" id="body-ref-r9-6" href-manipulated="true" aria-label="Reference 9">9</a></sup>; and effects on microvascular complications and cardiovascular disease and risk factors for these conditions.</div></section><section id="sec-1-5"><h3>Statistical Analysis</h3><div role="paragraph">The analyses were conducted in accordance with the intention-to-treat principle. We estimated that a sample of 5000 participants, with an assumed hazard rate of 0.0875 per year for the primary outcome, would provide the trial with 90% power, corrected for six pairwise tests at the 0.05 level, to detect a 25% reduction in the risk of treatment failure among the groups. Kaplan–Meier plots were used to capture the cumulative incidence of outcomes according to the time from randomization to the visit at which an event was first reported and subsequently confirmed. We used a Cox proportional-hazards model to assess differences among the treatment groups, and the results are described with hazard ratios and robust confidence limits.<sup><a href="#core-r14" role="doc-biblioref" data-xml-rid="r14" id="body-ref-r14" href-manipulated="true" aria-label="Reference 14">14</a></sup> Differences in the outcomes were also reported as the restricted mean survival time,<sup><a href="#core-r15" role="doc-biblioref" data-xml-rid="r15" id="body-ref-r15" href-manipulated="true" aria-label="Reference 15">15</a></sup> or time to event, over 4 years of follow-up (when 85.8% of the trial cohort was followed). Additional analyses compared each treatment group with the other three combined with the use of hazard ratios and confidence intervals.<sup><a href="#core-r16" role="doc-biblioref" data-xml-rid="r16" id="body-ref-r16-1" href-manipulated="true" aria-label="Reference 16">16</a></sup></div><div role="paragraph">For the primary outcome, a global log-rank test was used to test for any differences among the four groups, and additional tests were used to assess pairwise differences between groups. The closed-testing procedure provided protected P values for the six pairwise comparisons<sup><a href="#core-r17" role="doc-biblioref" data-xml-rid="r17" id="body-ref-r17" href-manipulated="true" aria-label="Reference 17">17</a></sup> and for the comparison of each treatment group with the other three combined.<sup><a href="#core-r16" role="doc-biblioref" data-xml-rid="r16" id="body-ref-r16-2" href-manipulated="true" aria-label="Reference 16">16</a></sup> The results of all other analyses were expressed as hazard ratios, estimates of effects (risk reductions), or mean values, all with accompanying 95% confidence intervals, or as simple percentages. The widths of the confidence intervals have not been adjusted for multiple testing, and any inferences drawn may not be reproducible; therefore, P values are not reported.</div><div role="paragraph">Prespecified subgroup analyses included baseline factors as categories (age &lt;45, 45 to 59, and ≥60 years; sex; and race or ethnic group) or strata in thirds (body-mass index [BMI; the weight in kilograms divided by the square of the height in meters], duration of diabetes, and glycated hemoglobin levels). Sensitivity analyses were conducted to assess the effect of coronavirus disease 2019 (Covid-19) and adherence to trial medications (“per-protocol analysis”). Details are provided in Figures S2 and S3.</div></section></section><section id="sec-2" data-type="results"><h2>Results</h2><section id="sec-2-1"><h3>Baseline Characteristics of the Participants</h3><div role="paragraph">The first participant underwent randomization in July 2013, and the last participant underwent randomization in August 2017 (Fig. S4). The baseline characteristics of the 5047 participants, which were reported previously<sup><a href="#core-r18" role="doc-biblioref" data-xml-rid="r18" id="body-ref-r18" href-manipulated="true" aria-label="Reference 18">18</a></sup> and are shown in Table S1, included a mean (±SD) age of 57.2±10.0 years. A total of 63.6% were men, which reflected the inclusion of 10 Veterans Affairs medical centers as trial sites, and 41.5% of the participants were at least 60 years of age. A total of 65.7% of the participants identified as White, 19.8% as Black, and 3.6% as Asian. Ethnic group was also reported by the participants: 18.6% identified as Hispanic or Latinx, 2.7% as American Indian or Alaska Native, and 0.6% as Native Hawaiian or Pacific Islander.</div><div role="paragraph">The mean duration of diabetes as reported by the participants was 4.2±2.7 years. The daily metformin dose was 1576±525 mg at initial screening and 1944±205 mg at randomization, and 92.3% of the participants received 2000 mg per day. The mean BMI was 34.3±6.8, and the mean glycated hemoglobin level was 7.5±0.5% (58.3±5.3 mmol per mole). There were no substantial differences in any baseline demographic characteristic or findings on physical examinations or laboratory measurements among the four treatment groups. The baseline characteristics of the recruited cohort resembled those in the U.S. population who had type 2 diabetes that was being treated with metformin, who were of a similar age, and who had a similar duration of diabetes and a similar glycated hemoglobin range (Table S2).</div></section><section id="sec-2-2"><h3>Participant Retention and Adherence to Trial Visits and Assigned Medications</h3><div role="paragraph">At the end of the trial in April 2021, the mean duration of follow-up was 5.0 years (range, 0 to 7.6), and 85.8% of the participants had been followed for at least 4 years. Retention and adherence were high; 94% of the participants completed a final visit, and they adhered to a mean of 92% of their expected trial visits (<a href="#t1">Table 1</a>). A total of 27 of 5047 participants (0.5%) were lost to follow-up, and 153 died during the trial. During the Covid-19 pandemic, which overlapped with the trial closeout period, many visits were conducted by telephone and data on the glycated hemoglobin level were collected with the use of a validated mail-in kit.<sup><a href="#core-r19" role="doc-biblioref" data-xml-rid="r19" id="body-ref-r19" href-manipulated="true" aria-label="Reference 19">19</a></sup> As a result, 89% of all expected visits were completed during the final year of the trial (May 1, 2020, through April 30, 2021).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 1</div><nav><a href="#t1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2200433_t1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t1" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2200433_t1.jpg"><img src="/cms/10.1056/NEJMoa2200433/asset/a955355f-bebd-41c2-93da-0189071e72e4/assets/images/large/nejmoa2200433_t1.jpg" height="1981" width="1999" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Variable</th><th class="txxx-borders">Glargine<br> (N=1263)</th><th class="txxx-borders">Glimepiride<br> (N=1254)</th><th class="txxx-borders">Liraglutide<br> (N=1262)</th><th class="txxr-borders">Sitagliptin<br> (N=1268)</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Retention — no./total no. (%)<a href="#t1fn1" role="doc-noteref">*</a></td><td class="xxxx-borders shading">1138/1221 (93.2)</td><td class="xxxx-borders shading">1142/1211 (94.3)</td><td class="xxxx-borders shading">1156/1235 (93.6)</td><td class="xxxr-borders shading">1144/1227 (93.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Overall adherence to trial visits — %<a href="#t1fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">91.4</td><td class="xxxx-borders">92.9</td><td class="xxxx-borders">92.3</td><td class="xxxr-borders">92.8</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Mean follow-up — yr<a href="#t1fn3" role="doc-noteref">‡</a><a href="#t1fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">4.9±1.4</td><td class="xxxx-borders shading">5.0±1.3</td><td class="xxxx-borders shading">5.0±1.3</td><td class="xxxr-borders shading">5.0±1.3</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Discontinuation of metformin — no. (%)</td><td class="xxxx-borders">105 (8.3)</td><td class="xxxx-borders">98 (7.8)</td><td class="xxxx-borders">88 (7.0)</td><td class="xxxr-borders">97 (7.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Use of nontrial, glucose-lowering medications outside the protocol, discontinuation of assigned trial treatment outside the protocol, or both — no. (%)<a href="#t1fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders shading">332 (26.3)</td><td class="xxxx-borders shading">426 (34.0)</td><td class="xxxx-borders shading">368 (29.2)</td><td class="xxxr-borders shading">347 (27.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">&lt;1 yr after randomization</td><td class="xxxx-borders">65 (5.1)</td><td class="xxxx-borders">61 (4.9)</td><td class="xxxx-borders">150 (11.9)</td><td class="xxxr-borders">60 (4.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">1 to &lt;2 yr after randomization</td><td class="xxxx-borders shading">51 (4.0)</td><td class="xxxx-borders shading">65 (5.2)</td><td class="xxxx-borders shading">51 (4.0)</td><td class="xxxr-borders shading">60 (4.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">≥2 yr after randomization</td><td class="xxxx-borders">216 (17.1)</td><td class="xxxx-borders">300 (23.9)</td><td class="xxxx-borders">167 (13.2)</td><td class="xxxr-borders">227 (17.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Duration of assigned trial treatment in accordance with the protocol — yr<a href="#t1fn4" role="doc-noteref">§</a><a href="#t1fn5" role="doc-noteref">¶</a><a href="#t1fn6" role="doc-noteref">‖</a></td><td class="xxxx-borders shading">4.3±1.8</td><td class="xxxx-borders shading">4.2±1.7</td><td class="xxxx-borders shading">4.1±2.0</td><td class="xxxr-borders shading">4.3±1.7</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Percentage of trial time during which participant received originally assigned treatment in accordance with the protocol <a href="#t1fn4" role="doc-noteref">§</a><a href="#t1fn5" role="doc-noteref">¶</a><a href="#t1fn6" role="doc-noteref">‖</a><a href="#t1fn7" role="doc-noteref">**</a></td><td class="xxxx-borders">83.7±28.9</td><td class="xxxx-borders">82.0±28.7</td><td class="xxxx-borders">79.1±34.6</td><td class="xxxr-borders">84.0±27.7</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Discontinuation of assigned trial treatment outside the protocol — no. (%)<a href="#t1fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders shading">172 (13.6)</td><td class="xxxx-borders shading">294 (23.4)</td><td class="xxxx-borders shading">289 (22.9)</td><td class="xxxr-borders shading">236 (18.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Maximum dose of assigned treatment received<a href="#t1fn8" role="doc-noteref">††</a><a href="#t1fn9" role="doc-noteref">‡‡</a></td><td class="xxxx-borders">51.4±39.7 U</td><td class="xxxx-borders">5.4±2.8 mg</td><td class="xxxx-borders">1.6±0.5 mg</td><td class="xxxr-borders">98.4±12.2 mg</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging02 shading" data-xml-align="left">Use of nontrial glucose-lowering medication outside the protocol — no. (%)</td><td class="xbxx-borders shading">176 (13.9)</td><td class="xbxx-borders shading">208 (16.6)</td><td class="xbxx-borders shading">136 (10.8)</td><td class="xbxr-borders shading">193 (15.2)</td></tr></tbody></table></div><figcaption><div class="caption">Protocol Completion and Adherence in the Treatment Groups during the Trial.</div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t1fn1" role="paragraph">Retention was defined as completion of the trial closeout visit. The denominators in this row sum to 4894 (i.e., participants who were not known to have died before the end of the trial).</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t1fn2" role="paragraph">Visit adherence was calculated for each participant as 100% multiplied by the number of trial visits attended, divided by the maximum number of trial visits according to either the expected closeout trial visit date in participants who survived to the end of the trial or the date of death.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t1fn3" role="paragraph">The duration of follow-up was calculated as the date of last trial contact minus the date of randomization.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="t1fn4" role="paragraph">Plus–minus values are means ±SE.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="t1fn5" role="paragraph">Participants were considered to have received assigned treatment if treatment was discontinued in accordance with the trial protocol (e.g., the randomized medication was discontinued because the participant had a tertiary outcome event, as stated in the protocol).</div></div><div role="doc-footnote" data-has="label"><div class="label">‖</div><div id="t1fn6" role="paragraph">The duration shown is the time from randomization to the date of first discontinuation of trial treatment, use of nontrial glucose-lowering medication, or both in participants who discontinued trial treatment, used nontrial glucose-lowering medication during the trial, or both, or the time from randomization to the date of the last trial contact in those who did not discontinue trial treatment, did not use nontrial glucose-lowering medication during the trial, or both.</div></div><div role="doc-footnote" data-has="label"><div class="label">**</div><div id="t1fn7" role="paragraph">The denominator for this percentage is the time from randomization to expected closeout visit date in participants who survived to the end of the trial, or the time from randomization to death, calculated for each participant.</div></div><div role="doc-footnote" data-has="label"><div class="label">††</div><div id="t1fn8" role="paragraph">Shown is the mean maximum dose of randomly assigned medication taken at any time during the trial.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡‡</div><div id="t1fn9" role="paragraph">Plus–minus values are means ±SD.</div></div></div></figcaption></figure></div><div role="paragraph">No differences were observed across the four treatment groups with respect to the retention of participants or adherence to trial visits (<a href="#t1">Table 1</a>). Slight differences were observed with respect to metformin use, with 8% of the participants overall discontinuing metformin during study follow-up. There were differences in adherence to randomly assigned medications, with a higher frequency of discontinuation in the glimepiride and liraglutide groups (23% of the participants in each group) than in the sitagliptin (19%) and glargine (14%) groups. In the liraglutide and sitagliptin groups, most participants received the maximum doses of their assigned treatment; the mean daily maximum doses in the glimepiride and glargine groups were 5.4 mg and 51.4 U, respectively (<a href="#t1">Table 1</a> and Table S3). The percentage of participants who received nontrial glucose-lowering medications was highest in the glimepiride group (17%) and the sitagliptin group (15%), with less use of nontrial glucose-lowering medications in the liraglutide (11%) and glargine (14%) groups (Table S4).</div></section><section id="sec-2-3"><h3>Efficacy</h3><div role="paragraph"><a href="#t2">Table 2</a> shows the numbers of participants in each treatment group with a glycated hemoglobin level of 7.0% or higher (the primary metabolic outcome), a glycated hemoglobin level greater than 7.5% (the secondary metabolic outcome), and the corresponding rates, as well as the pairwise hazard ratios among the treatment groups, hazard ratios for each treatment as compared with the other treatments combined, and the restricted mean survival time (time to event). Details regarding the tertiary-outcome results are provided in Table S5.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 2</div><nav><a href="#t2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2200433_t2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t2" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2200433_t2.jpg"><img src="/cms/10.1056/NEJMoa2200433/asset/b69a9b69-54d4-4433-bfb8-1acdd85fab7f/assets/images/large/nejmoa2200433_t2.jpg" height="2269" width="1999" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Outcome</th><th class="txxx-borders">Glargine<br> (N=1263)</th><th class="txxx-borders">Glimepiride<br> (N=1254)</th><th class="txxx-borders">Liraglutide<br> (N=1262)</th><th class="txxr-borders">Sitagliptin<br> (N=1268)</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Primary metabolic outcome<a href="#t2fn2" role="doc-noteref">†</a></b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Participants — no. (%)</td><td class="xxxx-borders">852 (67.4)</td><td class="xxxx-borders">908 (72.4)</td><td class="xxxx-borders">860 (68.2)</td><td class="xxxr-borders">981 (77.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Rate/100 participant-yr (95% CI)</td><td class="xxxx-borders shading">26.5<br>(24.8–28.4)</td><td class="xxxx-borders shading">30.4<br>(28.4–32.4)</td><td class="xxxx-borders shading">26.1<br>(24.4–27.9)</td><td class="xxxr-borders shading">38.1<br>(35.8–40.6)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Pairwise hazard ratios (95% CI)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Glargine</td><td class="xxxx-borders shading">—</td><td class="xxxx-borders shading">0.89<br>(0.81–0.98)<a href="#t2fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">1.02<br>(0.93–1.12)</td><td class="xxxr-borders shading">0.71<br>(0.64–0.78)<a href="#t2fn4" role="doc-noteref">§</a></td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Glimepiride</td><td class="xxxx-borders">—</td><td class="xxxx-borders">—</td><td class="xxxx-borders">1.15<br>(1.04–1.27)<a href="#t2fn5" role="doc-noteref">¶</a></td><td class="xxxr-borders">0.79<br>(0.72–0.88)<a href="#t2fn4" role="doc-noteref">§</a></td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Liraglutide</td><td class="xxxx-borders shading">—</td><td class="xxxx-borders shading">—</td><td class="xxxx-borders shading">—</td><td class="xxxr-borders shading">0.69<br>(0.63–0.76)<a href="#t2fn4" role="doc-noteref">§</a></td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Hazard ratio in the treatment group as compared with all other treatments combined (95% CI)</td><td class="xxxx-borders">0.87<br>(0.80–0.94)<a href="#t2fn4" role="doc-noteref">§</a></td><td class="xxxx-borders">1.01<br>(0.93–1.09)</td><td class="xxxx-borders">0.84<br>(0.78–0.91)<a href="#t2fn4" role="doc-noteref">§</a></td><td class="xxxr-borders">1.37<br>(1.27–1.48)<a href="#t2fn4" role="doc-noteref">§</a></td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Restricted mean survival time over 4 yr of follow-up (95% CI) — days</td><td class="xxxx-borders shading">861<br>(831–891)</td><td class="xxxx-borders shading">809<br>(780–838)</td><td class="xxxx-borders shading">882<br>(853–911)</td><td class="xxxr-borders shading">697<br>(667–726)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02"><b>Secondary metabolic outcome<a href="#t2fn6" role="doc-noteref">‖</a></b></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Participants — no. (%)</td><td class="xxxx-borders shading">498 (39.4)</td><td class="xxxx-borders shading">633 (50.5)</td><td class="xxxx-borders shading">583 (46.2)</td><td class="xxxr-borders shading">697 (55.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Rate/100 participant-yr (95% CI)</td><td class="xxxx-borders">10.7<br>(9.8–11.7)</td><td class="xxxx-borders">14.8<br>(13.6–16.0)</td><td class="xxxx-borders">13.0<br>(12.0–14.1)</td><td class="xxxr-borders">17.5<br>(16.3–18.9)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Pairwise hazard ratios (95% CI)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Glargine</td><td class="xxxx-borders">—</td><td class="xxxx-borders">0.73<br>(0.65–0.82)</td><td class="xxxx-borders">0.83<br>(0.73–0.93)</td><td class="xxxr-borders">0.61<br>(0.54–0.69)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Glimepiride</td><td class="xxxx-borders shading">—</td><td class="xxxx-borders shading">—</td><td class="xxxx-borders shading">1.13<br>(1.01–1.27)</td><td class="xxxr-borders shading">0.84<br>(0.75–0.93)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Liraglutide</td><td class="xxxx-borders">—</td><td class="xxxx-borders">—</td><td class="xxxx-borders">—</td><td class="xxxr-borders">0.74<br>(0.66–0.83)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Hazard ratio in the treatment group as compared with all other treatments combined (95% CI)</td><td class="xxxx-borders shading">0.72<br>(0.65–0.79)</td><td class="xxxx-borders shading">1.09<br>(1.00–1.20)</td><td class="xxxx-borders shading">0.92<br>(0.84–1.01)</td><td class="xxxr-borders shading">1.38<br>(1.26–1.51)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging02" data-xml-align="left">Restricted mean survival time over 4 yr of follow-up (95% CI) — days</td><td class="xbxx-borders">1188<br>(1163–1212)</td><td class="xbxx-borders">1115<br>(1090–1141)</td><td class="xbxx-borders">1154<br>(1129–1179)</td><td class="xbxr-borders">1030<br>(1002–1058)</td></tr></tbody></table></div><figcaption><div class="caption">Primary and Secondary Metabolic Outcomes.<a href="#t2fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t2fn1" role="paragraph">Shown are the numbers of participants with primary and secondary metabolic outcome events according to randomized treatment group (intention-to-treat) with overall rates and hazard ratios. Calculations for the tertiary outcome are provided in Table S5. CI denotes confidence interval.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t2fn2" role="paragraph">For the primary outcome, P values were obtained from closed testing of pairwise group differences corrected for six pairwise comparisons. Confidence limits corrected for six pairwise tests were obtained by inverting the closed-testing z-test value and then computing corrected 95% confidence intervals. P&lt;0.001 from a test of the log hazard ratios for treatment failure among the four treatment groups, with the use of a Cox proportional-hazards model, with treatment group as the only predictor variable.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t2fn3" role="paragraph">P≤0.05 for the specified comparison of two treatment groups.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="t2fn4" role="paragraph">P≤0.001 for the specified comparison of two treatment groups.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="t2fn5" role="paragraph">P≤0.01 for the specified comparison of two treatment groups.</div></div><div role="doc-footnote" data-has="label"><div class="label">‖</div><div id="t2fn6" role="paragraph">For the secondary outcome, confidence intervals obtained from the Cox proportional-hazards model are not corrected for multiple comparisons among groups.</div></div></div></figcaption></figure></div><div role="paragraph"><a id="exam-tint-one-b"></a><span id="tint1" class="named-content" data-type="exam-tint" data-answer-ids="one-b">Over the mean 5-year follow-up, 71% of the cohort had a primary metabolic outcome event, with the highest frequency in the sitagliptin group (77%), intermediate frequency in the glimepiride group (72%), and the lowest frequency in the liraglutide (68%) and glargine (67%) groups (<a href="#t2">Table 2</a>).</span> The between-group differences in the Kaplan–Meier estimates of the cumulative incidence of a primary-outcome event were significant (P&lt;0.001 by the log-rank test) (<a href="#f1">Figure 1A</a>). During the first year of the trial, 55% of the participants in the sitagliptin group had a primary metabolic outcome event, as compared with fewer than 40% in the other groups. The differences in cumulative incidences over the first 4 years of the trial translated into 697 mean days to a primary metabolic outcome event in the sitagliptin group and 809, 861, and 882 days in the glimepiride, glargine, and liraglutide groups, respectively.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 1</div><nav><a href="#f1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2200433_f1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f1" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2200433_f1.jpg"><img src="/cms/10.1056/NEJMoa2200433/asset/e7658d51-44ad-4465-b469-597495771f3b/assets/images/large/nejmoa2200433_f1.jpg" height="2248" width="2640" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Kaplan–Meier Analysis of Outcome Events and Mean Glycated Hemoglobin Levels.</div><div class="notes"><div role="doc-footnote">Shown are the cumulative incidences of a glycated hemoglobin level of 7.0% or higher (the primary metabolic outcome) (Panel A), a glycated hemoglobin level of greater than 7.5% (the secondary metabolic outcome) (Panel B), and a confirmed glycated hemoglobin level greater than 7.5% after the secondary outcome (the tertiary metabolic outcome) (Panel C), as well as the mean glycated hemoglobin levels (Panel D). In Panels A through C, the shaded bars along the x axis indicate the number of participants with data available for the analyses over time (i.e., the number of participants in whom a specified outcome event had not developed by that time). The vertical dashed lines indicate the results at 4 years, when 85.8% of the participants were undergoing follow-up. To convert values for glycated hemoglobin to millimoles per mole, multiply by 10.93 and then subtract 23.5.</div></div></figcaption></figure></div><div role="paragraph"><a id="exam-tint-one-a"></a><a id="exam-tint-one-c"></a><a id="exam-tint-one-d"></a><span id="tint2" class="named-content" data-type="exam-tint" data-answer-ids="one-a one-c one-d">The six pairwise comparisons among the groups (<a href="#t2">Table 2</a>) showed that the risk of a primary-outcome event was significantly lower with glargine than with sitagliptin (hazard ratio, 0.71, or a 29% risk reduction) and than with glimepiride (0.89, or an 11% risk reduction), with P values of less than or equal to 0.001 and 0.02, respectively, protected with the use of a closed testing procedure. The difference between the glargine and liraglutide groups was not significant. The risk of a primary-outcome event was 41% higher in the sitagliptin group than in the glargine group (hazard ratio in the sitagliptin group as compared with the glargine group, 1.41, which was obtained by inverting the hazard ratio in the glargine group as compared with the sitagliptin group [0.71]), 45% higher than in the liraglutide group, and 26% higher than in the glimepiride group (P≤0.001 for all comparisons) (<a href="#t2">Table 2</a>). The glimepiride group had a significantly lower risk of a primary-outcome event than the sitagliptin group and a higher risk than the glargine and liraglutide groups.</span></div><div role="paragraph">The rates of secondary-outcome events (<a href="#t2">Table 2</a>) and tertiary-outcome events followed a pattern that was similar to that for the primary outcome, with lower rates in the glargine and liraglutide groups, an intermediate rate in the glimepiride group, and the highest rate in the sitagliptin group. The Kaplan–Meier analyses of the cumulative incidences of the secondary-outcome events (<a href="#f1">Figure 1B</a>) and tertiary-outcome events (<a href="#f1">Figure 1C</a>) also resembled those of the primary-outcome events. A secondary-outcome event occurred in 55% of the participants in the sitagliptin group over a mean follow-up of 5 years, followed by glimepiride (in 50%), liraglutide (in 46%), and glargine (in 39%). The percentage of participants with a tertiary-outcome event increased slowly after the first year, reaching 27% at 4 years (<a href="#f1">Figure 1C</a>), with small differences among the groups and with the highest risk of a tertiary-outcome event in the glimepiride and sitagliptin groups and slightly lower risks in the glargine and liraglutide groups.</div><div role="paragraph">The mean glycated hemoglobin levels reached a nadir at 6 months in the glargine group and at 3 months in the other groups, with subsequent increases thereafter (<a href="#f1">Figure 1D</a>). At year 4, the absolute differences were small (Fig. S5), with mean glycated hemoglobin levels of 7.1% in the glargine and liraglutide groups as compared with 7.2% in the sitagliptin group and 7.3% in the glimepiride group.</div></section><section id="sec-2-4"><h3>Subgroup Analyses</h3><div role="paragraph">Prespecified subgroup analyses were performed to identify potential heterogeneity of the effects of the interventions. Table S6 describes the incidences of the primary and secondary metabolic outcome events in the treatment groups within subgroups. The risk of a primary-outcome event appeared to differ (increase) among the groups according to the increasing strata of baseline glycated hemoglobin level (<a href="#f2">Figure 2</a>). Even among participants in the lowest third of baseline glycated hemoglobin levels (6.8 to 7.2% [50.8 to 55.2 mmol per mole]), a glycated hemoglobin level of less than 7.0% was not achieved or maintained in approximately 60%.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 2</div><nav><a href="#f2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2200433_f2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f2" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2200433_f2.jpg"><img src="/cms/10.1056/NEJMoa2200433/asset/fbab790c-6212-4917-a0d2-b83d3dbf7ab6/assets/images/large/nejmoa2200433_f2.jpg" height="1169" width="2640" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">Analyses of the Primary Outcome According to Baseline Glycated Hemoglobin Levels.</div><div class="notes"><div role="doc-footnote">The risk reductions, calculated from the hazard ratios, with glargine, glimepiride, and liraglutide, as compared with sitagliptin, are shown with unadjusted 95% confidence intervals. To convert values for glycated hemoglobin to millimoles per mole, multiply by 10.93 and then subtract 23.5.</div></div></figcaption></figure></div><div role="paragraph">The hazard ratio in the glargine group as compared with the sitagliptin group differed among the strata of glycated hemoglobin levels. The risk reductions with glargine increased among participants from the lower to highest strata of baseline glycated hemoglobin levels, from 17% (95% confidence interval [CI], 3 to 29) to 32% (95% CI, 19 to 42) to 46% (95% CI, 36 to 55). In participants with higher baseline glycated hemoglobin levels, sitagliptin was progressively less effective than the other three medications in maintaining or achieving a glycated hemoglobin level of less than 7.0%. In each glycated hemoglobin stratum, the risk of treatment failure with sitagliptin increased at a rate that was faster than that in the other groups as the glycated hemoglobin level increased. There was no suggestion of heterogeneity among the subgroups with respect to the secondary outcome.</div></section><section id="sec-2-5"><h3>Sensitivity Analyses</h3><div role="paragraph">Results based on trial data from before the Covid-19 pandemic period (i.e., before March 15, 2020) showed that Covid-19 had no effect on the trial results as compared with the entire trial period. The results of per-protocol analyses, excluding data collected after the first instance of discontinuation of a trial medication (except for discontinuation in accordance with the protocol after a tertiary-outcome event) or initiation of a nontrial glucose-lowering medication, were similar to those in the intention-to-treat analyses with respect to the primary and secondary metabolic outcomes.</div></section><section id="sec-2-6"><h3>Serious and Targeted Adverse Events and Effects on Weight</h3><div role="paragraph">Data on serious adverse events and prespecified targeted adverse events are provided in <a href="#f3">Figure 3</a>. <a id="exam-tint-three-a"></a><a id="exam-tint-three-b"></a><a id="exam-tint-three-c"></a><a id="exam-tint-three-d"></a><span id="tint3" class="named-content" data-type="exam-tint" data-answer-ids="three-a three-b three-c three-d">The glimepiride and glargine groups had a significantly higher overall incidence of any adverse event (serious adverse events and prespecified adverse events) (in 38% and 37% of the participants, respectively) than the liraglutide group (in 34%) (uncorrected P=0.001 and P=0.02, respectively). Severe hypoglycemia was generally uncommon, but it affected more participants assigned to glimepiride (2.2%) than to sitagliptin (0.7%) (P≤0.001), liraglutide (1.0%) (P≤0.001), or glargine (1.3%) (P=0.02). There were no substantial differences among the treatment groups with respect to other targeted outcomes, including pancreatitis and pancreatic cancer (data not shown). Gastrointestinal symptoms were considerably more common with liraglutide than with the other three treatments. Over 4 years, the mean loss of weight was substantially higher in the liraglutide and sitagliptin groups (3.5 and 2.0 kg, respectively) than in the glargine and glimepiride groups (0.61 and 0.73 kg, respectively).</span></div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 3</div><nav><a href="#f3" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2200433_f3.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f3" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f3" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2200433_f3.jpg"><img src="/cms/10.1056/NEJMoa2200433/asset/1e05f48b-dd75-4aff-b516-ce26e8f66724/assets/images/large/nejmoa2200433_f3.jpg" height="1668" width="2640" aria-labelledby="f3" loading="lazy"></a><figcaption><div class="caption">Overall Incidence of Adverse Events.</div><div class="notes"><div role="doc-footnote">Event rates were calculated as the number of events per 100 participant-years. Simple P values (not corrected for multiple tests among event types or treatment groups) were obtained from a Poisson regression model of the rates. The diagram denotes the range of the P values for the six pairwise group comparisons of each adverse event. The following were adjudicated events: serious adverse events or any targeted events, including severe hypoglycemia, lactic acidosis, pancreatitis, diabetic ketoacidosis or hyperosmolar hyperglycemic syndrome, revascularization (coronary, peripheral, or cerebral), congestive heart failure, or cancer. The first occurrence of weight gain of 10% or more was compared with the baseline weight. Gastrointestinal symptoms included any one of the following symptoms that occurred at least once per week in the 30 days before the quarterly visit and were reported by the participant: nausea, vomiting, bloating or stomach pain, or diarrhea.</div></div></figcaption></figure></div></section></section><section id="sec-3" data-type="discussion"><h2>Discussion</h2><div role="paragraph"><span id="tint4" class="named-content" data-type="exam-tint" data-answer-ids="one-d">The overall results of the current trial highlight the difficulty in achieving and maintaining recommended glycated hemoglobin levels in participants with type 2 diabetes.</span> In this diverse trial cohort, which included participants who were representative of those in the U.S. population who had metformin-treated type 2 diabetes of brief duration, the mean baseline glycated hemoglobin level was 7.5% (range, 6.8 to 8.5). During the mean 5-year follow-up, the target glycated hemoglobin level of less than 7.0% was not reached or maintained in 71% of the participants who received approximately 2000 mg of metformin per day plus one of four commonly used glucose-lowering medications. Even among participants with an initial glycated hemoglobin level of 6.8 to 7.2%, a glycated hemoglobin level of less than 7.0% was not maintained in approximately 60% of the participants over the 5-year follow-up. Although a glycated hemoglobin level of less than 7.0% was not achieved and maintained in most participants, the mean glycated hemoglobin levels did decrease in all the treatment groups over the course of the trial, and at the end of the trial these levels were approximately 0.3 percentage points lower than baseline levels.</div><div role="paragraph">The comparison of the trial medications revealed differences in efficacy and adverse effects. All four medications had an acceptable safety profile, as expected with FDA-approved medications. However, glargine and liraglutide were more effective at maintaining glycated hemoglobin levels in the target range over time. This translated into a glycated hemoglobin level of less than 7.0% for approximately a half year longer with glargine and liraglutide than with sitagliptin, which was the least effective treatment in maintaining target glycated hemoglobin levels. <a id="exam-tint-two-a"></a><a id="exam-tint-two-b"></a><a id="exam-tint-two-c"></a><a id="exam-tint-two-d"></a><span id="tint5" class="named-content" data-type="exam-tint" data-answer-ids="two-a two-b two-c two-d">Glargine was most effective in maintaining the glycated hemoglobin level at 7.5% or lower, with only 39% of the participants having a glycated hemoglobin level greater than 7.5% (a secondary metabolic outcome event).</span></div><div role="paragraph">The diverse trial cohort lent itself to comparisons among subgroups, including across race and ethnic groups for which there are disparities in diabetes care and outcomes.<sup><a href="#core-r20" role="doc-biblioref" data-xml-rid="r20 r21" id="body-ref-r21" href-manipulated="true">20,21</a></sup> All the participants had similar access to care and to medications for diabetes, which were provided at no cost to the participants, with no major differences in response to the treatments across any of the demographic subgroups with respect to the primary outcome. The only notable difference in the primary metabolic outcome according to baseline factors was observed in the analysis of three strata of glycated hemoglobin levels; participants with higher baseline glycated hemoglobin levels at baseline had progressively worse metabolic outcomes with sitagliptin than with the other treatments.</div><div role="paragraph">There were notable differences in other effects of the four medications. Although the overall incidence of severe hypoglycemia was low, glimepiride was associated with the highest incidence, followed by glargine. Participants who received liraglutide and sitagliptin had a mean weight loss of 3.5 kg and 2.0 kg, respectively, at 4 years, whereas the insulin and glimepiride groups had relatively stable weight. As expected,<sup><a href="#core-r22" role="doc-biblioref" data-xml-rid="r22" id="body-ref-r22" href-manipulated="true" aria-label="Reference 22">22</a></sup> participants in the liraglutide group reported the highest frequency of gastrointestinal side effects.</div><div role="paragraph">The strengths of the current trial include its design as a comparative-effectiveness trial that used approved medications according to labeling, as well as its large size, diverse population, and long duration. The only other comparative-effectiveness trial of similar scale involving participants with type 2 diabetes was ADOPT (A Diabetes Outcome Progression Trial),<sup><a href="#core-r23" role="doc-biblioref" data-xml-rid="r23" id="body-ref-r23" href-manipulated="true" aria-label="Reference 23">23</a></sup> which compared three monotherapies in participants with recent-onset type 2 diabetes. In clinical practice, metabolic goals are often individualized. Considering the generally young age of the participants, the short duration of diabetes, and the low prevalence of coexisting conditions, we think that the unitary glycated hemoglobin goal used in this trial was clinically appropriate.</div><div role="paragraph">A limitation of our trial is the exclusion of thiazolidinediones and the SGLT2 inhibitor class of glucose-lowering medications, owing to safety concerns at the time of planning and the timing of FDA approval, respectively. Although the selection of single agents within the four medication classes facilitated the conduct of the trial, this selection limited extrapolation of the current results to other medications within the classes. The trial was unblinded for practical reasons; however, the metabolic outcomes were measured routinely and objectively in all the participants, reducing any potential bias of ascertainment. Finally, medication adjustments were carried out frequently in accordance with the protocol, a practice that may not reflect the slow rate of medication adjustments in the clinical setting.<sup><a href="#core-r24" role="doc-biblioref" data-xml-rid="r24" id="body-ref-r24" href-manipulated="true" aria-label="Reference 24">24</a></sup></div><div role="paragraph">The major implication of the current trial is that maintenance of target glycated hemoglobin levels is challenging, even in a clinical trial in which all care is provided free of charge. The data highlight the need for more effective interventions for long-term control of glycemia in persons with type 2 diabetes. Comparative-effectiveness studies are rarely performed by industry. Our trial presents a clear and objective comparison of the advantages and disadvantages of four commonly used glucose-lowering medications, added to metformin, and these findings should help guide the choice of medications used in the treatment of type 2 diabetes. These results can form the basis of shared decision making between providers and patients in selecting the medication to add to metformin. Sitagliptin had less efficacy and durability than the other medications, particularly at higher baseline strata of glycated hemoglobin, and these findings as well as the different adverse-event profiles should be considered along with other clinical benefits and costs in selecting medications used to manage hyperglycemia in persons with type 2 diabetes.</div><div role="paragraph">All four medications (glargine, glimepiride, liraglutide, and sitagliptin) improved glycated hemoglobin levels when added to metformin. However, glargine and liraglutide were significantly, albeit modestly, more effective in achieving and maintaining target glycated hemoglobin levels.</div></section>



        
        
</div></section><section id="backmatter" data-extent="backmatter" data-location="articleTab_article"><div class="core-container"><section id="backnotes" data-location="notes_article"><h2>Notes</h2><div data-type="writing-committee" role="paragraph">The members of the writing committee (David M. Nathan, M.D., John M. Lachin, Sc.D., Ashok Balasubramanyam, M.D., Henry B. Burch, M.D., John B. Buse, M.D., Nicole M. Butera, Ph.D., Robert M. Cohen, M.D., Jill P. Crandall, M.D., Steven E. Kahn, M.B., Ch.B., Heidi Krause-Steinrauf, M.S., Mary E. Larkin, R.N., Neda Rasouli, M.D., Margaret Tiktin, D.N.P., Deborah J. Wexler, M.D., and Naji Younes, Ph.D.) assume responsibility for the overall content and integrity of this article.</div><div data-type="disclaimer" role="paragraph">The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.</div><div data-type="data-sharing" role="paragraph">A <a href="#ap4">data sharing statement</a> provided by the authors is available with the full text of this article at NEJM.org.</div><div role="paragraph">Supported by a grant (U01DK098246) from the <span class="named-content" data-type="funder">National Institute of Diabetes and Digestive and Kidney Diseases</span> (NIDDK) of the National Institutes of Health (NIH); a U34 planning grant (U34-DK-088043) for the planning of the trial from the NIDDK; funding for the initial planning meeting regarding the U34 proposal from the <span class="named-content" data-type="funder">American Diabetes Association</span>; the <span class="named-content" data-type="funder">National Heart, Lung, and Blood Institute</span>; the <span class="named-content" data-type="funder">Centers for Disease Control and Prevention</span>; resources and facilities from the Department of Veterans Affairs; grants (P30 DK017047, P30 DK020541-44, P30 DK020572, P30 DK072476, P30 DK079626, P30 DK092926, U54 GM104940, UL1 TR000170, UL1 TR000439, UL1 TR000445, UL1 TR001102, UL1 TR001108, UL1 TR001409, 2UL1TR001425, UL1 TR001449, UL1 TR002243, UL1 TR002345, UL1 TR002378, UL1 TR002489, UL1 TR002529, UL1 TR002535, UL1 TR002537, UL1 TR002541, and UL1 TR002548) from the NIH; educational materials from the National Diabetes Education Program; and donated medications and supplies from Becton Dickinson, Bristol Myers Squibb, Merck, Novo Nordisk, Roche Diagnostics, and Sanofi.</div><div role="paragraph"><a href="#ap3">Disclosure forms</a> provided by the authors are available with the full text of this article at NEJM.org.</div><div role="paragraph">We thank the participants, whose loyal dedication made this trial possible.</div></section><section id="supplementary-materials" class="core-supplementary-materials"><h2>Supplementary Material</h2><div role="list"><div id="ap1" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Protocol</span> <span class="core-filename">(nejmoa2200433_protocol.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2200433/suppl_file/nejmoa2200433_protocol.pdf" download="nejmoa2200433_protocol.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2200433_protocol.pdf" data-doi="10.1056/NEJMoa2200433">Download</a></li><li>26.16 MB</li></ul></div></div><div id="ap2" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Supplementary Appendix</span> <span class="core-filename">(nejmoa2200433_appendix.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2200433/suppl_file/nejmoa2200433_appendix.pdf" download="nejmoa2200433_appendix.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2200433_appendix.pdf" data-doi="10.1056/NEJMoa2200433">Download</a></li><li>648.52 KB</li></ul></div></div><div id="ap3" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Disclosure Forms</span> <span class="core-filename">(nejmoa2200433_disclosures.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2200433/suppl_file/nejmoa2200433_disclosures.pdf" download="nejmoa2200433_disclosures.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2200433_disclosures.pdf" data-doi="10.1056/NEJMoa2200433">Download</a></li><li>562.25 KB</li></ul></div></div><div id="ap4" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Data Sharing Statement</span> <span class="core-filename">(nejmoa2200433_data-sharing.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2200433/suppl_file/nejmoa2200433_data-sharing.pdf" download="nejmoa2200433_data-sharing.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2200433_data-sharing.pdf" data-doi="10.1056/NEJMoa2200433">Download</a></li><li>70.04 KB</li></ul></div></div></div></section><section id="bibliography" class="core-reference-list" role="doc-bibliography" data-location="references_article"><h2>References</h2><div role="list" data-method="clamp" id="collapsible-text"><div role="listitem" data-has="label"><div class="label">1.</div><div id="r1" class="citations"><div class="citation"><div class="citation-content">Centers for Disease Control and Prevention. National diabetes statistics report. 2020 (<a href="https://www.cdc.gov/diabetes/data/statistics-report/index.html">https://www.cdc.gov/diabetes/data/statistics-report/index.html</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r2"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=Centers+for+Disease+Control+and+Prevention.+National+diabetes+statistics+report.+2020+%28https%3A%2F%2Fwww.cdc.gov%2Fdiabetes%2Fdata%2Fstatistics-report%2Findex.html%29." target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="r2" class="citations"><div class="citation"><div class="citation-content">International Diabetes Federation. IDF diabetes atlas. 2021 (<a href="https://diabetesatlas.org/">https://diabetesatlas.org/</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r2"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=IDF+diabetes+atlas&amp;publication_year=2021" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="r3" class="citations"><div class="citation"><div class="citation-content">American Diabetes Association. Economic costs of diabetes in the U.S. in 2017. <em>Diabetes Care</em> 2018;41:917-928.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r3"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.2337/dci18-0007" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29567642/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000430456100009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Economic+costs+of+diabetes+in+the+U.S.+in+2017.&amp;publication_year=2018&amp;journal=Diabetes+Care&amp;pages=917-928&amp;doi=10.2337%2Fdci18-0007&amp;pmid=29567642" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="r4" class="citations"><div class="citation"><div class="citation-content">UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). <em>Lancet</em> 1998;352:837-853.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r5"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(98)07019-6" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/9742976/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000075857300006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Intensive+blood-glucose+control+with+sulphonylureas+or+insulin+compared+with+conventional+treatment+and+risk+of+complications+in+patients+with+type+2+diabetes+%28UKPDS+33%29.&amp;publication_year=1998&amp;journal=Lancet&amp;pages=837-853&amp;doi=10.1016%2FS0140-6736%2898%2907019-6&amp;pmid=9742976" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="r5" class="citations"><div class="citation"><div class="citation-content">Hemmingsen B, Lund SS, Gluud C, Vaag A, Almdal TP, Wetterslev J. Withdrawn: targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. <em>Cochrane Database Syst Rev</em> 2015;7:CD008143-CD008143.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r5"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26222248/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000209933300014" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Withdrawn%3A+targeting+intensive+glycaemic+control+versus+targeting+conventional+glycaemic+control+for+type+2+diabetes+mellitus.&amp;publication_year=2015&amp;journal=Cochrane+Database+Syst+Rev&amp;pages=CD008143-CD008143&amp;pmid=26222248" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="r6" class="citations"><div class="citation"><div class="citation-content">American Diabetes Association. Glycemic targets: <i>Standards of Medical Care in Diabetes</i> — 2021. <em>Diabetes Care</em> 2021;44:Suppl 1:S73-S84.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r6"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.2337/dc21-S006" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33298417/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000609468800009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Glycemic+targets%3A+Standards+of+Medical+Care+in+Diabetes+%E2%80%94+2021.&amp;publication_year=2021&amp;journal=Diabetes+Care&amp;pages=S73-S84&amp;doi=10.2337%2Fdc21-S006&amp;pmid=33298417" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="r7" class="citations"><div class="citation"><div class="citation-content">American Diabetes Association, European Association for the Study of Diabetes. Pharmacologic approaches to glycemic treatment: <i>Standards of Medical Care in Diabetes</i> — 2021. <em>Diabetes Care</em> 2020;44:Suppl 1:S111-S124.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r8"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.2337/dc21-S009" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000609468800012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Pharmacologic+approaches+to+glycemic+treatment%3A+Standards+of+Medical+Care+in+Diabetes+%E2%80%94+2021.&amp;publication_year=2020&amp;journal=Diabetes+Care&amp;pages=S111-S124&amp;doi=10.2337%2Fdc21-S009" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="r8" class="citations"><div class="citation"><div class="citation-content">Diabetes Canada Clinical Practice Guidelines Expert Committee. Diabetes Canada 2018 clinical practice guidelines for the prevention and management of diabetes in Canada. <em>Can J Diabetes</em> 2018;42:Suppl 1:S1-S325.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r8"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29650079/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000438154400001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Diabetes+Canada+2018+clinical+practice+guidelines+for+the+prevention+and+management+of+diabetes+in+Canada.&amp;publication_year=2018&amp;journal=Can+J+Diabetes&amp;pages=S1-S325&amp;pmid=29650079" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="r9" class="citations"><div class="citation"><div class="citation-content">Nathan DM, Buse JB, Kahn SE, et al. Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE). <em>Diabetes Care</em> 2013;36:2254-2261.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r9" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.2337/dc13-0356" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23690531/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000327252600038" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Rationale+and+design+of+the+glycemia+reduction+approaches+in+diabetes%3A+a+comparative+effectiveness+study+%28GRADE%29.&amp;publication_year=2013&amp;journal=Diabetes+Care&amp;pages=2254-2261&amp;doi=10.2337%2Fdc13-0356&amp;pmid=23690531" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r9" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r9-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] persons with recent-onset type 2 diabetes. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r9-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] the investigators with NIDDK participation. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r9-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] the age at diagnosis was at least 20 years. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r9-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] hemoglobin level of 7.0% or higher. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r9-5" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>e [...] group after a secondary-outcome event. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r9-6" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>f [...] skin cancer) adjudicated by committee </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="r10" class="citations"><div class="citation"><div class="citation-content">The GRADE Study Research Group. Glycemia reduction in type 2 diabetes — microvascular and cardiovascular outcomes. <em>N Engl J Med</em> 2022;387:1075-1088.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_11_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2200433&amp;key=10.1056%2FNEJMoa2200436&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/36129997/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000865461700005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Glycemia+reduction+in+type+2+diabetes+%E2%80%94+microvascular+and+cardiovascular+outcomes.&amp;publication_year=2022&amp;journal=N+Engl+J+Med&amp;pages=1075-1088&amp;doi=10.1056%2FNEJMoa2200436&amp;pmid=36129997" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="r11" class="citations"><div class="citation"><div class="citation-content">Dormandy JA, Charbonnel B, Eckland DJA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. <em>Lancet</em> 2005;366:1279-1289.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r11"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(05)67528-9" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/16214598/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000232405700026" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Secondary+prevention+of+macrovascular+events+in+patients+with+type+2+diabetes+in+the+PROactive+Study+%28PROspective+pioglitAzone+Clinical+Trial+In+macroVascular+Events%29%3A+a+randomised+controlled+trial.&amp;publication_year=2005&amp;journal=Lancet&amp;pages=1279-1289&amp;doi=10.1016%2FS0140-6736%2805%2967528-9&amp;pmid=16214598" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="r12" class="citations"><div class="citation"><div class="citation-content">Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018: a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <em>Diabetes Care</em> 2018;41:2669-2701.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.2337/dci18-0033" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30291106/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000450560000037" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Management+of+hyperglycemia+in+type+2+diabetes%2C+2018%3A+a+consensus+report+by+the+American+Diabetes+Association+%28ADA%29+and+the+European+Association+for+the+Study+of+Diabetes+%28EASD%29.&amp;publication_year=2018&amp;journal=Diabetes+Care&amp;pages=2669-2701&amp;doi=10.2337%2Fdci18-0033&amp;pmid=30291106" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="r13" class="citations"><div class="citation"><div class="citation-content">Buse JB, Wexler DJ, Tsapas A, et al. 2019 update to: Management of Hyperglycemia in Type 2 Diabetes, 2018: a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <em>Diabetes Care</em> 2020;43:487-493.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.2337/dci19-0066" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31857443/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000508199900043" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=2019+update+to%3A+Management+of+Hyperglycemia+in+Type+2+Diabetes%2C+2018%3A+a+consensus+report+by+the+American+Diabetes+Association+%28ADA%29+and+the+European+Association+for+the+Study+of+Diabetes+%28EASD%29.&amp;publication_year=2020&amp;journal=Diabetes+Care&amp;pages=487-493&amp;doi=10.2337%2Fdci19-0066&amp;pmid=31857443" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="r14" class="citations"><div class="citation"><div class="citation-content">Lachin JM. <em>Biostatistical methods: the assessment of relative risks.</em> 2nd ed. Hoboken, NJ: John Wiley, 2011.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r14"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Biostatistical+methods%3A+the+assessment+of+relative+risks.&amp;publication_year=2011" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="r15" class="citations"><div class="citation"><div class="citation-content">Zhao L, Claggett B, Tian L, et al. On the restricted mean survival time curve in survival analysis. <em>Biometrics</em> 2016;72:215-221.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r15"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/biom.12384" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26302239/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000373914700022" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=On+the+restricted+mean+survival+time+curve+in+survival+analysis.&amp;publication_year=2016&amp;journal=Biometrics&amp;pages=215-221&amp;doi=10.1111%2Fbiom.12384&amp;pmid=26302239" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="r16" class="citations"><div class="citation"><div class="citation-content">Lachin JM, Bebu I. Closed testing of each group versus the others combined in a multiple group analysis. <em>Clin Trials</em> 2020;17:77-86.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r16" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1177/1740774519879932" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31647326/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000492518800001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Closed+testing+of+each+group+versus+the+others+combined+in+a+multiple+group+analysis.&amp;publication_year=2020&amp;journal=Clin+Trials&amp;pages=77-86&amp;doi=10.1177%2F1740774519879932&amp;pmid=31647326" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r16" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r16-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] of hazard ratios and confidence intervals. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r16-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] group with the other three combined. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="r17" class="citations"><div class="citation"><div class="citation-content">Marcus R, Peritz E, Gabriel KR. On closed testing procedures with special reference to ordered analysis of variance. <em>Biometrika</em> 1976;63:655-660.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r17"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/biomet/63.3.655" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1976CP66700034" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=On+closed+testing+procedures+with+special+reference+to+ordered+analysis+of+variance.&amp;publication_year=1976&amp;journal=Biometrika&amp;pages=655-660&amp;doi=10.1093%2Fbiomet%2F63.3.655" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="r18" class="citations"><div class="citation"><div class="citation-content">Wexler DJ, Krause-Steinrauf H, Crandall JP, et al. Baseline characteristics of randomized participants in the Glycemia Reduction Approaches in Diabetes: a Comparative Effectiveness study (GRADE). <em>Diabetes Care</em> 2019;42:2098-2107.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r18"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.2337/dc19-0901" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31391203/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000491450200017" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Baseline+characteristics+of+randomized+participants+in+the+Glycemia+Reduction+Approaches+in+Diabetes%3A+a+Comparative+Effectiveness+study+%28GRADE%29.&amp;publication_year=2019&amp;journal=Diabetes+Care&amp;pages=2098-2107&amp;doi=10.2337%2Fdc19-0901&amp;pmid=31391203" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="r19" class="citations"><div class="citation"><div class="citation-content">Nathan DM, Krause-Steinrauf H, Braffett BH, et al. Comparison of central laboratory HbA1c measurements obtained from a capillary collection versus a standard venous whole blood collection in the GRADE and EDIC studies. <em>PLoS One</em> 2021;16(11):e0257154-e0257154.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r19"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1371/journal.pone.0257154" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34780485/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000755305800006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Comparison+of+central+laboratory+HbA1c+measurements+obtained+from+a+capillary+collection+versus+a+standard+venous+whole+blood+collection+in+the+GRADE+and+EDIC+studies.&amp;publication_year=2021&amp;journal=PLoS+One&amp;pages=e0257154-e0257154&amp;doi=10.1371%2Fjournal.pone.0257154&amp;pmid=34780485" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="r20" class="citations"><div class="citation"><div class="citation-content">Walker RJ, Strom Williams J, Egede LE. Influence of race, ethnicity and social determinants of health on diabetes outcomes. <em>Am J Med Sci</em> 2016;351:366-373.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r21"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.amjms.2016.01.008" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27079342/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000382665400007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Influence+of+race%2C+ethnicity+and+social+determinants+of+health+on+diabetes+outcomes.&amp;publication_year=2016&amp;journal=Am+J+Med+Sci&amp;pages=366-373&amp;doi=10.1016%2Fj.amjms.2016.01.008&amp;pmid=27079342" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="r21" class="citations"><div class="citation"><div class="citation-content">Mayberry LS, Bergner EM, Chakkalakal RJ, Elasy TA, Osborn CY. Self-care disparities among adults with type 2 diabetes in the USA. <em>Curr Diab Rep</em> 2016;16:113-113.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r21"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s11892-016-0796-5" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27671320/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000388592700011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Self-care+disparities+among+adults+with+type+2+diabetes+in+the+USA.&amp;publication_year=2016&amp;journal=Curr+Diab+Rep&amp;pages=113-113&amp;doi=10.1007%2Fs11892-016-0796-5&amp;pmid=27671320" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="r22" class="citations"><div class="citation"><div class="citation-content">Kayaniyil S, Lozano-Ortega G, Bennett HA, et al. A network meta-analysis comparing exenatide once weekly with other GLP-1 receptor agonists for the treatment of type 2 diabetes mellitus. <em>Diabetes Ther</em> 2016;7:27-43.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r22"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s13300-016-0155-1" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26886440/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+network+meta-analysis+comparing+exenatide+once+weekly+with+other+GLP-1+receptor+agonists+for+the+treatment+of+type+2+diabetes+mellitus.&amp;publication_year=2016&amp;journal=Diabetes+Ther&amp;pages=27-43&amp;doi=10.1007%2Fs13300-016-0155-1&amp;pmid=26886440" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="r23" class="citations"><div class="citation"><div class="citation-content">Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. <em>N Engl J Med</em> 2006;355:2427-2443.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r23"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_24_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2200433&amp;key=10.1056%2FNEJMoa066224&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/17145742/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000242581400007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Glycemic+durability+of+rosiglitazone%2C+metformin%2C+or+glyburide+monotherapy.&amp;publication_year=2006&amp;journal=N+Engl+J+Med&amp;pages=2427-2443&amp;doi=10.1056%2FNEJMoa066224&amp;pmid=17145742" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="r24" class="citations"><div class="citation"><div class="citation-content">Khunti K, Gomes MB, Pocock S, et al. Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: a systematic review. <em>Diabetes Obes Metab</em> 2018;20:427-437.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/dom.13088" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28834075/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000422678600022" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Therapeutic+inertia+in+the+treatment+of+hyperglycaemia+in+patients+with+type+2+diabetes%3A+a+systematic+review.&amp;publication_year=2018&amp;journal=Diabetes+Obes+Metab&amp;pages=427-437&amp;doi=10.1111%2Fdom.13088&amp;pmid=28834075" target="_blank">Google Scholar</a></div></div></div></div></div></div><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary" aria-expanded="false" aria-controls="collapsible-text"><span>Show all references</span></button></div></section></div></section></div><div class="core-collateral"><div id="core-collateral-info" role="tabpanel" data-core-tabs="core-collateral-info" tabindex="-1" aria-labelledby="pane-core-collateral-info"><header><h2 id="pane-core-collateral-info"><i class="icon-info" aria-hidden="true"></i>Information &amp; Authors</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-information" role="tab" id="tab-information-label" aria-selected="true" class="active">Information</button><button aria-controls="tab-contributors" role="tab" id="tab-contributors-label" tabindex="-1" aria-selected="false">Authors</button></div><section id="tab-information" aria-labelledby="tab-information-label" role="tabpanel" tabindex="0"><h3>Information</h3><section class="core-self-citation"><h4>Published In</h4><div class="core-journal-presentation"><div class="core-journal-description"><div property="isPartOf" typeof="Periodical"><span property="name">New England Journal of Medicine</span></div><div class="core-enumeration"><a href="/toc/nejm/387/12"><span property="isPartOf" typeof="PublicationVolume">Volume <span property="volumeNumber">387</span></span> • <span property="isPartOf" typeof="PublicationIssue">Number <span property="issueNumber">12</span></span> • <span property="datePublished">September 22, 2022</span></a></div><div class="core-pagination"><span class="heading">Pages</span>: <span class="content"><span property="pageStart">1063</span>-<span property="pageEnd">1074</span></span></div></div></div></section><section class="core-copyright"><h4>Copyright</h4><div role="paragraph">Copyright © 2022 Massachusetts Medical Society. All rights reserved.</div><div>For personal use only. Any commercial reuse of NEJM Group content requires <a href="mailto:permissions@nejm.org">permission</a>.</div></section><section class="core-history"><h4>History</h4><div><b class="core-label">Published online</b>: September 21, 2022</div><div><b class="core-label">Published in issue</b>: September 22, 2022</div></section><section data-location="recirc_topics_article" class="core-classifications"><h4>Topics</h4><div class="keywords"><ol><li><a href="/browse/topic/cardiology-general" alt="View article keyword Cardiology General" data-interactiontype="article_recirculation_click">Cardiology General</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/clinical-medicine-general" alt="View article keyword Clinical Medicine General" data-interactiontype="article_recirculation_click">Clinical Medicine General</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/diabetes" alt="View article keyword Diabetes" data-interactiontype="article_recirculation_click">Diabetes</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li></ol></div></section></section><section id="tab-contributors" aria-labelledby="tab-contributors-label" role="tabpanel" tabindex="-1"><h3>Authors</h3><section class="core-authors"><h4>Authors</h4><div role="paragraph"><span property="author" typeof="Person">The GRADE Study Research Group<sup class="xref"><a href="#fn1" role="doc-noteref">*</a></sup></span></div></section><section class="core-affiliations"><h4>Affiliations</h4><div property="affiliation" typeof="Organization"><span property="name">From the Massachusetts General Hospital Diabetes Center, Harvard Medical School, Boston (D.M.N., M.E.L., D.J.W.); the Biostatistics Center, Department of Biostatistics and Bioinformatics, Milken Institute School of Public Health, George Washington University, Rockville (J.M.L., N.M.B., H.K.-S., N.Y.), and the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda (H.B.B.) — both in Maryland; the Section of Endocrinology, Diabetes, and Metabolism, Baylor College of Medicine, Houston (A.B.); the Division of Endocrinology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill (J.B.B.); the Cincinnati Veterans Affairs (VA) Medical Center, University of Cincinnati College of Medicine, Cincinnati (R.M.C.); the Division of Endocrinology and Diabetes and the Fleischer Institute for Diabetes and Metabolism, Albert Einstein College of Medicine, Bronx, NY (J.P.C.); the Division of Metabolism, Endocrinology, and Nutrition, Department of Medicine, VA Puget Sound Health Care System, University of Washington, Seattle (S.E.K.); the Division of Endocrinology, Metabolism, and Diabetes, University of Colorado School of Medicine, and the VA Eastern Colorado Health Care System — both in Aurora (N.R.); and the Louis Stokes Cleveland VA Medical Center, Case Western Reserve University, Cleveland (M.T.).</span></div></section><section class="core-authors-notes"><h4>Notes</h4><div role="doc-footnote">Dr. Lachin can be contacted at <a href="mailto:grademail@bsc.gwu.edu">grademail@bsc.gwu.edu</a> or at the George Washington University Biostatistics Center–GRADE Coordinating Center, 6110 Executive Blvd., Ste. 750, Rockville, MD 20852.</div><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="fn1" role="paragraph">The members of the GRADE Study Research Group are listed in the <a href="#ap2">Supplementary Appendix</a>, available at NEJM.org.</div></div></section></section></div><div id="core-collateral-metrics" role="tabpanel" data-core-tabs="core-collateral-metrics" tabindex="-1" aria-labelledby="pane-core-collateral-metrics"><header><h2 id="pane-core-collateral-metrics"><i class="icon-timeline" aria-hidden="true"></i>Metrics &amp; Citations</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-metrics-inner" role="tab" id="tab-metrics-inner-label" aria-selected="true" class="active" data-interactiontype="article_tab" data-tabname="metricsWindow">Metrics</button><button aria-controls="tab-citations" role="tab" id="tab-citations-label" tabindex="-1" aria-selected="false" data-interactiontype="article_tab" data-tabname="metricsWindow">Citations<span class="citations-count">142</span></button></div><section id="tab-metrics-inner" aria-labelledby="tab-metrics-inner-label" role="tabpanel" tabindex="0"><h3>Metrics</h3><section>









    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="95ea9f58-ec0e-4db2-b2ab-280fc876af53" data-location="article_metrics_article">
        



        
            <h4 class="">
                Altmetrics
            </h4>
        
        <div data-badge-details="right" data-badge-type="large-donut" data-doi="10.1056/NEJMoa2200433" data-hide-no-mentions="true" data-link-target="_blank" class="altmetric-embed" data-uuid="2a55d9d7-4604-b112-d04d-628eecc97c50"><div style="overflow:hidden;">
    <div class="altmetric-normal-legend">
        <a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=136230339" style="display:inline-block;">
                <img alt="Article has an altmetric score of 684" src="https://badges.altmetric.com/?size=320&amp;score=684&amp;types=mbvrtwf1" width="180" height="180" style="border:0; margin:0; max-width: none;">
        </a>
        <p class="altmetric-see-more-details" style="padding-top: 10px; text-align: center;"><a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=136230339">See more details</a></p>
    </div>
    <div id="_altmetric_popover_el_2a55d9d7-4604-b112-d04d-628eecc97c50" class="altmetric-embed right" style="margin:0; padding:0; display:inline-block; float:left; position:relative;">
        <div class="altmetric_container">
            <div class="altmetric-embed altmetric-popover-inner right">
                <div style="padding:0; margin: 0;" class="altmetric-embed altmetric-popover-content">
                        <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #FF0000;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=136230339&amp;tab=news">
          Picked up by <b>76</b> news outlets
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #ffd140;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=136230339&amp;tab=blogs">
          Blogged by <b>5</b>
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #74CFED;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=136230339&amp;tab=twitter">
          Posted by <b>183</b> X users
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #2445bd;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=136230339&amp;tab=facebook">
          On <b>5</b> Facebook pages
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #958899;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=136230339&amp;tab=wikipedia">
          Referenced in <b>3</b> Wikipedia pages
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #D5E8F0;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=136230339&amp;tab=reddit">
          Reddited by <b>2</b>
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #F4006E;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=136230339&amp;tab=research-highlights">
          Highlighted by <b>1</b> platforms
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #94DB5E;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=136230339&amp;tab=video">
          On <b>1</b> videos
      </a>
    </div>

    <div class="altmetric-embed readers" style="margin-top: 10px;">
          <div class="altmetric-embed tip_mendeley" style="padding-left: 10px; line-height:18px; border-left: 16px solid #A60000;">
              <b>188</b> readers on Mendeley
          </div>
    </div>

                </div>
            </div>
        </div>
    </div>
</div></div>
<script async="" type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" nonce="9523b28971f9626e-SJC"></script>

        </div>
    

</section></section><section id="tab-citations" aria-labelledby="tab-citations-label" role="tabpanel" tabindex="-1"><h3>Citations</h3><section>



        
            <h4 class="">
                Export citation
            </h4>
        
        <div class="citation-download cd-sec">
<p class="citation-download_msg">Select the format you want to export the citation of this publication.</p>
<form action="/action/downloadCitation" name="frmCitmgr" method="post" target="_self" class="citation-download_form"><input type="hidden" name="doi" value="10.1056/NEJMoa2200433"> <input type="hidden" name="downloadFileName" value="csp_387_"> <input type="hidden" name="include" value="abs">
<div class="dropdown dropdown-selectable dropdown-selectable--form-control"><input type="hidden" name="format" value=""> <label class="form-label">Format*</label> <button id="slct_format" type="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="btn dropdown-toggle d-flex align-items-center justify-content-between">Please Select </button>
<div aria-labelledby="slct_format" role="listbox" class="dropdown-menu"><a href="#" data-value="ris" class="dropdown-item">RIS (ProCite, Reference Manager)</a><a href="#" data-value="endnote" class="dropdown-item">EndNote</a><a href="#" data-value="bibtex" class="dropdown-item">BibTex</a><a href="#" data-value="medlars" class="dropdown-item">Medlars</a><a href="#" data-value="refworks" class="dropdown-item">RefWorks</a></div>
<div class="invalid-feedback">Please select an item in the list</div>
</div>
<div class="citation-download_checkbox"><label class="checkbox--primary"><input type="checkbox" name="direct" value="true"><span class="checkbox--primary-icons"><span class="checkbox--primary-unchecked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxUnchecked"></use></svg></span></span><span class="checkbox--primary-checked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxChecked"></use></svg></span></span></span><span class="checkbox--primary-label"><span class="checkbox--primary-label-text">Direct Import</span></span></label></div>
<div class="citation-download_btn"><button type="submit" name="submit" value="Download" class="ng-btn_default ng-btn_iconLeft" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#citations"></use></svg></span><span class="ng-btn_text">Export citation</span></button></div>
</form></div>
</section><section>









    
    
        <div data-widget-def="UX3CitedByWidget" data-widget-id="efb4df9a-8e1a-47f9-bfb7-271959277a9f" data-location="citedby_article">
        



        
            <h4 class="">
                Cited by
            </h4>
        
        <section id="cited-by" class="cited-by"><div class="cited-by__wrapper"><div id="cited-by__content" class="cited-by__content"><ol data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2200433%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2022.387.issue-12%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" data-lazyload="false" data-total="142" class="cited-by__list list-unstyled"><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Kamlesh Khunti, </li><li class="list-inline-item cited-by__entry__author">Dimitris Papamargaritis, </li><li class="list-inline-item cited-by__entry__author">Vanita R Aroda, </li><li class="list-inline-item cited-by__entry__author">Ranjit Mohan Anjana, </li><li class="list-inline-item cited-by__entry__author">Sangeeta R Kashyap, </li></ul><span class="cited-by__entry__title">Re-evaluating the concept of remission in type 2 diabetes: a call for patient-centric approaches, </span><span class="cited-by__entry__series-title">The Lancet Diabetes &amp; Endocrinology, </span><span class="cited-by__entry__volume"><strong>13</strong>, </span><span class="cited-by__entry__issue">7, </span><span class="cited-by__entry__page-range">(615-634), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/S2213-8587(25)00134-2" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/S2213-8587(25)00134-2</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/S2213-8587(25)00134-2" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Samuel N. Goldman, </li><li class="list-inline-item cited-by__entry__author">Kyle Mani, </li><li class="list-inline-item cited-by__entry__author">Thomas Scharfenberger, </li><li class="list-inline-item cited-by__entry__author">Emily Kleinbart, </li><li class="list-inline-item cited-by__entry__author">Aaron T. Hui, </li><li class="list-inline-item cited-by__entry__author">Rafael De la Garza Ramos, </li><li class="list-inline-item cited-by__entry__author">Mitchell S. Fourman, </li><li class="list-inline-item cited-by__entry__author">Ananth S. Eleswarapu, </li></ul><span class="cited-by__entry__title">Glucagon-like peptide-1 receptor agonist use prior to spinal surgery results in reduced postoperative length of stay: A propensity-score matched analysis, </span><span class="cited-by__entry__series-title">North American Spine Society Journal (NASSJ), </span><span class="cited-by__entry__volume"><strong>22</strong>, </span><span class="cited-by__entry__page-range">(100612), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.xnsj.2025.100612" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.xnsj.2025.100612</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.xnsj.2025.100612" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Lanxuan Jiang, </li><li class="list-inline-item cited-by__entry__author">Liyuan Zhou, </li><li class="list-inline-item cited-by__entry__author">Jia Liu, </li><li class="list-inline-item cited-by__entry__author">Guang Wang, </li></ul><span class="cited-by__entry__title">Baseline glucagon impacts glucose-lowering effects of acarbose but not metformin: A sub-analysis of MARCH study, </span><span class="cited-by__entry__series-title">Diabetes Research and Clinical Practice, </span><span class="cited-by__entry__volume"><strong>224</strong>, </span><span class="cited-by__entry__page-range">(112207), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.diabres.2025.112207" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.diabres.2025.112207</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.diabres.2025.112207" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Stephen O’Neill, </li><li class="list-inline-item cited-by__entry__author">Patrick Bidulka, </li><li class="list-inline-item cited-by__entry__author">David G. Lugo-Palacios, </li><li class="list-inline-item cited-by__entry__author">Orlagh Carroll, </li><li class="list-inline-item cited-by__entry__author">Ignacio Leiva-Escobar, </li><li class="list-inline-item cited-by__entry__author">Richard Silverwood, </li><li class="list-inline-item cited-by__entry__author">Andrew Briggs, </li><li class="list-inline-item cited-by__entry__author">Amanda I. Adler, </li><li class="list-inline-item cited-by__entry__author">Kamlesh Khunti, </li><li class="list-inline-item cited-by__entry__author">Richard Grieve, </li></ul><span class="cited-by__entry__title">Comparative effectiveness of alternative second-line oral glucose-lowering therapies for type 2 diabetes: a precision medicine approach applied to routine data, </span><span class="cited-by__entry__series-title">Diabetologia, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1007/s00125-025-06447-x" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1007/s00125-025-06447-x</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1007/s00125-025-06447-x" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Giovanni Antonio Silverii, </li><li class="list-inline-item cited-by__entry__author">Christian Marinelli, </li><li class="list-inline-item cited-by__entry__author">Costanza Bettarini, </li><li class="list-inline-item cited-by__entry__author">Gloria Giovanna Del Vescovo, </li><li class="list-inline-item cited-by__entry__author">Matteo Monami, </li><li class="list-inline-item cited-by__entry__author">Edoardo Mannucci, </li></ul><span class="cited-by__entry__title">
                  GLP
              ‐1 receptor agonists and the risk for cancer: A meta‐analysis of randomized controlled trials
            , </span><span class="cited-by__entry__series-title">Diabetes, Obesity and Metabolism, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1111/dom.16489" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1111/dom.16489</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1111/dom.16489" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">John W. Ostrominski, </li><li class="list-inline-item cited-by__entry__author">Vanita R. Aroda, </li><li class="list-inline-item cited-by__entry__author">Uffe C. Braae, </li><li class="list-inline-item cited-by__entry__author">Christian Kruse, </li><li class="list-inline-item cited-by__entry__author">Kabirdev Mandavya, </li><li class="list-inline-item cited-by__entry__author">John B. Buse, </li></ul><span class="cited-by__entry__title">Time to Treatment Intensification with Glucagon-Like Peptide-1 Receptor Agonists Versus Comparators in People with Type 2 Diabetes Treated with Metformin, </span><span class="cited-by__entry__series-title">Diabetes Therapy, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1007/s13300-025-01751-6" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1007/s13300-025-01751-6</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1007/s13300-025-01751-6" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Orlagh U. Carroll, </li><li class="list-inline-item cited-by__entry__author">Patrick Bidulka, </li><li class="list-inline-item cited-by__entry__author">Anirban Basu, </li><li class="list-inline-item cited-by__entry__author">Amanda I. Adler, </li><li class="list-inline-item cited-by__entry__author">Stephen O'Neill, </li><li class="list-inline-item cited-by__entry__author">Andrew H. Briggs, </li><li class="list-inline-item cited-by__entry__author">David G. Lugo‐Palacios, </li><li class="list-inline-item cited-by__entry__author">Kamlesh Khunti, </li><li class="list-inline-item cited-by__entry__author">Richard Grieve, </li></ul><span class="cited-by__entry__title">
              Long‐term outcomes following alternative second‐line oral glucose‐lowering treatments: Results from the real‐world progression in type 2 diabetes mellitus United Kingdom (
              RAPIDS
              ‐
              UK
              ) model
            , </span><span class="cited-by__entry__series-title">Diabetes, Obesity and Metabolism, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1111/dom.16447" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1111/dom.16447</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1111/dom.16447" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Arooba Rubbani, </li><li class="list-inline-item cited-by__entry__author">Danial Khalid, </li><li class="list-inline-item cited-by__entry__author">Savera Nadeem, </li><li class="list-inline-item cited-by__entry__author">Ayesha Ghazal Jamali, </li><li class="list-inline-item cited-by__entry__author">Saiyeda Asma  B Rizvi, </li><li class="list-inline-item cited-by__entry__author">Aftab Rabbani, </li><li class="list-inline-item cited-by__entry__author">Sundeep Sahitia, </li><li class="list-inline-item cited-by__entry__author">Malik Asfand Yar, </li><li class="list-inline-item cited-by__entry__author">Amro A. M. Albatrawi, </li><li class="list-inline-item cited-by__entry__author">Maha M Abdul-Latif, </li></ul><span class="cited-by__entry__title">Iron Deficiency Anemia and Oxidative Stress in Type 2 Diabetic Patients on Metformin: A Meta-Analysis, </span><span class="cited-by__entry__series-title">Cureus, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.7759/cureus.84386" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.7759/cureus.84386</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.7759/cureus.84386" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">José A. Luchsinger, </li><li class="list-inline-item cited-by__entry__author">Samuel P. Rosin, </li><li class="list-inline-item cited-by__entry__author">Erin J. Kazemi, </li><li class="list-inline-item cited-by__entry__author">Naji Younes, </li><li class="list-inline-item cited-by__entry__author">Colleen E. Suratt, </li><li class="list-inline-item cited-by__entry__author">Basma N. Fattaleh, </li><li class="list-inline-item cited-by__entry__author">Hermes J. Florez, </li><li class="list-inline-item cited-by__entry__author">Jeffrey S. Gonzalez, </li><li class="list-inline-item cited-by__entry__author">Priscilla Hollander, </li><li class="list-inline-item cited-by__entry__author">Sophia H. Hox, </li><li class="list-inline-item cited-by__entry__author">Shihchen Kuo, </li><li class="list-inline-item cited-by__entry__author">Melissa S. Lee, </li><li class="list-inline-item cited-by__entry__author">Thomas Martens, </li><li class="list-inline-item cited-by__entry__author">Rodica Pop-Busui, </li><li class="list-inline-item cited-by__entry__author">Elizabeth R. Seaquist, </li><li class="list-inline-item cited-by__entry__author">Andrea H. Waltje, </li><li class="list-inline-item cited-by__entry__author">Joshua I. Barzilay, </li><li class="list-inline-item cited-by__entry__author">Jill P. Crandall, </li><li class="list-inline-item cited-by__entry__author">Melissa Diane McKee, </li><li class="list-inline-item cited-by__entry__author">Stephanie Beringher-Massera, </li><li class="list-inline-item cited-by__entry__author">Janet Brown-Friday, </li><li class="list-inline-item cited-by__entry__author">Entila Xhori, </li><li class="list-inline-item cited-by__entry__author">Keisha Ballentine-Cargill, </li><li class="list-inline-item cited-by__entry__author">Sally Duran, </li><li class="list-inline-item cited-by__entry__author">Hayley Estrella, </li><li class="list-inline-item cited-by__entry__author">Susana Gonzalez de la torre, </li><li class="list-inline-item cited-by__entry__author">Jennifer Lukin, </li><li class="list-inline-item cited-by__entry__author">Lawrence Phillips, </li><li class="list-inline-item cited-by__entry__author">Elizabeth Burgess, </li><li class="list-inline-item cited-by__entry__author">Darin Olson, </li><li class="list-inline-item cited-by__entry__author">Mary Rhee, </li><li class="list-inline-item cited-by__entry__author">Peter Wilson, </li><li class="list-inline-item cited-by__entry__author">Tasha Stephanie Raines, </li><li class="list-inline-item cited-by__entry__author">Johanna Boers, </li><li class="list-inline-item cited-by__entry__author">Julie Costello, </li><li class="list-inline-item cited-by__entry__author">Maxine Maher-Albertelli, </li><li class="list-inline-item cited-by__entry__author">Radhika Mungara, </li><li class="list-inline-item cited-by__entry__author">Louise Savoye, </li><li class="list-inline-item cited-by__entry__author">CarolAnn White, </li><li class="list-inline-item cited-by__entry__author">Chona Gullett, </li><li class="list-inline-item cited-by__entry__author">Leah Holloway, </li><li class="list-inline-item cited-by__entry__author">Folayan Morehead, </li><li class="list-inline-item cited-by__entry__author">Saranjit Person, </li><li class="list-inline-item cited-by__entry__author">Mabil Sibymon, </li><li class="list-inline-item cited-by__entry__author">Sridhar Tanukonda, </li><li class="list-inline-item cited-by__entry__author">Cynthia Adams, </li><li class="list-inline-item cited-by__entry__author">April Ross, </li><li class="list-inline-item cited-by__entry__author">Ashok Balasubramanyam, </li><li class="list-inline-item cited-by__entry__author">Ruchi Gaba, </li><li class="list-inline-item cited-by__entry__author">Erica Gonzalez, </li><li class="list-inline-item cited-by__entry__author">Adrienne Ideozu, </li><li class="list-inline-item cited-by__entry__author">Julizza Jimenez, </li><li class="list-inline-item cited-by__entry__author">Gabriela Montes, </li><li class="list-inline-item cited-by__entry__author">Charlyne Wright, </li><li class="list-inline-item cited-by__entry__author">Priscilla Hollander, </li><li class="list-inline-item cited-by__entry__author">Erin Roe, </li><li class="list-inline-item cited-by__entry__author">Analyn Jackson, </li><li class="list-inline-item cited-by__entry__author">Ashley Smiley, </li><li class="list-inline-item cited-by__entry__author">Polly Burt, </li><li class="list-inline-item cited-by__entry__author">Lorie Estrada, </li><li class="list-inline-item cited-by__entry__author">Kris Chionh, </li><li class="list-inline-item cited-by__entry__author">Faramarz Ismail-Beigi, </li><li class="list-inline-item cited-by__entry__author">Corinna Falck-Ytter, </li><li class="list-inline-item cited-by__entry__author">Laure Sayyed Kassem, </li><li class="list-inline-item cited-by__entry__author">Ajay Sood, </li><li class="list-inline-item cited-by__entry__author">Margaret Tiktin, </li><li class="list-inline-item cited-by__entry__author">Bethany Cramer, </li><li class="list-inline-item cited-by__entry__author">Jacalyn Iacoboni, </li><li class="list-inline-item cited-by__entry__author">Maria V. Kononets, </li><li class="list-inline-item cited-by__entry__author">Tanya Kulow, </li><li class="list-inline-item cited-by__entry__author">Cynthia Newman, </li><li class="list-inline-item cited-by__entry__author">Katherine A. Stancil, </li><li class="list-inline-item cited-by__entry__author">Cristina Sanders, </li><li class="list-inline-item cited-by__entry__author">Lisa Tucker, </li><li class="list-inline-item cited-by__entry__author">Amanda Werner, </li><li class="list-inline-item cited-by__entry__author">Adrienne Krol, </li><li class="list-inline-item cited-by__entry__author">Gloria McPhee, </li><li class="list-inline-item cited-by__entry__author">Christine Patel, </li><li class="list-inline-item cited-by__entry__author">Linda Colosimo, </li><li class="list-inline-item cited-by__entry__author">Audrey Maxwell, </li><li class="list-inline-item cited-by__entry__author">Robin Goland, </li><li class="list-inline-item cited-by__entry__author">James Pring, </li><li class="list-inline-item cited-by__entry__author">Lucia Alfano, </li><li class="list-inline-item cited-by__entry__author">Patricia Kringas, </li><li class="list-inline-item cited-by__entry__author">Camille Hausheer, </li><li class="list-inline-item cited-by__entry__author">Jessica Tejada, </li><li class="list-inline-item cited-by__entry__author">Kelly Gumpel, </li><li class="list-inline-item cited-by__entry__author">Amanda Kirpitch, </li><li class="list-inline-item cited-by__entry__author">Harvey Schneier, </li><li class="list-inline-item cited-by__entry__author">Jennifer B. Green, </li><li class="list-inline-item cited-by__entry__author">Hiba AbouAssi, </li><li class="list-inline-item cited-by__entry__author">Ranee Chatterjee, </li><li class="list-inline-item cited-by__entry__author">Mark N. Feinglos, </li><li class="list-inline-item cited-by__entry__author">Jennifer English Jones, </li><li class="list-inline-item cited-by__entry__author">Shubi A. Khan, </li><li class="list-inline-item cited-by__entry__author">Jeanne B. Kimpel, </li><li class="list-inline-item cited-by__entry__author">Ronna P. Zimmer, </li><li class="list-inline-item cited-by__entry__author">Mary Furst, </li><li class="list-inline-item cited-by__entry__author">Barbara M. Satterwhite, </li><li class="list-inline-item cited-by__entry__author">Connie R Thacker, </li><li class="list-inline-item cited-by__entry__author">Kathryn Evans Kreider, </li><li class="list-inline-item cited-by__entry__author">Cary N Mariash, </li><li class="list-inline-item cited-by__entry__author">Kieren J. Mather, </li><li class="list-inline-item cited-by__entry__author">Heba M Ismail, </li><li class="list-inline-item cited-by__entry__author">Amale Lteif, </li><li class="list-inline-item cited-by__entry__author">Maureen Mullen, </li><li class="list-inline-item cited-by__entry__author">Tonya Hamilton, </li><li class="list-inline-item cited-by__entry__author">Nick Patel, </li><li class="list-inline-item cited-by__entry__author">Gabriela Riera, </li><li class="list-inline-item cited-by__entry__author">Marcia Jackson, </li><li class="list-inline-item cited-by__entry__author">Vivian Pirics, </li><li class="list-inline-item cited-by__entry__author">Devin Howard, </li><li class="list-inline-item cited-by__entry__author">Danielle Aguillar, </li><li class="list-inline-item cited-by__entry__author">Sloan Hurt, </li><li class="list-inline-item cited-by__entry__author">Richard Bergenstal, </li><li class="list-inline-item cited-by__entry__author">Anders Carlson, </li><li class="list-inline-item cited-by__entry__author">Thomas Martens, </li><li class="list-inline-item cited-by__entry__author">Mary Johnson, </li><li class="list-inline-item cited-by__entry__author">Renae Hill, </li><li class="list-inline-item cited-by__entry__author">Jamie Hyatt, </li><li class="list-inline-item cited-by__entry__author">Connie Jensen, </li><li class="list-inline-item cited-by__entry__author">Marcia Madden, </li><li class="list-inline-item cited-by__entry__author">Dianna Martin, </li><li class="list-inline-item cited-by__entry__author">Holly Willis, </li><li class="list-inline-item cited-by__entry__author">Wanda Konerza, </li><li class="list-inline-item cited-by__entry__author">Shoua Yang, </li><li class="list-inline-item cited-by__entry__author">Rebecca Passi, </li><li class="list-inline-item cited-by__entry__author">Kathleen Kleeberger, </li><li class="list-inline-item cited-by__entry__author">Stephen Fortmann, </li><li class="list-inline-item cited-by__entry__author">Michael Herson, </li><li class="list-inline-item cited-by__entry__author">Karen Mularski, </li><li class="list-inline-item cited-by__entry__author">Harry Glauber, </li><li class="list-inline-item cited-by__entry__author">James Prihoda, </li><li class="list-inline-item cited-by__entry__author">Britt Ash, </li><li class="list-inline-item cited-by__entry__author">Christina Carlson, </li><li class="list-inline-item cited-by__entry__author">Phyllis Anne Ramey, </li><li class="list-inline-item cited-by__entry__author">Emily Schield, </li><li class="list-inline-item cited-by__entry__author">Britta Torgrimson-Ojerio, </li><li class="list-inline-item cited-by__entry__author">Kathy Arnold, </li><li class="list-inline-item cited-by__entry__author">Bryan Kauffman, </li><li class="list-inline-item cited-by__entry__author">Elease Panos, </li><li class="list-inline-item cited-by__entry__author">Samantha Sahnow, </li><li class="list-inline-item cited-by__entry__author">Kristi Bays, </li><li class="list-inline-item cited-by__entry__author">Jennifer Cook, </li><li class="list-inline-item cited-by__entry__author">Jennifer Gluth, </li><li class="list-inline-item cited-by__entry__author">Debra Ghioni, </li><li class="list-inline-item cited-by__entry__author">Katrina Schell, </li><li class="list-inline-item cited-by__entry__author">Jennifer Criscola, </li><li class="list-inline-item cited-by__entry__author">Camille Friason, </li><li class="list-inline-item cited-by__entry__author">Suzi Jones, </li><li class="list-inline-item cited-by__entry__author">Sergey Nazarov, </li><li class="list-inline-item cited-by__entry__author">Joshua Barzilay, </li><li class="list-inline-item cited-by__entry__author">Negah Rassouli, </li><li class="list-inline-item cited-by__entry__author">Rachel Puttnam, </li><li class="list-inline-item cited-by__entry__author">Olubukola Ojoawo, </li><li class="list-inline-item cited-by__entry__author">Roslin Nelson, </li><li class="list-inline-item cited-by__entry__author">Michelle Curtis, </li><li class="list-inline-item cited-by__entry__author">Bonita Hollis, </li><li class="list-inline-item cited-by__entry__author">Cynthia Sanders-Jones, </li><li class="list-inline-item cited-by__entry__author">Kia Stokes, </li><li class="list-inline-item cited-by__entry__author">Zakiah El-Haqq, </li><li class="list-inline-item cited-by__entry__author">Abby Kolli, </li><li class="list-inline-item cited-by__entry__author">Tu Tran, </li><li class="list-inline-item cited-by__entry__author">Deborah Wexler, </li><li class="list-inline-item cited-by__entry__author">Mary Larkin, </li><li class="list-inline-item cited-by__entry__author">James Meigs, </li><li class="list-inline-item cited-by__entry__author">Brittany Chambers, </li><li class="list-inline-item cited-by__entry__author">Amy Dushkin, </li><li class="list-inline-item cited-by__entry__author">Gianna Rocchio, </li><li class="list-inline-item cited-by__entry__author">Mike Yepes, </li><li class="list-inline-item cited-by__entry__author">Barbara Steiner, </li><li class="list-inline-item cited-by__entry__author">Hilary Dulin, </li><li class="list-inline-item cited-by__entry__author">Melody Cayford, </li><li class="list-inline-item cited-by__entry__author">Andrea DeManbey, </li><li class="list-inline-item cited-by__entry__author">Mallory Hillard, </li><li class="list-inline-item cited-by__entry__author">Kimberly Martin, </li><li class="list-inline-item cited-by__entry__author">Nopporn Thangthaeng, </li><li class="list-inline-item cited-by__entry__author">Lindsey Gurry, </li><li class="list-inline-item cited-by__entry__author">Raquel Kochis, </li><li class="list-inline-item cited-by__entry__author">Elyse Raymond, </li><li class="list-inline-item cited-by__entry__author">Valerie Ripley, </li><li class="list-inline-item cited-by__entry__author">Christine Stevens, </li><li class="list-inline-item cited-by__entry__author">Jean Park, </li><li class="list-inline-item cited-by__entry__author">Vanita Aroda, </li><li class="list-inline-item cited-by__entry__author">Adline Ghazi, </li><li class="list-inline-item cited-by__entry__author">Michelle Magee, </li><li class="list-inline-item cited-by__entry__author">Ann Ressing, </li><li class="list-inline-item cited-by__entry__author">Amy Loveland, </li><li class="list-inline-item cited-by__entry__author">Mia Hamm, </li><li class="list-inline-item cited-by__entry__author">Maria Hurtado, </li><li class="list-inline-item cited-by__entry__author">Alexander Kuhn, </li><li class="list-inline-item cited-by__entry__author">Jayme L. Leger, </li><li class="list-inline-item cited-by__entry__author">Lumanti Manandhar, </li><li class="list-inline-item cited-by__entry__author">Florence Mwicigi, </li><li class="list-inline-item cited-by__entry__author">Osirelis Sanchez, </li><li class="list-inline-item cited-by__entry__author">Theresa Young, </li><li class="list-inline-item cited-by__entry__author">Rajesh Garg, </li><li class="list-inline-item cited-by__entry__author">Victoria Lagari-Libhaber, </li><li class="list-inline-item cited-by__entry__author">Hermes J Florez, </li><li class="list-inline-item cited-by__entry__author">Willy M Valencia, </li><li class="list-inline-item cited-by__entry__author">Jennifer Mark, </li><li class="list-inline-item cited-by__entry__author">Sabina Casula, </li><li class="list-inline-item cited-by__entry__author">Lisset Oropesa-Gonzalez, </li><li class="list-inline-item cited-by__entry__author">Lisa Hue, </li><li class="list-inline-item cited-by__entry__author">Alain Cuadot, </li><li class="list-inline-item cited-by__entry__author">Ramfis Nieto-Martinez, </li><li class="list-inline-item cited-by__entry__author">Ana K Riccio Veliz, </li><li class="list-inline-item cited-by__entry__author">Miriam Gutt, </li><li class="list-inline-item cited-by__entry__author">Yvette J Kendal, </li><li class="list-inline-item cited-by__entry__author">Bertha Veciana, </li><li class="list-inline-item cited-by__entry__author">Andrew Ahmann, </li><li class="list-inline-item cited-by__entry__author">Diana Aby-Daniel, </li><li class="list-inline-item cited-by__entry__author">Farahnaz Joarder, </li><li class="list-inline-item cited-by__entry__author">Victoria Morimoto, </li><li class="list-inline-item cited-by__entry__author">Carol Sprague, </li><li class="list-inline-item cited-by__entry__author">Daisuke Yamashita, </li><li class="list-inline-item cited-by__entry__author">Nancy Cady, </li><li class="list-inline-item cited-by__entry__author">Nadia Rivera-Eschright, </li><li class="list-inline-item cited-by__entry__author">Patricia Kirchhoff, </li><li class="list-inline-item cited-by__entry__author">Brianna Morales Gonzalez, </li><li class="list-inline-item cited-by__entry__author">Joseph Adducci, </li><li class="list-inline-item cited-by__entry__author">Alina Goncharova, </li><li class="list-inline-item cited-by__entry__author">Sophia H Hox, </li><li class="list-inline-item cited-by__entry__author">Helen Petrovich, </li><li class="list-inline-item cited-by__entry__author">Michael Matwichyna, </li><li class="list-inline-item cited-by__entry__author">Victoria Jenkins, </li><li class="list-inline-item cited-by__entry__author">L Broadwater, </li><li class="list-inline-item cited-by__entry__author">Renée R. Ishii, </li><li class="list-inline-item cited-by__entry__author">Nina O. Bermudez, </li><li class="list-inline-item cited-by__entry__author">Daniel S. Hsia, </li><li class="list-inline-item cited-by__entry__author">William T. Cefalu, </li><li class="list-inline-item cited-by__entry__author">Frank L. Greenway, </li><li class="list-inline-item cited-by__entry__author">Celeste Waguespack, </li><li class="list-inline-item cited-by__entry__author">Erin King, </li><li class="list-inline-item cited-by__entry__author">Greta Fry, </li><li class="list-inline-item cited-by__entry__author">Amber Dragg, </li><li class="list-inline-item cited-by__entry__author">Bethany Gildersleeve, </li><li class="list-inline-item cited-by__entry__author">Jennifer Arceneaux, </li><li class="list-inline-item cited-by__entry__author">Natalie Haynes, </li><li class="list-inline-item cited-by__entry__author">Amy Thomassie, </li><li class="list-inline-item cited-by__entry__author">Mallory Pavlionis, </li><li class="list-inline-item cited-by__entry__author">Brandi Bourgeois, </li><li class="list-inline-item cited-by__entry__author">Claire Hazlett, </li><li class="list-inline-item cited-by__entry__author">Sunder Mudaliar, </li><li class="list-inline-item cited-by__entry__author">Henry Robert, </li><li class="list-inline-item cited-by__entry__author">Schafer Boeder, </li><li class="list-inline-item cited-by__entry__author">Jeremy Pettus, </li><li class="list-inline-item cited-by__entry__author">Elsa Diaz, </li><li class="list-inline-item cited-by__entry__author">Daneila Garcia-Acosta, </li><li class="list-inline-item cited-by__entry__author">Sarah Maggs, </li><li class="list-inline-item cited-by__entry__author">Catherine DeLue, </li><li class="list-inline-item cited-by__entry__author">Andrea Stallings, </li><li class="list-inline-item cited-by__entry__author">Erick Castro, </li><li class="list-inline-item cited-by__entry__author">Sylvia Hernandez, </li><li class="list-inline-item cited-by__entry__author">Jonathan Krakoff, </li><li class="list-inline-item cited-by__entry__author">Jeffrey M. Curtis, </li><li class="list-inline-item cited-by__entry__author">Tina Killean, </li><li class="list-inline-item cited-by__entry__author">Meshall Khalid, </li><li class="list-inline-item cited-by__entry__author">Erica Joshevama, </li><li class="list-inline-item cited-by__entry__author">Enrique Diaz, </li><li class="list-inline-item cited-by__entry__author">Denelle Martin, </li><li class="list-inline-item cited-by__entry__author">Kaylee Tsingine, </li><li class="list-inline-item cited-by__entry__author">Tracey Karshner, </li><li class="list-inline-item cited-by__entry__author">Jeanine Albu, </li><li class="list-inline-item cited-by__entry__author">F. Xavier Pi-Sunyer, </li><li class="list-inline-item cited-by__entry__author">Sylvaine Frances, </li><li class="list-inline-item cited-by__entry__author">Carol Maggio, </li><li class="list-inline-item cited-by__entry__author">Emily Ellis, </li><li class="list-inline-item cited-by__entry__author">Joseph Bastawrose, </li><li class="list-inline-item cited-by__entry__author">Xiuqun Gong, </li><li class="list-inline-item cited-by__entry__author">Mary Ann Banerji, </li><li class="list-inline-item cited-by__entry__author">Phyllis August, </li><li class="list-inline-item cited-by__entry__author">Melissa Lee, </li><li class="list-inline-item cited-by__entry__author">Daniel Lorber, </li><li class="list-inline-item cited-by__entry__author">Brown Necole M., </li><li class="list-inline-item cited-by__entry__author">Debra H. Josephson, </li><li class="list-inline-item cited-by__entry__author">Lorraine L. Thomas, </li><li class="list-inline-item cited-by__entry__author">Maria Tsovian, </li><li class="list-inline-item cited-by__entry__author">Ajini Cherian, </li><li class="list-inline-item cited-by__entry__author">Marlo H. Jacobson, </li><li class="list-inline-item cited-by__entry__author">Motria M. Mishko, </li><li class="list-inline-item cited-by__entry__author">Sue M. Kirkman, </li><li class="list-inline-item cited-by__entry__author">John B. Buse, </li><li class="list-inline-item cited-by__entry__author">Jeanine Dostou, </li><li class="list-inline-item cited-by__entry__author">Sriram Machineni, </li><li class="list-inline-item cited-by__entry__author">Laura Young, </li><li class="list-inline-item cited-by__entry__author">Katherine Bergamo, </li><li class="list-inline-item cited-by__entry__author">April Goley, </li><li class="list-inline-item cited-by__entry__author">Jeffrey Kerr, </li><li class="list-inline-item cited-by__entry__author">Joseph F. Largay, </li><li class="list-inline-item cited-by__entry__author">Sonia Guarda, </li><li class="list-inline-item cited-by__entry__author">Juanita Cuffee, </li><li class="list-inline-item cited-by__entry__author">Dawn Culmer, </li><li class="list-inline-item cited-by__entry__author">Rachael Fraser, </li><li class="list-inline-item cited-by__entry__author">Hope Almeida, </li><li class="list-inline-item cited-by__entry__author">Samantha Coffer, </li><li class="list-inline-item cited-by__entry__author">Elizabeth Debnam, </li><li class="list-inline-item cited-by__entry__author">Lauren Kiker, </li><li class="list-inline-item cited-by__entry__author">Sarah Morton, </li><li class="list-inline-item cited-by__entry__author">Kim Josey, </li><li class="list-inline-item cited-by__entry__author">Gail Fuller, </li><li class="list-inline-item cited-by__entry__author">W. Timothy Garvey, </li><li class="list-inline-item cited-by__entry__author">Andrea L. Cherrington, </li><li class="list-inline-item cited-by__entry__author">Dana Dyer, </li><li class="list-inline-item cited-by__entry__author">Mary Catherine Robertson Lawson, </li><li class="list-inline-item cited-by__entry__author">Olivia Griffith, </li><li class="list-inline-item cited-by__entry__author">April Agne, </li><li class="list-inline-item cited-by__entry__author">Steve McCullars, </li><li class="list-inline-item cited-by__entry__author">Robert M. Cohen, </li><li class="list-inline-item cited-by__entry__author">Jacqueline Craig, </li><li class="list-inline-item cited-by__entry__author">M. Colleen Rogge, </li><li class="list-inline-item cited-by__entry__author">Kathryn Burton, </li><li class="list-inline-item cited-by__entry__author">Kimberly Kersey, </li><li class="list-inline-item cited-by__entry__author">Carla Wilson, </li><li class="list-inline-item cited-by__entry__author">Sonia Lipp, </li><li class="list-inline-item cited-by__entry__author">Mary Beth Vonder Meulen, </li><li class="list-inline-item cited-by__entry__author">Connie Adkins, </li><li class="list-inline-item cited-by__entry__author">Tolu Onadeko, </li><li class="list-inline-item cited-by__entry__author">Neda Rasouli, </li><li class="list-inline-item cited-by__entry__author">Chelsea Baker, </li><li class="list-inline-item cited-by__entry__author">Emily Schroeder, </li><li class="list-inline-item cited-by__entry__author">Mitra Razzaghi, </li><li class="list-inline-item cited-by__entry__author">Corey Lyon, </li><li class="list-inline-item cited-by__entry__author">Richard Penaloza, </li><li class="list-inline-item cited-by__entry__author">Chantal Underkofler, </li><li class="list-inline-item cited-by__entry__author">Rebecca Lorch, </li><li class="list-inline-item cited-by__entry__author">Sarah Douglass, </li><li class="list-inline-item cited-by__entry__author">Stephanie Steiner, </li><li class="list-inline-item cited-by__entry__author">William Sivitz, </li><li class="list-inline-item cited-by__entry__author">Erin Cline, </li><li class="list-inline-item cited-by__entry__author">Laura K Knosp, </li><li class="list-inline-item cited-by__entry__author">Jennifer McConnell, </li><li class="list-inline-item cited-by__entry__author">Tamara Lowe, </li><li class="list-inline-item cited-by__entry__author">William H. Herman, </li><li class="list-inline-item cited-by__entry__author">Rodica Pop-Busui, </li><li class="list-inline-item cited-by__entry__author">Meng H. Tan, </li><li class="list-inline-item cited-by__entry__author">Catherine Martin, </li><li class="list-inline-item cited-by__entry__author">Andrea Waltje, </li><li class="list-inline-item cited-by__entry__author">Aimee Katona, </li><li class="list-inline-item cited-by__entry__author">Lynn Goodhall, </li><li class="list-inline-item cited-by__entry__author">Rebecca Eggleston, </li><li class="list-inline-item cited-by__entry__author">Shihchen Kuo, </li><li class="list-inline-item cited-by__entry__author">Stefana Bojescu, </li><li class="list-inline-item cited-by__entry__author">Stephanie Bule, </li><li class="list-inline-item cited-by__entry__author">Nancy Kessler, </li><li class="list-inline-item cited-by__entry__author">Elizabeth LaSalle, </li><li class="list-inline-item cited-by__entry__author">Kelly Whitley, </li><li class="list-inline-item cited-by__entry__author">Elizabeth R. Seaquist, </li><li class="list-inline-item cited-by__entry__author">Anne Bantle, </li><li class="list-inline-item cited-by__entry__author">Tasma Harindhanavudhi, </li><li class="list-inline-item cited-by__entry__author">Anjali Kumar, </li><li class="list-inline-item cited-by__entry__author">Bruce Redmon, </li><li class="list-inline-item cited-by__entry__author">John Bantle, </li><li class="list-inline-item cited-by__entry__author">Mary Coe, </li><li class="list-inline-item cited-by__entry__author">Michael Mech, </li><li class="list-inline-item cited-by__entry__author">Abdisa Taddese, </li><li class="list-inline-item cited-by__entry__author">Lesia Lesne, </li><li class="list-inline-item cited-by__entry__author">Shannon Smith, </li><li class="list-inline-item cited-by__entry__author">Cyrus Desouza, </li><li class="list-inline-item cited-by__entry__author">Lisa Kuechenmeister, </li><li class="list-inline-item cited-by__entry__author">Vijay Shivaswamv, </li><li class="list-inline-item cited-by__entry__author">Susan Burbach, </li><li class="list-inline-item cited-by__entry__author">Maria Grace Rodriguez, </li><li class="list-inline-item cited-by__entry__author">Kris Seipel, </li><li class="list-inline-item cited-by__entry__author">Alissa Alfred, </li><li class="list-inline-item cited-by__entry__author">Ana Laura Morales, </li><li class="list-inline-item cited-by__entry__author">Jenna Eggert, </li><li class="list-inline-item cited-by__entry__author">Grace Lord, </li><li class="list-inline-item cited-by__entry__author">William Taylor, </li><li class="list-inline-item cited-by__entry__author">Renee Tillson, </li><li class="list-inline-item cited-by__entry__author">David S. Schade, </li><li class="list-inline-item cited-by__entry__author">Allen Adolphe, </li><li class="list-inline-item cited-by__entry__author">Mark Burge, </li><li class="list-inline-item cited-by__entry__author">Elizabeth Duran-Valdez, </li><li class="list-inline-item cited-by__entry__author">Janae Martinez, </li><li class="list-inline-item cited-by__entry__author">Anna Bancroft, </li><li class="list-inline-item cited-by__entry__author">Susan Kunkel, </li><li class="list-inline-item cited-by__entry__author">Fadi Ali Jamaleddin Ahmad, </li><li class="list-inline-item cited-by__entry__author">Doris Hernandez McGinnis, </li><li class="list-inline-item cited-by__entry__author">Benjamin Pucchetti, </li><li class="list-inline-item cited-by__entry__author">Elizabeth Scripsick, </li><li class="list-inline-item cited-by__entry__author">Amy Zamorano, </li><li class="list-inline-item cited-by__entry__author">Ralph A. DeFronzo, </li><li class="list-inline-item cited-by__entry__author">Eugenio Cersosimo, </li><li class="list-inline-item cited-by__entry__author">Muhammad Abdul-Ghani, </li><li class="list-inline-item cited-by__entry__author">Curtis Triplitt, </li><li class="list-inline-item cited-by__entry__author">Deanna Juarez, </li><li class="list-inline-item cited-by__entry__author">Rosa Irene Garza, </li><li class="list-inline-item cited-by__entry__author">Hector Verastiqui, </li><li class="list-inline-item cited-by__entry__author">Kathryn Wright, </li><li class="list-inline-item cited-by__entry__author">Curtiss Puckett, </li><li class="list-inline-item cited-by__entry__author">Philip Raskin, </li><li class="list-inline-item cited-by__entry__author">Chanhaeng Rhee, </li><li class="list-inline-item cited-by__entry__author">Soma Abraham, </li><li class="list-inline-item cited-by__entry__author">Lin Fan Jordan, </li><li class="list-inline-item cited-by__entry__author">Serey Sao, </li><li class="list-inline-item cited-by__entry__author">Luisa Morton, </li><li class="list-inline-item cited-by__entry__author">Oralenda Smith, </li><li class="list-inline-item cited-by__entry__author">Laura Osornio Walker, </li><li class="list-inline-item cited-by__entry__author">Laura Schnurr-Breen, </li><li class="list-inline-item cited-by__entry__author">Rosa Irene Ayala, </li><li class="list-inline-item cited-by__entry__author">Robert Brian Kreymer, </li><li class="list-inline-item cited-by__entry__author">Daytheon Sturgess, </li><li class="list-inline-item cited-by__entry__author">Kristina M Utzschneider, </li><li class="list-inline-item cited-by__entry__author">Steven E. Kahn, </li><li class="list-inline-item cited-by__entry__author">Lorena Alarcon-Casas Wright, </li><li class="list-inline-item cited-by__entry__author">Edward J. Boyko, </li><li class="list-inline-item cited-by__entry__author">Elaine C. Tsiai, </li><li class="list-inline-item cited-by__entry__author">Dace L. Trence, </li><li class="list-inline-item cited-by__entry__author">Subblaxmi Trikudanathan, </li><li class="list-inline-item cited-by__entry__author">Basma N. Fattaleh, </li><li class="list-inline-item cited-by__entry__author">Brenda K Montgomery, </li><li class="list-inline-item cited-by__entry__author">Karen M. Atkinson, </li><li class="list-inline-item cited-by__entry__author">Alexandra Kozedub, </li><li class="list-inline-item cited-by__entry__author">Tessa Concepcion, </li><li class="list-inline-item cited-by__entry__author">Cameron Moak, </li><li class="list-inline-item cited-by__entry__author">Nina Prikhodko, </li><li class="list-inline-item cited-by__entry__author">Samantha Rhothisen, </li><li class="list-inline-item cited-by__entry__author">Tom A. Elasy, </li><li class="list-inline-item cited-by__entry__author">Stephanie Martin, </li><li class="list-inline-item cited-by__entry__author">Laura Shackelford, </li><li class="list-inline-item cited-by__entry__author">Rita Goidel, </li><li class="list-inline-item cited-by__entry__author">Nina Hinkle, </li><li class="list-inline-item cited-by__entry__author">Cynthia Lovell, </li><li class="list-inline-item cited-by__entry__author">Janet Myers, </li><li class="list-inline-item cited-by__entry__author">Janie Lipps Hogan, </li><li class="list-inline-item cited-by__entry__author">Janet B. McGill, </li><li class="list-inline-item cited-by__entry__author">Maamoun Salam, </li><li class="list-inline-item cited-by__entry__author">Toni Schweiger, </li><li class="list-inline-item cited-by__entry__author">Sarah Kissel, </li><li class="list-inline-item cited-by__entry__author">Carol Recklein, </li><li class="list-inline-item cited-by__entry__author">Mary Jane Clifton, </li><li class="list-inline-item cited-by__entry__author">William Tamborlane, </li><li class="list-inline-item cited-by__entry__author">Anne Camp, </li><li class="list-inline-item cited-by__entry__author">Barbara Gulanski, </li><li class="list-inline-item cited-by__entry__author">Silvio E Inzucchi, </li><li class="list-inline-item cited-by__entry__author">Kim Pham, </li><li class="list-inline-item cited-by__entry__author">Michele Alguard, </li><li class="list-inline-item cited-by__entry__author">Patricia Gatcomb, </li><li class="list-inline-item cited-by__entry__author">Katarzyna Lessard, </li><li class="list-inline-item cited-by__entry__author">Magalys Perez, </li><li class="list-inline-item cited-by__entry__author">Lynne Iannone, </li><li class="list-inline-item cited-by__entry__author">Elizabeth Magenheimer, </li><li class="list-inline-item cited-by__entry__author">Abmaridel Montosa, </li><li class="list-inline-item cited-by__entry__author">William T Cefalu, </li><li class="list-inline-item cited-by__entry__author">Judith Fradkin, </li><li class="list-inline-item cited-by__entry__author">Henry B. Burch, </li><li class="list-inline-item cited-by__entry__author">Andrew Bremer, </li><li class="list-inline-item cited-by__entry__author">David M. Nathan, </li><li class="list-inline-item cited-by__entry__author">John M. Lachin, </li><li class="list-inline-item cited-by__entry__author">Heidi Krause-Steinrauf, </li><li class="list-inline-item cited-by__entry__author">Naji Younes, </li><li class="list-inline-item cited-by__entry__author">Ionut Bebu, </li><li class="list-inline-item cited-by__entry__author">Nicole Butera, </li><li class="list-inline-item cited-by__entry__author">CJ Buys, </li><li class="list-inline-item cited-by__entry__author">Anna Fagan, </li><li class="list-inline-item cited-by__entry__author">Yuping Gao, </li><li class="list-inline-item cited-by__entry__author">Alokananda Ghosh, </li><li class="list-inline-item cited-by__entry__author">Michaela R. Gramzinski, </li><li class="list-inline-item cited-by__entry__author">Stephanie D. Hall, </li><li class="list-inline-item cited-by__entry__author">Erin Kazemi, </li><li class="list-inline-item cited-by__entry__author">Elizabeth Legowski, </li><li class="list-inline-item cited-by__entry__author">Haiyin Liu, </li><li class="list-inline-item cited-by__entry__author">Colleen E. Suratt, </li><li class="list-inline-item cited-by__entry__author">Mark Tripputi, </li><li class="list-inline-item cited-by__entry__author">Alyssa Arey, </li><li class="list-inline-item cited-by__entry__author">Michael Backman, </li><li class="list-inline-item cited-by__entry__author">Joel Bethepu, </li><li class="list-inline-item cited-by__entry__author">Claire Lund, </li><li class="list-inline-item cited-by__entry__author">Pam Mangat Dhaliwal, </li><li class="list-inline-item cited-by__entry__author">Paula McGee, </li><li class="list-inline-item cited-by__entry__author">Emily Mesimer, </li><li class="list-inline-item cited-by__entry__author">Lisa Ngo, </li><li class="list-inline-item cited-by__entry__author">Michael Steffes, </li><li class="list-inline-item cited-by__entry__author">Jesse Seegmiller, </li><li class="list-inline-item cited-by__entry__author">Amy Saenger, </li><li class="list-inline-item cited-by__entry__author">Valerie Arends, </li><li class="list-inline-item cited-by__entry__author">Deanna Gabrielson, </li><li class="list-inline-item cited-by__entry__author">Todd Conner, </li><li class="list-inline-item cited-by__entry__author">Stuart Warren, </li><li class="list-inline-item cited-by__entry__author">Jolene Day, </li><li class="list-inline-item cited-by__entry__author">Jeffrey Huminik, </li><li class="list-inline-item cited-by__entry__author">Alexandra Scrymgeour, </li><li class="list-inline-item cited-by__entry__author">Elsayed Z. Soliman, </li><li class="list-inline-item cited-by__entry__author">Yashashwi Pokharel, </li><li class="list-inline-item cited-by__entry__author">Zhu-Ming Zhang, </li><li class="list-inline-item cited-by__entry__author">Charles Campbell, </li><li class="list-inline-item cited-by__entry__author">Julie Hu, </li><li class="list-inline-item cited-by__entry__author">Lisa Keasler, </li><li class="list-inline-item cited-by__entry__author">Susan Hensley, </li><li class="list-inline-item cited-by__entry__author">Yabing Li, </li><li class="list-inline-item cited-by__entry__author">Rada Mihalcea, </li><li class="list-inline-item cited-by__entry__author">Do June Min, </li><li class="list-inline-item cited-by__entry__author">Veronica Perez-Rosas, </li><li class="list-inline-item cited-by__entry__author">Lisa Prosser, </li><li class="list-inline-item cited-by__entry__author">Kenneth Resnicow, </li><li class="list-inline-item cited-by__entry__author">Wen Ye, </li><li class="list-inline-item cited-by__entry__author">Hui Shao, </li><li class="list-inline-item cited-by__entry__author">Ping Zhang, </li><li class="list-inline-item cited-by__entry__author">Jose Luchsinger, </li><li class="list-inline-item cited-by__entry__author">Danurys Sanchez, </li><li class="list-inline-item cited-by__entry__author">Stephanie Assuras, </li><li class="list-inline-item cited-by__entry__author">Erik Groessl, </li><li class="list-inline-item cited-by__entry__author">Fatema Sakha, </li><li class="list-inline-item cited-by__entry__author">Helen Chong, </li><li class="list-inline-item cited-by__entry__author">Naomi Hillery, </li><li class="list-inline-item cited-by__entry__author">Ivan Abdouch, </li><li class="list-inline-item cited-by__entry__author">Gul Bahityar, </li><li class="list-inline-item cited-by__entry__author">Paula Brantley, </li><li class="list-inline-item cited-by__entry__author">Frances E. Broyles, </li><li class="list-inline-item cited-by__entry__author">Gay Canaris, </li><li class="list-inline-item cited-by__entry__author">Paul Copeland, </li><li class="list-inline-item cited-by__entry__author">Jeri J. Craine, </li><li class="list-inline-item cited-by__entry__author">Warren L. Fein, </li><li class="list-inline-item cited-by__entry__author">Agnieska Gliwa, </li><li class="list-inline-item cited-by__entry__author">Lisel M. Hope, </li><li class="list-inline-item cited-by__entry__author">Melissa S. Lee, </li><li class="list-inline-item cited-by__entry__author">Rebecca Meiners, </li><li class="list-inline-item cited-by__entry__author">Vaughn Meiners, </li><li class="list-inline-item cited-by__entry__author">Hollis O'Neal, </li><li class="list-inline-item cited-by__entry__author">James E. Park, </li><li class="list-inline-item cited-by__entry__author">Alan Sacerdote, </li><li class="list-inline-item cited-by__entry__author">Edward Sledge, </li><li class="list-inline-item cited-by__entry__author">Lisa Soni, </li><li class="list-inline-item cited-by__entry__author">Jeanne Steppel-Reznik, </li><li class="list-inline-item cited-by__entry__author">Alexander Turchin, </li></ul><span class="cited-by__entry__title">Glucose-Lowering Medications, Glycemia, and Cognitive Outcomes, </span><span class="cited-by__entry__series-title">JAMA Internal Medicine, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1001/jamainternmed.2025.1189" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1001/jamainternmed.2025.1189</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1001/jamainternmed.2025.1189" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Nan Yu, </li><li class="list-inline-item cited-by__entry__author">Wenjie Xu, </li><li class="list-inline-item cited-by__entry__author">Xiaohui Guo, </li><li class="list-inline-item cited-by__entry__author">Mingtong Xu, </li><li class="list-inline-item cited-by__entry__author">Wei Zhang, </li><li class="list-inline-item cited-by__entry__author">Chaoli Yan, </li><li class="list-inline-item cited-by__entry__author">Shuguang Pang, </li><li class="list-inline-item cited-by__entry__author">Xiuhai Shu, </li><li class="list-inline-item cited-by__entry__author">Wei Zhang, </li><li class="list-inline-item cited-by__entry__author">Weixia Peng, </li><li class="list-inline-item cited-by__entry__author">Yawei Zhang, </li><li class="list-inline-item cited-by__entry__author">Gaixian Li, </li><li class="list-inline-item cited-by__entry__author">Xin Zhang, </li><li class="list-inline-item cited-by__entry__author">Dongmei Zhou, </li></ul><span class="cited-by__entry__title">Fotagliptin add‐on therapy to metformin in patients with uncontrolled type 2 diabetes: A randomised, multicentre, double‐blind, placebo‐controlled, phase 3 trial, </span><span class="cited-by__entry__series-title">Diabetes, Obesity and Metabolism, </span><span class="cited-by__entry__volume"><strong>27</strong>, </span><span class="cited-by__entry__issue">7, </span><span class="cited-by__entry__page-range">(3933-3942), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1111/dom.16427" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1111/dom.16427</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1111/dom.16427" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry--see-more"><a href="javascript:void(0)" data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2200433%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2022.387.issue-12%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" class="cited-by__see-more">See more</a></li></ol></div><div class="cited-by__spinner justify-content-center align-items-center d-none"><div role="status" class="spinner-border text-gray"><span class="sr-only">Loading...</span></div></div></div></section>

        </div>
    

</section></section></div><div id="core-collateral-fulltext-options" role="tabpanel" data-core-tabs="core-collateral-fulltext-options" tabindex="-1" aria-labelledby="pane-core-collateral-fulltext-options"><header><h2 id="pane-core-collateral-fulltext-options"><i class="icon-eye" aria-hidden="true"></i>View Options</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div class="section--wrapper"><h3>View options</h3><section class="format--pdf"><h4> <abbr title="Portable Document Format">PDF</abbr></h4><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2200433" class="btn btn--pdf" aria-label="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2200433" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2200433.pdf"><i aria-hidden="true" class="icon-pdf"></i><span>View PDF</span></a></section></div><!-- Its needed to duplicate this for PB check Collateral.js as well--></div><div id="core-collateral-media" role="tabpanel" data-core-tabs="core-collateral-media" tabindex="-1" aria-labelledby="pane-core-collateral-media"><header><h2 id="pane-core-collateral-media"><i class="icon-photo" aria-hidden="true"></i>Media</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-figures" role="tab" id="tab-figures-label" aria-selected="true" class="active">Figures</button><button aria-controls="tab-other" role="tab" id="tab-other-label" tabindex="-1" aria-selected="false" class="inactive" aria-disabled="true">Other</button></div><section id="tab-figures" aria-labelledby="tab-figures-label" role="tabpanel" tabindex="0"><h3>Figures</h3><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#figures"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-f1"><figure class="graphic"><a class="open-in-viewer" href="#f1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2200433_f1.jpg"><img src="/cms/10.1056/NEJMoa2200433/asset/e7658d51-44ad-4465-b469-597495771f3b/assets/images/large/nejmoa2200433_f1.jpg" height="2248" width="2640" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Kaplan–Meier Analysis of Outcome Events and Mean Glycated Hemoglobin Levels.</div><div class="notes"><div role="doc-footnote">Shown are the cumulative incidences of a glycated hemoglobin level of 7.0% or higher (the primary metabolic outcome) (Panel A), a glycated hemoglobin level of greater than 7.5% (the secondary metabolic outcome) (Panel B), and a confirmed glycated hemoglobin level greater than 7.5% after the secondary outcome (the tertiary metabolic outcome) (Panel C), as well as the mean glycated hemoglobin levels (Panel D). In Panels A through C, the shaded bars along the x axis indicate the number of participants with data available for the analyses over time (i.e., the number of participants in whom a specified outcome event had not developed by that time). The vertical dashed lines indicate the results at 4 years, when 85.8% of the participants were undergoing follow-up. To convert values for glycated hemoglobin to millimoles per mole, multiply by 10.93 and then subtract 23.5.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f1"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2200433_f1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-f2"><figure class="graphic"><a class="open-in-viewer" href="#f2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2200433_f2.jpg"><img src="/cms/10.1056/NEJMoa2200433/asset/fbab790c-6212-4917-a0d2-b83d3dbf7ab6/assets/images/large/nejmoa2200433_f2.jpg" height="1169" width="2640" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">Analyses of the Primary Outcome According to Baseline Glycated Hemoglobin Levels.</div><div class="notes"><div role="doc-footnote">The risk reductions, calculated from the hazard ratios, with glargine, glimepiride, and liraglutide, as compared with sitagliptin, are shown with unadjusted 95% confidence intervals. To convert values for glycated hemoglobin to millimoles per mole, multiply by 10.93 and then subtract 23.5.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f2"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2200433_f2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-f3"><figure class="graphic"><a class="open-in-viewer" href="#f3" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2200433_f3.jpg"><img src="/cms/10.1056/NEJMoa2200433/asset/1e05f48b-dd75-4aff-b516-ce26e8f66724/assets/images/large/nejmoa2200433_f3.jpg" height="1668" width="2640" aria-labelledby="f3" loading="lazy"></a><figcaption><div class="caption">Overall Incidence of Adverse Events.</div><div class="notes"><div role="doc-footnote">Event rates were calculated as the number of events per 100 participant-years. Simple P values (not corrected for multiple tests among event types or treatment groups) were obtained from a Poisson regression model of the rates. The diagram denotes the range of the P values for the six pairwise group comparisons of each adverse event. The following were adjudicated events: serious adverse events or any targeted events, including severe hypoglycemia, lactic acidosis, pancreatitis, diabetic ketoacidosis or hyperosmolar hyperglycemic syndrome, revascularization (coronary, peripheral, or cerebral), congestive heart failure, or cancer. The first occurrence of weight gain of 10% or more was compared with the baseline weight. Gastrointestinal symptoms included any one of the following symptoms that occurred at least once per week in the 30 days before the quarterly visit and were reported by the participant: nausea, vomiting, bloating or stomach pain, or diarrhea.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f3"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f3" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2200433_f3.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></section><section id="tab-other" aria-labelledby="tab-other-label" role="tabpanel" tabindex="-1"><h3>Other</h3></section></div><div id="core-collateral-tables" role="tabpanel" data-core-tabs="core-collateral-tables" tabindex="-1" aria-labelledby="pane-core-collateral-tables"><header><h2 id="pane-core-collateral-tables"><i class="icon-tables" aria-hidden="true"></i>Tables</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><!-- There is no content. --><div class="section--wrapper"><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#tables"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-t1"><figure class="table"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2200433_t1.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2200433/asset/a955355f-bebd-41c2-93da-0189071e72e4/assets/images/large/nejmoa2200433_t1.jpg" height="1981" width="1999" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Variable</th><th class="txxx-borders">Glargine<br> (N=1263)</th><th class="txxx-borders">Glimepiride<br> (N=1254)</th><th class="txxx-borders">Liraglutide<br> (N=1262)</th><th class="txxr-borders">Sitagliptin<br> (N=1268)</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Retention — no./total no. (%)<a href="#core-t1fn1" role="doc-noteref">*</a></td><td class="xxxx-borders shading">1138/1221 (93.2)</td><td class="xxxx-borders shading">1142/1211 (94.3)</td><td class="xxxx-borders shading">1156/1235 (93.6)</td><td class="xxxr-borders shading">1144/1227 (93.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Overall adherence to trial visits — %<a href="#core-t1fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">91.4</td><td class="xxxx-borders">92.9</td><td class="xxxx-borders">92.3</td><td class="xxxr-borders">92.8</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Mean follow-up — yr<a href="#core-t1fn3" role="doc-noteref">‡</a><a href="#core-t1fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">4.9±1.4</td><td class="xxxx-borders shading">5.0±1.3</td><td class="xxxx-borders shading">5.0±1.3</td><td class="xxxr-borders shading">5.0±1.3</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Discontinuation of metformin — no. (%)</td><td class="xxxx-borders">105 (8.3)</td><td class="xxxx-borders">98 (7.8)</td><td class="xxxx-borders">88 (7.0)</td><td class="xxxr-borders">97 (7.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Use of nontrial, glucose-lowering medications outside the protocol, discontinuation of assigned trial treatment outside the protocol, or both — no. (%)<a href="#core-t1fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders shading">332 (26.3)</td><td class="xxxx-borders shading">426 (34.0)</td><td class="xxxx-borders shading">368 (29.2)</td><td class="xxxr-borders shading">347 (27.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">&lt;1 yr after randomization</td><td class="xxxx-borders">65 (5.1)</td><td class="xxxx-borders">61 (4.9)</td><td class="xxxx-borders">150 (11.9)</td><td class="xxxr-borders">60 (4.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">1 to &lt;2 yr after randomization</td><td class="xxxx-borders shading">51 (4.0)</td><td class="xxxx-borders shading">65 (5.2)</td><td class="xxxx-borders shading">51 (4.0)</td><td class="xxxr-borders shading">60 (4.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">≥2 yr after randomization</td><td class="xxxx-borders">216 (17.1)</td><td class="xxxx-borders">300 (23.9)</td><td class="xxxx-borders">167 (13.2)</td><td class="xxxr-borders">227 (17.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Duration of assigned trial treatment in accordance with the protocol — yr<a href="#core-t1fn4" role="doc-noteref">§</a><a href="#core-t1fn5" role="doc-noteref">¶</a><a href="#core-t1fn6" role="doc-noteref">‖</a></td><td class="xxxx-borders shading">4.3±1.8</td><td class="xxxx-borders shading">4.2±1.7</td><td class="xxxx-borders shading">4.1±2.0</td><td class="xxxr-borders shading">4.3±1.7</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Percentage of trial time during which participant received originally assigned treatment in accordance with the protocol <a href="#core-t1fn4" role="doc-noteref">§</a><a href="#core-t1fn5" role="doc-noteref">¶</a><a href="#core-t1fn6" role="doc-noteref">‖</a><a href="#core-t1fn7" role="doc-noteref">**</a></td><td class="xxxx-borders">83.7±28.9</td><td class="xxxx-borders">82.0±28.7</td><td class="xxxx-borders">79.1±34.6</td><td class="xxxr-borders">84.0±27.7</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Discontinuation of assigned trial treatment outside the protocol — no. (%)<a href="#core-t1fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders shading">172 (13.6)</td><td class="xxxx-borders shading">294 (23.4)</td><td class="xxxx-borders shading">289 (22.9)</td><td class="xxxr-borders shading">236 (18.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Maximum dose of assigned treatment received<a href="#core-t1fn8" role="doc-noteref">††</a><a href="#core-t1fn9" role="doc-noteref">‡‡</a></td><td class="xxxx-borders">51.4±39.7 U</td><td class="xxxx-borders">5.4±2.8 mg</td><td class="xxxx-borders">1.6±0.5 mg</td><td class="xxxr-borders">98.4±12.2 mg</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging02 shading" data-xml-align="left">Use of nontrial glucose-lowering medication outside the protocol — no. (%)</td><td class="xbxx-borders shading">176 (13.9)</td><td class="xbxx-borders shading">208 (16.6)</td><td class="xbxx-borders shading">136 (10.8)</td><td class="xbxr-borders shading">193 (15.2)</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t1fn1" role="paragraph" data-to-manipulate="true">Retention was defined as completion of the trial closeout visit. The denominators in this row sum to 4894 (i.e., participants who were not known to have died before the end of the trial).</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t1fn2" role="paragraph" data-to-manipulate="true">Visit adherence was calculated for each participant as 100% multiplied by the number of trial visits attended, divided by the maximum number of trial visits according to either the expected closeout trial visit date in participants who survived to the end of the trial or the date of death.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t1fn3" role="paragraph" data-to-manipulate="true">The duration of follow-up was calculated as the date of last trial contact minus the date of randomization.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="core-t1fn4" role="paragraph" data-to-manipulate="true">Plus–minus values are means ±SE.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="core-t1fn5" role="paragraph" data-to-manipulate="true">Participants were considered to have received assigned treatment if treatment was discontinued in accordance with the trial protocol (e.g., the randomized medication was discontinued because the participant had a tertiary outcome event, as stated in the protocol).</div></div><div role="doc-footnote" data-has="label"><div class="label">‖</div><div id="core-t1fn6" role="paragraph" data-to-manipulate="true">The duration shown is the time from randomization to the date of first discontinuation of trial treatment, use of nontrial glucose-lowering medication, or both in participants who discontinued trial treatment, used nontrial glucose-lowering medication during the trial, or both, or the time from randomization to the date of the last trial contact in those who did not discontinue trial treatment, did not use nontrial glucose-lowering medication during the trial, or both.</div></div><div role="doc-footnote" data-has="label"><div class="label">**</div><div id="core-t1fn7" role="paragraph" data-to-manipulate="true">The denominator for this percentage is the time from randomization to expected closeout visit date in participants who survived to the end of the trial, or the time from randomization to death, calculated for each participant.</div></div><div role="doc-footnote" data-has="label"><div class="label">††</div><div id="core-t1fn8" role="paragraph" data-to-manipulate="true">Shown is the mean maximum dose of randomly assigned medication taken at any time during the trial.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡‡</div><div id="core-t1fn9" role="paragraph" data-to-manipulate="true">Plus–minus values are means ±SD.</div></div></div></figcaption></a><figcaption><div class="caption">Protocol Completion and Adherence in the Treatment Groups during the Trial.</div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t1"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2200433_t1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t2"><figure class="table"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2200433_t2.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2200433/asset/b69a9b69-54d4-4433-bfb8-1acdd85fab7f/assets/images/large/nejmoa2200433_t2.jpg" height="2269" width="1999" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Outcome</th><th class="txxx-borders">Glargine<br> (N=1263)</th><th class="txxx-borders">Glimepiride<br> (N=1254)</th><th class="txxx-borders">Liraglutide<br> (N=1262)</th><th class="txxr-borders">Sitagliptin<br> (N=1268)</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Primary metabolic outcome<a href="#core-t2fn2" role="doc-noteref">†</a></b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Participants — no. (%)</td><td class="xxxx-borders">852 (67.4)</td><td class="xxxx-borders">908 (72.4)</td><td class="xxxx-borders">860 (68.2)</td><td class="xxxr-borders">981 (77.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Rate/100 participant-yr (95% CI)</td><td class="xxxx-borders shading">26.5<br>(24.8–28.4)</td><td class="xxxx-borders shading">30.4<br>(28.4–32.4)</td><td class="xxxx-borders shading">26.1<br>(24.4–27.9)</td><td class="xxxr-borders shading">38.1<br>(35.8–40.6)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Pairwise hazard ratios (95% CI)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Glargine</td><td class="xxxx-borders shading">—</td><td class="xxxx-borders shading">0.89<br>(0.81–0.98)<a href="#core-t2fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">1.02<br>(0.93–1.12)</td><td class="xxxr-borders shading">0.71<br>(0.64–0.78)<a href="#core-t2fn4" role="doc-noteref">§</a></td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Glimepiride</td><td class="xxxx-borders">—</td><td class="xxxx-borders">—</td><td class="xxxx-borders">1.15<br>(1.04–1.27)<a href="#core-t2fn5" role="doc-noteref">¶</a></td><td class="xxxr-borders">0.79<br>(0.72–0.88)<a href="#core-t2fn4" role="doc-noteref">§</a></td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Liraglutide</td><td class="xxxx-borders shading">—</td><td class="xxxx-borders shading">—</td><td class="xxxx-borders shading">—</td><td class="xxxr-borders shading">0.69<br>(0.63–0.76)<a href="#core-t2fn4" role="doc-noteref">§</a></td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Hazard ratio in the treatment group as compared with all other treatments combined (95% CI)</td><td class="xxxx-borders">0.87<br>(0.80–0.94)<a href="#core-t2fn4" role="doc-noteref">§</a></td><td class="xxxx-borders">1.01<br>(0.93–1.09)</td><td class="xxxx-borders">0.84<br>(0.78–0.91)<a href="#core-t2fn4" role="doc-noteref">§</a></td><td class="xxxr-borders">1.37<br>(1.27–1.48)<a href="#core-t2fn4" role="doc-noteref">§</a></td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Restricted mean survival time over 4 yr of follow-up (95% CI) — days</td><td class="xxxx-borders shading">861<br>(831–891)</td><td class="xxxx-borders shading">809<br>(780–838)</td><td class="xxxx-borders shading">882<br>(853–911)</td><td class="xxxr-borders shading">697<br>(667–726)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02"><b>Secondary metabolic outcome<a href="#core-t2fn6" role="doc-noteref">‖</a></b></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Participants — no. (%)</td><td class="xxxx-borders shading">498 (39.4)</td><td class="xxxx-borders shading">633 (50.5)</td><td class="xxxx-borders shading">583 (46.2)</td><td class="xxxr-borders shading">697 (55.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Rate/100 participant-yr (95% CI)</td><td class="xxxx-borders">10.7<br>(9.8–11.7)</td><td class="xxxx-borders">14.8<br>(13.6–16.0)</td><td class="xxxx-borders">13.0<br>(12.0–14.1)</td><td class="xxxr-borders">17.5<br>(16.3–18.9)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Pairwise hazard ratios (95% CI)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Glargine</td><td class="xxxx-borders">—</td><td class="xxxx-borders">0.73<br>(0.65–0.82)</td><td class="xxxx-borders">0.83<br>(0.73–0.93)</td><td class="xxxr-borders">0.61<br>(0.54–0.69)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Glimepiride</td><td class="xxxx-borders shading">—</td><td class="xxxx-borders shading">—</td><td class="xxxx-borders shading">1.13<br>(1.01–1.27)</td><td class="xxxr-borders shading">0.84<br>(0.75–0.93)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Liraglutide</td><td class="xxxx-borders">—</td><td class="xxxx-borders">—</td><td class="xxxx-borders">—</td><td class="xxxr-borders">0.74<br>(0.66–0.83)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Hazard ratio in the treatment group as compared with all other treatments combined (95% CI)</td><td class="xxxx-borders shading">0.72<br>(0.65–0.79)</td><td class="xxxx-borders shading">1.09<br>(1.00–1.20)</td><td class="xxxx-borders shading">0.92<br>(0.84–1.01)</td><td class="xxxr-borders shading">1.38<br>(1.26–1.51)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging02" data-xml-align="left">Restricted mean survival time over 4 yr of follow-up (95% CI) — days</td><td class="xbxx-borders">1188<br>(1163–1212)</td><td class="xbxx-borders">1115<br>(1090–1141)</td><td class="xbxx-borders">1154<br>(1129–1179)</td><td class="xbxr-borders">1030<br>(1002–1058)</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t2fn1" role="paragraph" data-to-manipulate="true">Shown are the numbers of participants with primary and secondary metabolic outcome events according to randomized treatment group (intention-to-treat) with overall rates and hazard ratios. Calculations for the tertiary outcome are provided in Table S5. CI denotes confidence interval.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t2fn2" role="paragraph" data-to-manipulate="true">For the primary outcome, P values were obtained from closed testing of pairwise group differences corrected for six pairwise comparisons. Confidence limits corrected for six pairwise tests were obtained by inverting the closed-testing z-test value and then computing corrected 95% confidence intervals. P&lt;0.001 from a test of the log hazard ratios for treatment failure among the four treatment groups, with the use of a Cox proportional-hazards model, with treatment group as the only predictor variable.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t2fn3" role="paragraph" data-to-manipulate="true">P≤0.05 for the specified comparison of two treatment groups.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="core-t2fn4" role="paragraph" data-to-manipulate="true">P≤0.001 for the specified comparison of two treatment groups.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="core-t2fn5" role="paragraph" data-to-manipulate="true">P≤0.01 for the specified comparison of two treatment groups.</div></div><div role="doc-footnote" data-has="label"><div class="label">‖</div><div id="core-t2fn6" role="paragraph" data-to-manipulate="true">For the secondary outcome, confidence intervals obtained from the Cox proportional-hazards model are not corrected for multiple comparisons among groups.</div></div></div></figcaption></a><figcaption><div class="caption">Primary and Secondary Metabolic Outcomes.<a href="#core-t2fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t2"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2200433_t2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></div></div><div id="core-collateral-share" role="tabpanel" data-core-tabs="core-collateral-share" tabindex="-1" aria-labelledby="pane-core-collateral-share"><header><h2 id="pane-core-collateral-share"><i class="icon-share" aria-hidden="true"></i>Share</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>Share</h3><div class="section--wrapper"><section><h4>CONTENT LINK</h4><div id="share-self"><p data-id="article-share-self-link" class="share-self__source">https://www.nejm.org/doi/full/10.1056/NEJMoa2200433</p><button data-id="article-share-access" aria-label="CONTENT LINK" class="share-self__action btn btn--inverse"><i aria-hidden="true" class="icon-copy-o"></i><span>Copy Link</span></button><div aria-live="polite" class="share-self__status"><p class="share-self__success"><i aria-hidden="true" class="icon-check_circle"></i><span>Copied!</span></p><p class="share-self__failed"><i aria-hidden="true" class="icon-x_btnclose"></i><span>Copying failed.</span></p></div></div></section><section data-location="share_tools_article"><h4>Share</h4><div class="share-buttons a2a a2a_kit" style="line-height: 16px;"><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i><span>Facebook</span></a><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i><span>X (formerly Twitter)</span></a><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i><span>LinkedIn</span></a><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i><span>email</span></a><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i><span>Bluesky</span></a></div></section></div></div><div data-location="references_article" id="core-collateral-references" role="tabpanel" aria-labelledby="pane-core-collateral-references" data-core-tabs="core-collateral-references" tabindex="-1"><header><h2 id="pane-core-collateral-references"><i aria-hidden="true" class="icon-references"></i>References</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>References</h3><div role="list" class="section--wrapper"><div role="listitem" data-has="label"><div class="label">1.</div><div id="core-r1" class="citations"><div class="citation"><div class="citation-content">Centers for Disease Control and Prevention. National diabetes statistics report. 2020 (<a href="https://www.cdc.gov/diabetes/data/statistics-report/index.html">https://www.cdc.gov/diabetes/data/statistics-report/index.html</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r2"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=Centers+for+Disease+Control+and+Prevention.+National+diabetes+statistics+report.+2020+%28https%3A%2F%2Fwww.cdc.gov%2Fdiabetes%2Fdata%2Fstatistics-report%2Findex.html%29." target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="core-r2" class="citations"><div class="citation"><div class="citation-content">International Diabetes Federation. IDF diabetes atlas. 2021 (<a href="https://diabetesatlas.org/">https://diabetesatlas.org/</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r2"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=IDF+diabetes+atlas&amp;publication_year=2021" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="core-r3" class="citations"><div class="citation"><div class="citation-content">American Diabetes Association. Economic costs of diabetes in the U.S. in 2017. <em>Diabetes Care</em> 2018;41:917-928.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r3"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.2337/dci18-0007" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29567642/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000430456100009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Economic+costs+of+diabetes+in+the+U.S.+in+2017.&amp;publication_year=2018&amp;journal=Diabetes+Care&amp;pages=917-928&amp;doi=10.2337%2Fdci18-0007&amp;pmid=29567642" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="core-r4" class="citations"><div class="citation"><div class="citation-content">UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). <em>Lancet</em> 1998;352:837-853.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r5"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(98)07019-6" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/9742976/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000075857300006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Intensive+blood-glucose+control+with+sulphonylureas+or+insulin+compared+with+conventional+treatment+and+risk+of+complications+in+patients+with+type+2+diabetes+%28UKPDS+33%29.&amp;publication_year=1998&amp;journal=Lancet&amp;pages=837-853&amp;doi=10.1016%2FS0140-6736%2898%2907019-6&amp;pmid=9742976" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="core-r5" class="citations"><div class="citation"><div class="citation-content">Hemmingsen B, Lund SS, Gluud C, Vaag A, Almdal TP, Wetterslev J. Withdrawn: targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. <em>Cochrane Database Syst Rev</em> 2015;7:CD008143-CD008143.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r5"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26222248/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000209933300014" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Withdrawn%3A+targeting+intensive+glycaemic+control+versus+targeting+conventional+glycaemic+control+for+type+2+diabetes+mellitus.&amp;publication_year=2015&amp;journal=Cochrane+Database+Syst+Rev&amp;pages=CD008143-CD008143&amp;pmid=26222248" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="core-r6" class="citations"><div class="citation"><div class="citation-content">American Diabetes Association. Glycemic targets: <i>Standards of Medical Care in Diabetes</i> — 2021. <em>Diabetes Care</em> 2021;44:Suppl 1:S73-S84.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r6"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.2337/dc21-S006" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33298417/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000609468800009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Glycemic+targets%3A+Standards+of+Medical+Care+in+Diabetes+%E2%80%94+2021.&amp;publication_year=2021&amp;journal=Diabetes+Care&amp;pages=S73-S84&amp;doi=10.2337%2Fdc21-S006&amp;pmid=33298417" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="core-r7" class="citations"><div class="citation"><div class="citation-content">American Diabetes Association, European Association for the Study of Diabetes. Pharmacologic approaches to glycemic treatment: <i>Standards of Medical Care in Diabetes</i> — 2021. <em>Diabetes Care</em> 2020;44:Suppl 1:S111-S124.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r8"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.2337/dc21-S009" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000609468800012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Pharmacologic+approaches+to+glycemic+treatment%3A+Standards+of+Medical+Care+in+Diabetes+%E2%80%94+2021.&amp;publication_year=2020&amp;journal=Diabetes+Care&amp;pages=S111-S124&amp;doi=10.2337%2Fdc21-S009" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="core-r8" class="citations"><div class="citation"><div class="citation-content">Diabetes Canada Clinical Practice Guidelines Expert Committee. Diabetes Canada 2018 clinical practice guidelines for the prevention and management of diabetes in Canada. <em>Can J Diabetes</em> 2018;42:Suppl 1:S1-S325.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r8"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29650079/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000438154400001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Diabetes+Canada+2018+clinical+practice+guidelines+for+the+prevention+and+management+of+diabetes+in+Canada.&amp;publication_year=2018&amp;journal=Can+J+Diabetes&amp;pages=S1-S325&amp;pmid=29650079" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="core-r9" class="citations"><div class="citation"><div class="citation-content">Nathan DM, Buse JB, Kahn SE, et al. Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE). <em>Diabetes Care</em> 2013;36:2254-2261.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r9-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.2337/dc13-0356" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23690531/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000327252600038" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Rationale+and+design+of+the+glycemia+reduction+approaches+in+diabetes%3A+a+comparative+effectiveness+study+%28GRADE%29.&amp;publication_year=2013&amp;journal=Diabetes+Care&amp;pages=2254-2261&amp;doi=10.2337%2Fdc13-0356&amp;pmid=23690531" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r9-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r9-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] persons with recent-onset type 2 diabetes. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r9-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] the investigators with NIDDK participation. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r9-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] the age at diagnosis was at least 20 years. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r9-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] hemoglobin level of 7.0% or higher. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r9-5" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>e [...] group after a secondary-outcome event. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r9-6" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>f [...] skin cancer) adjudicated by committee </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="core-r10" class="citations"><div class="citation"><div class="citation-content">The GRADE Study Research Group. Glycemia reduction in type 2 diabetes — microvascular and cardiovascular outcomes. <em>N Engl J Med</em> 2022;387:1075-1088.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_11_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2200433&amp;key=10.1056%2FNEJMoa2200436&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/36129997/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000865461700005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Glycemia+reduction+in+type+2+diabetes+%E2%80%94+microvascular+and+cardiovascular+outcomes.&amp;publication_year=2022&amp;journal=N+Engl+J+Med&amp;pages=1075-1088&amp;doi=10.1056%2FNEJMoa2200436&amp;pmid=36129997" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="core-r11" class="citations"><div class="citation"><div class="citation-content">Dormandy JA, Charbonnel B, Eckland DJA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. <em>Lancet</em> 2005;366:1279-1289.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r11"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(05)67528-9" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/16214598/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000232405700026" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Secondary+prevention+of+macrovascular+events+in+patients+with+type+2+diabetes+in+the+PROactive+Study+%28PROspective+pioglitAzone+Clinical+Trial+In+macroVascular+Events%29%3A+a+randomised+controlled+trial.&amp;publication_year=2005&amp;journal=Lancet&amp;pages=1279-1289&amp;doi=10.1016%2FS0140-6736%2805%2967528-9&amp;pmid=16214598" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="core-r12" class="citations"><div class="citation"><div class="citation-content">Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018: a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <em>Diabetes Care</em> 2018;41:2669-2701.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.2337/dci18-0033" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30291106/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000450560000037" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Management+of+hyperglycemia+in+type+2+diabetes%2C+2018%3A+a+consensus+report+by+the+American+Diabetes+Association+%28ADA%29+and+the+European+Association+for+the+Study+of+Diabetes+%28EASD%29.&amp;publication_year=2018&amp;journal=Diabetes+Care&amp;pages=2669-2701&amp;doi=10.2337%2Fdci18-0033&amp;pmid=30291106" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="core-r13" class="citations"><div class="citation"><div class="citation-content">Buse JB, Wexler DJ, Tsapas A, et al. 2019 update to: Management of Hyperglycemia in Type 2 Diabetes, 2018: a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <em>Diabetes Care</em> 2020;43:487-493.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.2337/dci19-0066" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31857443/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000508199900043" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=2019+update+to%3A+Management+of+Hyperglycemia+in+Type+2+Diabetes%2C+2018%3A+a+consensus+report+by+the+American+Diabetes+Association+%28ADA%29+and+the+European+Association+for+the+Study+of+Diabetes+%28EASD%29.&amp;publication_year=2020&amp;journal=Diabetes+Care&amp;pages=487-493&amp;doi=10.2337%2Fdci19-0066&amp;pmid=31857443" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="core-r14" class="citations"><div class="citation"><div class="citation-content">Lachin JM. <em>Biostatistical methods: the assessment of relative risks.</em> 2nd ed. Hoboken, NJ: John Wiley, 2011.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r14"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Biostatistical+methods%3A+the+assessment+of+relative+risks.&amp;publication_year=2011" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="core-r15" class="citations"><div class="citation"><div class="citation-content">Zhao L, Claggett B, Tian L, et al. On the restricted mean survival time curve in survival analysis. <em>Biometrics</em> 2016;72:215-221.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r15"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/biom.12384" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26302239/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000373914700022" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=On+the+restricted+mean+survival+time+curve+in+survival+analysis.&amp;publication_year=2016&amp;journal=Biometrics&amp;pages=215-221&amp;doi=10.1111%2Fbiom.12384&amp;pmid=26302239" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="core-r16" class="citations"><div class="citation"><div class="citation-content">Lachin JM, Bebu I. Closed testing of each group versus the others combined in a multiple group analysis. <em>Clin Trials</em> 2020;17:77-86.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r16-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1177/1740774519879932" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31647326/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000492518800001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Closed+testing+of+each+group+versus+the+others+combined+in+a+multiple+group+analysis.&amp;publication_year=2020&amp;journal=Clin+Trials&amp;pages=77-86&amp;doi=10.1177%2F1740774519879932&amp;pmid=31647326" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r16-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r16-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] of hazard ratios and confidence intervals. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r16-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] group with the other three combined. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="core-r17" class="citations"><div class="citation"><div class="citation-content">Marcus R, Peritz E, Gabriel KR. On closed testing procedures with special reference to ordered analysis of variance. <em>Biometrika</em> 1976;63:655-660.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r17"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/biomet/63.3.655" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1976CP66700034" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=On+closed+testing+procedures+with+special+reference+to+ordered+analysis+of+variance.&amp;publication_year=1976&amp;journal=Biometrika&amp;pages=655-660&amp;doi=10.1093%2Fbiomet%2F63.3.655" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="core-r18" class="citations"><div class="citation"><div class="citation-content">Wexler DJ, Krause-Steinrauf H, Crandall JP, et al. Baseline characteristics of randomized participants in the Glycemia Reduction Approaches in Diabetes: a Comparative Effectiveness study (GRADE). <em>Diabetes Care</em> 2019;42:2098-2107.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r18"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.2337/dc19-0901" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31391203/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000491450200017" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Baseline+characteristics+of+randomized+participants+in+the+Glycemia+Reduction+Approaches+in+Diabetes%3A+a+Comparative+Effectiveness+study+%28GRADE%29.&amp;publication_year=2019&amp;journal=Diabetes+Care&amp;pages=2098-2107&amp;doi=10.2337%2Fdc19-0901&amp;pmid=31391203" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="core-r19" class="citations"><div class="citation"><div class="citation-content">Nathan DM, Krause-Steinrauf H, Braffett BH, et al. Comparison of central laboratory HbA1c measurements obtained from a capillary collection versus a standard venous whole blood collection in the GRADE and EDIC studies. <em>PLoS One</em> 2021;16(11):e0257154-e0257154.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r19"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1371/journal.pone.0257154" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34780485/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000755305800006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Comparison+of+central+laboratory+HbA1c+measurements+obtained+from+a+capillary+collection+versus+a+standard+venous+whole+blood+collection+in+the+GRADE+and+EDIC+studies.&amp;publication_year=2021&amp;journal=PLoS+One&amp;pages=e0257154-e0257154&amp;doi=10.1371%2Fjournal.pone.0257154&amp;pmid=34780485" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="core-r20" class="citations"><div class="citation"><div class="citation-content">Walker RJ, Strom Williams J, Egede LE. Influence of race, ethnicity and social determinants of health on diabetes outcomes. <em>Am J Med Sci</em> 2016;351:366-373.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r21"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.amjms.2016.01.008" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27079342/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000382665400007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Influence+of+race%2C+ethnicity+and+social+determinants+of+health+on+diabetes+outcomes.&amp;publication_year=2016&amp;journal=Am+J+Med+Sci&amp;pages=366-373&amp;doi=10.1016%2Fj.amjms.2016.01.008&amp;pmid=27079342" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="core-r21" class="citations"><div class="citation"><div class="citation-content">Mayberry LS, Bergner EM, Chakkalakal RJ, Elasy TA, Osborn CY. Self-care disparities among adults with type 2 diabetes in the USA. <em>Curr Diab Rep</em> 2016;16:113-113.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r21"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s11892-016-0796-5" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27671320/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000388592700011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Self-care+disparities+among+adults+with+type+2+diabetes+in+the+USA.&amp;publication_year=2016&amp;journal=Curr+Diab+Rep&amp;pages=113-113&amp;doi=10.1007%2Fs11892-016-0796-5&amp;pmid=27671320" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="core-r22" class="citations"><div class="citation"><div class="citation-content">Kayaniyil S, Lozano-Ortega G, Bennett HA, et al. A network meta-analysis comparing exenatide once weekly with other GLP-1 receptor agonists for the treatment of type 2 diabetes mellitus. <em>Diabetes Ther</em> 2016;7:27-43.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r22"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s13300-016-0155-1" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26886440/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+network+meta-analysis+comparing+exenatide+once+weekly+with+other+GLP-1+receptor+agonists+for+the+treatment+of+type+2+diabetes+mellitus.&amp;publication_year=2016&amp;journal=Diabetes+Ther&amp;pages=27-43&amp;doi=10.1007%2Fs13300-016-0155-1&amp;pmid=26886440" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="core-r23" class="citations"><div class="citation"><div class="citation-content">Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. <em>N Engl J Med</em> 2006;355:2427-2443.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r23"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_24_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2200433&amp;key=10.1056%2FNEJMoa066224&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/17145742/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000242581400007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Glycemic+durability+of+rosiglitazone%2C+metformin%2C+or+glyburide+monotherapy.&amp;publication_year=2006&amp;journal=N+Engl+J+Med&amp;pages=2427-2443&amp;doi=10.1056%2FNEJMoa066224&amp;pmid=17145742" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="core-r24" class="citations"><div class="citation"><div class="citation-content">Khunti K, Gomes MB, Pocock S, et al. Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: a systematic review. <em>Diabetes Obes Metab</em> 2018;20:427-437.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/dom.13088" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28834075/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000422678600022" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Therapeutic+inertia+in+the+treatment+of+hyperglycaemia+in+patients+with+type+2+diabetes%3A+a+systematic+review.&amp;publication_year=2018&amp;journal=Diabetes+Obes+Metab&amp;pages=427-437&amp;doi=10.1111%2Fdom.13088&amp;pmid=28834075" target="_blank">Google Scholar</a></div></div></div></div></div></div></div></div><aside data-core-aside="right-rail">



        
        <div id="DTM_Position_MedRectangle" class="ad">
 <!--emptycomment-->
</div>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="relatedArticlesWidget" data-widget-id="8206d5cd-cb8c-4ff9-8c46-3d22e0dee215" data-location="recirc_curatedRelated_article">
        



        
        <div class="ng-related-articles"><h3 class="ng-subsection-title"><span class="ng-subsection-title_text">Related articles</span></h3><ul class="ng-related-articles_list"><li class="ng-related-articles_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Sep 21, 2022</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2200436" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Glycemia Reduction in Type 2 Diabetes — Microvascular and Cardiovascular Outcomes</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">The GRADE Study Research Group</span></div></div></div></div></div></li><li class="ng-related-articles_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/editorial" class="issue-item_type">Editorial</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Sep 21, 2022</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMe2210531" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">After Metformin — Next Steps for Type 2 Diabetes with Low Cardiovascular Risk</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">L. Rydén and E. Standl</span></div></div></div></div></div></li></ul></div>

        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <div id="nejm_jobs" class="nejm_jobs"> <!-- top red rectangle --><div id="nejm-widget" class="nejm-widget" style="display: block;"><div class="nejm-widget_logo">	<a target="nejm-win" href="https://www.nejmcareercenter.org/?query=fjw">		<img alt="CareerCenter" src="https://apps1.nejmcareercenter.org/images/nejmCCID-JobsWidget.gif" width="140" height="36">	</a></div><div class="nejm-widget_cont"> <!-- content --><div class="nejm-widget_title">PHYSICIAN JOBS</div><div class="nejm-widget_date">June 19, 2025</div><div class="nejm-widget_item"><div><span> New York City, New York</span></div><div><span>Surgery, Transplant</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/883926/surgical-director-for-pediatric-liver-transplantation/?query=fjwp&amp;rid=3059">Surgical Director for Pediatric Liver Transplantation</a></div></div><div class="nejm-widget_item"><div><span> Nashville, Tennessee</span></div><div><span>Hematology / Oncology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/890643/breast-surgeon-scri-oncology-partners-nashville/?query=fjwp&amp;rid=5696">Breast Surgeon - SCRI Oncology Partners Nashville</a></div></div><div class="nejm-widget_item"><div><span> Las Vegas, Nevada</span></div><div><span>Endocrinology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/889996/physician-endocrinology-and-diabetology/?query=fjwf&amp;rid=751">Physician-Endocrinology and Diabetology</a></div></div><div class="nejm-widget_item"><div><span> Norman, Oklahoma</span></div><div><span>Neonatal / Perinatal Medicine</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/883499/neonatologist/?query=fjwf&amp;rid=49812">Neonatologist</a></div></div><div class="nejm-widget_item"><div><span> Staten Island, New York</span></div><div><span>Maternal-Fetal Medicine</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/774444/maternal-fetal-medicine-siuh-/?query=fjwp&amp;rid=3059">Maternal Fetal Medicine (SIUH)</a></div></div><div class="nejm-widget_item"><div><span> Poughkeepsie, New York</span></div><div><span>Gastroenterology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/888648/gastroenterologist/?query=fjwp&amp;rid=22466">Gastroenterologist</a></div></div></div> <!-- content --> <!-- footer --></div> <!-- nejm-widget --></div><script src="https://apps1.nejmcareercenter.org/?width=300&amp;sp=all"></script>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="literatumAd" data-widget-id="001e4aa7-b6fe-4b21-9d5b-5bde81227c67" id="ad-article-right-rail-300x250-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <a href="/action/clickThrough?id=128129&amp;url=https%3A%2F%2Fstore.nejm.org%2Fsignup%2Fnejm%2Fregister%2Falerts%3Fpromo%3DONFQSR51%26query%3Dcm_rr%26utm_source%3Dnejm%26utm_medium%3Dcm%26utm_campaign%3Dalerts23&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2200433&amp;pubId=41396607&amp;placeholderId=101337&amp;productId=1035"><img src="/sda/128129/rightRail--SpecialtyUpdates23-001.jpg" width="300" height="250"></a>
            
        </div>
    

    

    



        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <script src="https://widgets.nejm.org/onepub-widgets/loader/webcomponents-loader.js" async="" nonce="9523b28971f9626e-SJC">
<script src="https://widgets.nejm.org/onepub-widgets/loader/polyfill-support.js"  nonce="9523b28971f9626e-SJC"></script>
<script src="https://widgets.nejm.org/onepub-widgets/more-like-this.js" type="module" nonce="9523b28971f9626e-SJC"></script>

<more-like-this class="onepub-widget" dataid="onepub-more-like-this" collections="catalyst-article, clinician-article, evidence-article, nejm-ai-article, nejm-article" headertitle="More Like This" maxitems="5"><!----><div class="more-like-this onepub-more-like-this_"><!--?lit$748415750$--><onepub-fonts><wc-fetch></wc-fetch><!--?lit$748415750$--><div class="mlt-wrapper"><div class="mlt-header-container"><div class="mlt-header-content-left"><div class="mlt-header-title-container"><span class="mlt-header-title">More Like This</span></div><!--?lit$748415750$--></div></div><div class="mlt-body"><!--?lit$748415750$--><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$748415750$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$748415750$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$748415750$-->Nov 26, 2020</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2022474?query=recirc_Semantic" target="_self">Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment</a></div><div class="mlt-article-authors"><!--?lit$748415750$-->J. Rosenstock and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$748415750$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$748415750$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$748415750$-->Jul 27, 2023</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2303208?query=recirc_Semantic" target="_self">Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin</a></div><div class="mlt-article-authors"><!--?lit$748415750$-->J. Rosenstock and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/review-article" target="_self"><!--?lit$748415750$-->Review Article</a> <span class="mlt-article-site-label"><!--?lit$748415750$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$748415750$-->Nov 30, 2023</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMra2215899?query=recirc_Semantic" target="_self">Wearable Digital Health Technologies in Medicine: Digital Technology for Diabetes</a></div><div class="mlt-article-authors"><!--?lit$748415750$-->M.S. Hughes, A. Addala, and B. Buckingham</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/editorial" target="_self"><!--?lit$748415750$-->Editorial</a> <span class="mlt-article-site-label"><!--?lit$748415750$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$748415750$-->Jul 27, 2023</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMe2307280?query=recirc_Semantic" target="_self">Building a Better Insulin — Whom Will It Help?</a></div><div class="mlt-article-authors"><!--?lit$748415750$-->J.E. Reusch</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/editorial" target="_self"><!--?lit$748415750$-->Editorial</a> <span class="mlt-article-site-label"><!--?lit$748415750$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$748415750$-->Nov 26, 2020</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMe2031596?query=recirc_Semantic" target="_self">Advances in Diabetes Treatment — Once-Weekly Insulin</a></div><div class="mlt-article-authors"><!--?lit$748415750$-->P.A. Gottlieb and A.W. Michels</div></div><!----></div><div class="mlt-footer"></div></div></onepub-fonts><style>:host{display:block}@keyframes fadeIn{0%{opacity:0}100%{opacity:1}}.more-like-this{max-width:25rem}.more-like-this *{font-variant-numeric:lining-nums}.mlt-wrapper{animation:fadeIn 1s}.mlt-header-container{border-bottom:#4d4d4d solid .0625rem;border-top:#4d4d4d solid .125rem}.mlt-header-title{color:#1a1a1a;display:block;font-family:var(--sans-serif);font-size:1rem;font-weight:700;letter-spacing:.02rem;line-height:1.5rem;padding-bottom:.94rem;padding-top:.94rem;text-transform:uppercase}.mlt-header-description{color:#333;display:block;font-family:ff-scala-sans-pro;font-size:.75rem;letter-spacing:.05rem;margin-top:-.5rem;padding-bottom:1rem;text-transform:uppercase}.mlt-article-container{border-bottom:#e5e5e5 solid .0625rem;margin-top:1.38rem}.mlt-article-container-header{font-family:var(--sans-serif);font-size:.6875rem;letter-spacing:.04em;line-height:1.125rem;margin:0 0 1rem;text-transform:uppercase}.mlt-article-type{font-weight:700;line-height:1.25rem;letter-spacing:.04rem;text-decoration:none}.mlt-article-type:hover{text-decoration:underline}.nejm{color:#f30}.nejm-ai{color:#006197}.nejm-catalyst{color:#5708a6}.nejm-evidence{color:#69a323}.mlt-article-site-label::after,.mlt-article-type::after{border-right:1px solid #e5e5e5;content:'';display:inline;padding:.1875rem .375rem .125rem 0;margin:0 .375rem 0 0}.mlt-article-pubdate{color:#666;font-style:normal;font-weight:700;line-height:1.25rem;letter-spacing:.04em}.mlt-article-authors{color:#666;font-family:var(--sans-serif);font-size:1rem;font-style:normal;font-weight:400;letter-spacing:normal;line-height:1.5rem;margin-bottom:1.38rem}.mlt-article-site-label{color:#666;font-style:normal;font-weight:700;letter-spacing:.04em}.mlt-article-title{margin-bottom:.5rem}.mlt-article-title>a{background-image:linear-gradient(#f30,#f30);background-position:0 90%;background-repeat:no-repeat;background-size:0 0;color:#1a1a1a;font-family:var(--quadraat-web);font-size:1.25rem;font-style:normal;font-weight:700;letter-spacing:normal;line-height:1.8rem;margin:1.5rem 0 .35rem 0;text-decoration:none;transition:background .25s ease-in-out}.mlt-article-title>a:hover{background-position:0 98%;background-size:100% .125rem;text-decoration:none}.skeleton-card{box-shadow:0 0 4px 1px rgba(0,0,0,.1);margin:1rem 0;padding:1rem}</style></div></more-like-this>




        
        <div><div class="pb-dropzone" data-pb-dropzone="col-0" title="col-0"></div></div>










    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="ad06db99-f228-4c92-9ad7-c4ae0fdbdbf1" id="bc-web-rec">
        



        
        <!-- BlueConic TEST empty HTML widget with DIV wrapper with id=bc-web-rec -->

        </div>
    

</aside></article><div data-extent="article-wrapper"><div class="core-container"></div><div class="after-credits"><div class="core-container"><a href="/doi/pdf/10.1056/NEJMoa2200433?download=true" id="downloadPdfUrl" data-doi="10.1056/NEJMoa2200433" data-behavior="trackDownloadEvent" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2200433.pdf"><span>Download PDF</span></a></div></div></div><script id="axel-publication-metadata" type="application/json">{"doi":"10.1056/NEJMoa2200433"}
</script><script type="text/javascript" data-ot-ignore="data-ot-ignore" defer="defer" src="https://static.addtoany.com/menu/page.js" class="optanon-category-C0004 ot-vscat-C0004"></script><div class="articles-nav"></div><template id="figure_nav_template"><nav><a href="#" title="Open in viewer" class="open-in-viewer"><i aria-hidden="true" class="icon-expand"></i></a></nav></template><template id="fv_panel_template" data-sharesocial="Share"><div class="fv__panel js--hidden"><div class="fv__panel__text"><div class="fv__panel__contentTitle"></div><div class="fv__panel__contentText"></div></div></div></template>
<template id="fv_directory_template" data-overlay="View figure"><div class="fv__directory"><div class="fv__header"><nav class="tab__nav"></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"></div></div></template><template id="fv_directory_tabItem_template" data-figures="Figures" data-others="Others" data-tables="Tables"><button role="tab" data-toggle="tab" class="tab__nav__item"></button></template>
<template id="fv_lightbox_template" data-sr-back="Go to figure location within the article" data-sr-closealt="Close" data-sr-download="Toggle download panel" data-sr-download-pptx="Download PPT" data-sr-info="Toggle information panel" data-sr-panel="Close panel" data-sr-share="Toggle share panel" data-sr-zoom="Zoom" data-text-close="Back to article" data-text-nav-figures="All figures" data-text-nav-others="All others" data-text-nav-tables="All tables" data-text-viewall="View all material" data-title-back="Back to article" data-title-closealt="Close" data-title-download="Download" data-title-download-pptx="Download PPT" data-title-info="Info" data-title-share="Share" data-title-zoom="Zoom"></template>
<template id="fv_toolbar_template"><div class="fv__toolbar__info"><strong class="fv__toolbar__contentTitle uppercase"></strong><p class="fv__toolbar__contentText"></p></div></template><template id="toCitationLink" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></a></div></template><template id="toCitationButton" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><button class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></button></div></template><template id="toCitationAccordion" data-collapse-citation="Hide Citations" data-expand-citation="Show Citations" data-collapse-footnote="Hide Footnotes" data-expand-footnote="Show Footnotes"><div class="to-citation__wrapper"><button aria-controls="aria-controls" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="data-expand-title" data-collapsed-title="data-collapsed-title" class="accordion__toggle__title"></span></button><div role="menu" aria-label="links" class="to-citation__accordion no-separator"><ul></ul></div></div></template><template id="toCitationAccordionItem"><li><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span></span></a></li></template><template id="citations_truncate_template"><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary"><span>Show all references</span></button></div></template><template id="collateral_texts_template" data-references="References" data-figure="Go to Figure" data-media="Go to Media" data-more="More" data-original="Go to original" data-table="Go to Table" data-inviewer="Open in Viewer" data-allinviewer="Open all in viewer"><svg data-tags="copyright" viewBox="0 0 24 24"><path d="M12 20.016q3.281 0 5.648-2.368T20.016 12t-2.368-5.648T12 3.984 6.352 6.352 3.984 12t2.368 5.648T12 20.016zm0-18q4.125 0 7.055 2.93T21.985 12t-2.93 7.055T12 21.985t-7.055-2.93T2.015 12t2.93-7.055T12 2.015zm-.14 7.125q-1.876 0-1.876 2.718v.282q0 2.718 1.875 2.718.704 0 1.172-.398t.469-1.008h1.781q0 1.172-1.031 2.063-.984.843-2.39.843-1.876 0-2.86-1.125t-.984-3.093v-.282q0-1.921.937-3 1.125-1.265 2.906-1.265 1.547 0 2.438.89.984.985.984 2.297H13.5q0-.328-.14-.61-.235-.468-.329-.562-.469-.468-1.172-.468z"></path></svg><span>Request permissions</span><i aria-hidden="true" class="icon-open_in_new"></i></template><template id="collapsible_authors_template"><button aria-expanded="false" data-expandable="all" data-label-expand="Expand All" data-label-collapse="Collapse All" class="collateral-contributors-control"><span>Expand All</span></button></template>
<template id="collapsible_tables_collapse_template"><div class="collapsible-figure-btn__wrapper expanded"><button aria-expanded="true" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-up"></i><span class="text-uppercase">Collapse</span></button></div></template>
<template id="collapsible_tables_expand_template"><div class="collapsible-figure-btn__wrapper collapsed"><button aria-expanded="false" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-down"></i><span class="text-uppercase">Expand Table</span></button></div></template><template id="authorsAffiliationsLink"><a href="#tab-contributors" class="to-authors-affiliations">Authors Info &amp; Affiliations</a></template>

        <div role="navigation" aria-label="Sticky Navigation" class="st-header"><div class="st-header__content"><div class="st-header__item st-header__menu"></div><div class="st-header__current st-header__item"><div class="st-header__label">Now Reading:</div><div class="st-header__title">Glycemia Reduction in Type 2 Diabetes — Glycemic Outcomes</div></div><div class="st-header__share st-header__item"><div class="share-dropblock dropdown"><a id="sticky-header-dropBlock" href="#" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="dropdown-toggle"><span title="" data-toggle="tooltip" data-trigger="hover" data-original-title="Share options"><span class="sr-only">Share</span><i aria-hidden="true" class="icon-share"></i></span></a><div aria-labelledby="sticky-header-dropBlock" data-location="share_tools_article" class="dropdown-menu"><ul class="rlist--inline a2a a2a_kit" style="line-height: 16px;"><li><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i></a></li><li><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i></a></li><li><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i></a></li><li><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i></a></li><li><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i></a></li></ul></div></div></div><div class="st-header__nav st-header__item"><div class="content-navigation"><a href="/doi/full/10.1056/NEJMp2203571" aria-label="Previous article" aria-disabled="false" class="content-navigation__prev"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>PREVIOUS ARTICLE</h6><div>The Seeds of Ignorance — Consequences of a Booming Betel-Nut Economy</div></div></div><i aria-hidden="true" class="icon-arrow-left"></i><span>Previous</span></a><a href="/doi/full/10.1056/NEJMoa2200436" aria-label="Next article" aria-disabled="false" class="content-navigation__next"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>NEXT ARTICLE</h6><div>Glycemia Reduction in Type 2 Diabetes — Microvascular and Cardiovascular Outcomes</div></div></div><span>Next</span><i aria-hidden="true" class="icon-arrow-right"></i></a></div></div></div><div class="st-header__track"><div id="progress-tracker" class="st-header__tracker" style="width: 0px;"></div></div></div><div class="fv figureViewer js--has-focus-mode"><div class="fv__directory" data-core-tabs="default" style="display: flex;"><div class="fv__header"><nav class="tab__nav" role="tablist"><button role="tab" data-toggle="tab" class="tab__nav__item active" aria-controls="#tab-pane-figures" aria-selected="true">Figures</button><button role="tab" data-toggle="tab" class="tab__nav__item" aria-controls="#tab-pane-tables" tabindex="-1" aria-selected="false">Tables</button></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"><div class="tab__pane fv__list fv__list--figures" id="tab-pane-figures" aria-label="All figures" tabindex="0" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f1" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2200433_f1.jpg"><img src="/cms/10.1056/NEJMoa2200433/asset/e7658d51-44ad-4465-b469-597495771f3b/assets/images/large/nejmoa2200433_f1.jpg" height="2248" width="2640" aria-labelledby="f1" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 1</div><div class="fv__item__description"><figcaption><div class="caption">Kaplan–Meier Analysis of Outcome Events and Mean Glycated Hemoglobin Levels.</div><div class="notes"><div role="doc-footnote">Shown are the cumulative incidences of a glycated hemoglobin level of 7.0% or higher (the primary metabolic outcome) (Panel A), a glycated hemoglobin level of greater than 7.5% (the secondary metabolic outcome) (Panel B), and a confirmed glycated hemoglobin level greater than 7.5% after the secondary outcome (the tertiary metabolic outcome) (Panel C), as well as the mean glycated hemoglobin levels (Panel D). In Panels A through C, the shaded bars along the x axis indicate the number of participants with data available for the analyses over time (i.e., the number of participants in whom a specified outcome event had not developed by that time). The vertical dashed lines indicate the results at 4 years, when 85.8% of the participants were undergoing follow-up. To convert values for glycated hemoglobin to millimoles per mole, multiply by 10.93 and then subtract 23.5.</div></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f2" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2200433_f2.jpg"><img src="/cms/10.1056/NEJMoa2200433/asset/fbab790c-6212-4917-a0d2-b83d3dbf7ab6/assets/images/large/nejmoa2200433_f2.jpg" height="1169" width="2640" aria-labelledby="f2" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 2</div><div class="fv__item__description"><figcaption><div class="caption">Analyses of the Primary Outcome According to Baseline Glycated Hemoglobin Levels.</div><div class="notes"><div role="doc-footnote">The risk reductions, calculated from the hazard ratios, with glargine, glimepiride, and liraglutide, as compared with sitagliptin, are shown with unadjusted 95% confidence intervals. To convert values for glycated hemoglobin to millimoles per mole, multiply by 10.93 and then subtract 23.5.</div></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f3" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2200433_f3.jpg"><img src="/cms/10.1056/NEJMoa2200433/asset/1e05f48b-dd75-4aff-b516-ce26e8f66724/assets/images/large/nejmoa2200433_f3.jpg" height="1668" width="2640" aria-labelledby="f3" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 3</div><div class="fv__item__description"><figcaption><div class="caption">Overall Incidence of Adverse Events.</div><div class="notes"><div role="doc-footnote">Event rates were calculated as the number of events per 100 participant-years. Simple P values (not corrected for multiple tests among event types or treatment groups) were obtained from a Poisson regression model of the rates. The diagram denotes the range of the P values for the six pairwise group comparisons of each adverse event. The following were adjudicated events: serious adverse events or any targeted events, including severe hypoglycemia, lactic acidosis, pancreatitis, diabetic ketoacidosis or hyperosmolar hyperglycemic syndrome, revascularization (coronary, peripheral, or cerebral), congestive heart failure, or cancer. The first occurrence of weight gain of 10% or more was compared with the baseline weight. Gastrointestinal symptoms included any one of the following symptoms that occurred at least once per week in the 30 days before the quarterly visit and were reported by the participant: nausea, vomiting, bloating or stomach pain, or diarrhea.</div></div></figcaption></div></div></div><div class="tab__pane fv__list fv__list--tables" id="tab-pane-tables" aria-label="All tables" tabindex="-1" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t1" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 1</div><div class="fv__item__description"><figcaption><div class="caption">Protocol Completion and Adherence in the Treatment Groups during the Trial.</div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t2" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 2</div><div class="fv__item__description"><figcaption><div class="caption">Primary and Secondary Metabolic Outcomes.<a href="#fv-t2fn1" role="doc-noteref">*</a></div></figcaption></div></div></div></div></div></div><div class="references-pop-up fade" aria-hidden="true"><div class="references-pop-up__heading text-dark d-flex align-items-center"><div class="references-pop-up__title flex-grow-1">Reference <span class="references-pop-up__heading-number">1</span></div><a class="references-pop-up__close text-dark" href="#" title="close pop-up" tabindex="-1" aria-hidden="true"><i class="icon-close" aria-hidden="true"></i></a></div><div class="references-pop-up__items citations to-citation__accordion external-links"></div></div></main>
    

</div>

                    
                        



        
        <div class="ng-page_layout ng-page_layout-fullWidth"><div class="container-fluid"><div class="row"><div class="col-12">



        
        




        
        <div class="ng-page_layout-contentSpacing"></div>










    
    
        <div data-widget-def="oneSearchMultiSearch" data-widget-id="778b3ad8-1a8d-43d8-8196-63b03df4a138" data-location="recirc_inIssue_bottom_article">
        



        
        <div class="os-ms os-ms-more-from-issue"><h3 class="ng-subsection-title"><a href="/toc/nejm/387/12" class="ng-subsection-title_link animation-icon-shift"><span class="ng-subsection-title_text">More from Vol. 387 No. 12</span><span class="ng-subsection-title_icon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-longArrowRight"></use></svg></span></span></a></h3><ul class="os-ms-more-from-issue_list"><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Sep 22, 2022</span></li><li data-toggle="tooltip" data-original-title="Video" class="issue-item_meta-item"><span role="img" aria-label="Video" tabindex="0" class="issue-item_video"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-video"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2204705" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Trial of Antisense Oligonucleotide Tofersen for <em>SOD1</em> ALS</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">T.M. Miller and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Sep 22, 2022</span></li><li data-toggle="tooltip" data-original-title="Video" class="issue-item_meta-item"><span role="img" aria-label="Video" tabindex="0" class="issue-item_video"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-video"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2206286" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">S.D. Solomon and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/review-article" class="issue-item_type">Review Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Sep 22, 2022</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMra2025746" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Burkitt’s Lymphoma</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">M. Roschewski, L.M. Staudt, and W.H. Wilson</span></div></div></div></div></div></li></ul></div>

        </div>
    

</div></div></div></div>

                    
                        



        
        <div class="ng-page_layout-bottomAd"><div class="container-fluid"><div class="row"><div class="col-12">









    
    
        <div data-widget-def="literatumAd" data-widget-id="7e022d0d-4a48-44a7-af66-033cf5c13eb8" id="ad-article-bottom-FULLx320-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <!-- START: Circulation Footer 3 -->
<aside class="g-cta-subscribe">
	<style>
.bads_footer-banner24-ONJQNRF1{background:url(/pb-assets/contextual_messaging/footer-yel-background-2x-1513629627453.jpg) center center no-repeat;padding:20px;display:block;margin:0;min-height:inherit;background-size:cover;text-decoration:none!important;color:#1a1a1a;text-align:left}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:42px;line-height:44px;letter-spacing:.2px;margin:0 0 20px;font-family:ff-quadraat-web-pro,sans-serif;font-weight:600}.bads_footer-banner24-ONJQNRF1-inner{max-width:1300px;margin:0 auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions .a-btn{width:130px;padding-left:12px}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{position:static;color:#000;font-size:18px;line-height:27px;border:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:20px 0 20px 0;list-style-type:none;padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login a{color:#0a68ad}.bads_clearfix:after{visibility:hidden;display:block;font-size:0;content:" ";clear:both;height:0}.bads_clearfix{display:block}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{float:left;width:50%;padding:30px 0}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{float:left;padding-left:30px;width:50%}.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{display:block;max-width:100%;height:auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:18px;text-transform:uppercase;line-height:24px;font-weight:600;margin:-15px 0 0;letter-spacing:.2px}@media only screen and (max-width:480px){.bads_footer-banner24-ONJQNRF1-inner .bads_device-img,.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{width:100%;float:none}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{padding-left:0}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:27px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding-top:0;padding-bottom:0}.bads_footer-banner24-ONJQNRF1{height:auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:0 0 12px;list-style-type:none}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{line-height:25px;font-size:15px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1 .bads_device-img{width:280px!important;margin:0 auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 3px;font-size:14px}}@media only screen and (min-width:480px) and (max-width:1024px){.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:30px;margin-bottom:15px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{font-size:14px}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:13px;margin-top:0}}@media only screen and (min-width:1025px) and (max-width:1200px){.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:10px 0}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 5px}}@media only screen and (min-width:1401px){.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{float:right}}
	</style>
	<div class="bads_footer-banner24-ONJQNRF1">
	  <div class="bads_footer-banner24-ONJQNRF1-inner bads_clearfix">
		 <div class="bads_subs-btn">
			<p class="g-cta-subscribe__title">Tap into groundbreaking research and clinically relevant insights</p>
			<ul class="g-cta-subscribe__actions">
				<li class="g-cta-subscribe__actions-primary">
				  <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dsubscribe%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2200433%26promo%3DONFQNRF1&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2200433&amp;pubId=41396607&amp;placeholderId=101336&amp;productId=1035" class="ng-btn_primary ng-btn_iconRight"><span class="ng-btn_text">Subscribe </span><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#arrows-longArrowRight"></use></svg></span></a>
				</li>
			</ul>
			<p class="g-cta-subscribe__login">Already a subscriber? <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dactivate%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2200433%26promo%3DONFQANR4&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2200433&amp;pubId=41396607&amp;placeholderId=101336&amp;productId=1035">Activate</a> your online access.</p>
		 </div>

		<div class="bads_device-img">
		   <img src="/sda/127716/footer-devices-2x.png" alt="Devices">
		</div>
	   </div>
	</div>
</aside>
<!--/END: Circulation Footer 3 -->
            
        </div>
    

    

    



        </div>
    

</div></div></div></div>

                    
                        



        
        <footer class="ng-footer footer__top" style="position: relative;"><div data-location="footer" class="ng-footer_columns"><div class="container-fluid"><div class="row"><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">ARTICLE CATEGORIES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item">
        <a href="/browse/nejm-article-category/research" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Research</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/review" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reviews</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/clinical-cases" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Clinical Cases</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/perspective" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Perspective</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/commentary" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Commentary</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/other" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Other</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/medical-article-index" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Browse all Articles</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/toc/nejm/current" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Current Issue</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/loi/nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Issue Index</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">RESOURCES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Authors &amp; Reviewers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Submit a Manuscript</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Subscribers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://tools.ovid.com/ovidtools/nejm.html" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Administrators</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/media" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Media</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/how-to-advertise" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertisers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/information-for-subscription-agents" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Agents</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/permissions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Permissions &amp; Licensing</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/reprints" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reprints</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a>
    </li>
</ul>
</div></div></div><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="About us">ABOUT US</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/about-nejm/about-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">About NEJM</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmgroup.org/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM Group</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Products &amp; Services</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/editors-and-publishers" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Editors &amp; Publishers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/advertising-policies" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertising Policies</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/contact-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text" aria-label="Contact us">Contact Us</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions?#Accessibility" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Accessibility</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">FAQs</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/help" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Help</span></a></li>
    <li class="ng-footer_column-list-item"><a href="mailto:sitefeedback@nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Site Feedback</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">SUBSCRIPTIONS</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Subscribe</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=renew&amp;product=nejm&amp;promo=ONFLNRR3&amp;prc=ONFARN52" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Renew</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=activate&amp;promo=ONFLNAA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Activate Subscription</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC4" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Manage Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=paybill&amp;product=nejm&amp;promo=BNFLPBA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Pay Bill</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.wolterskluwer.com/en/solutions/ovid/nejm-complete-collection" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Sales</span></a></li>    
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/special-content" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Special Content</span></a></li>
</ul>
</div></div></div><div class="col-lg-4 col-md-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">STAY CONNECTED</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/emails?section=NEJM" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Email Alerts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Apps</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Podcasts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">RSS Feed</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/institutional-access" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Remote Access</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="Follow us">FOLLOW US</h4>
<ul class="ng-footer_column-list">
<li class="ng-footer_column-list-item"><a href="https://www.facebook.com/TheNewEnglandJournalofMedicine" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-facebook"></use></svg></span></span><span class="ng-footer_column-link-text">Facebook</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://twitter.com/nejm" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-twitter"></use></svg></span></span><span class="ng-footer_column-link-text">X (formerly Twitter)</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.instagram.com/nejm/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-instagram"></use></svg></span></span><span class="ng-footer_column-link-text">Instagram</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.youtube.com/user/NEJMvideo" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-youtube"></use></svg></span></span><span class="ng-footer_column-link-text">Youtube</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.linkedin.com/company/nejm-group" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-linkedin"></use></svg></span></span><span class="ng-footer_column-link-text">LinkedIn</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://bsky.app/profile/nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-bluesky"></use></svg></span></span><span class="ng-footer_column-link-text">Bluesky</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.tiktok.com/@nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-tiktok"></use></svg></span></span><span class="ng-footer_column-link-text">TikTok</span></a></li>
</ul>
</div></div></div></div></div></div><div data-location="footer" class="ng-footer_journals"><div class="container-fluid"><div class="row"><div class="col-12">



        
        <h4 class="ng-footer_journals-label">JOURNALS</h4>
<ul class="ng-footer_journals-list">
<li class="ng-footer_journals-item"><a href="https://www.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">The New England Journal of Medicine</a></li>
<li class="ng-footer_journals-item"><a href="https://catalyst.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Catalyst Innovations in Care Delivery</a></li>
<li class="ng-footer_journals-item"><a href="https://evidence.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Evidence</a></li>
<li class="ng-footer_journals-item"><a href="https://ai.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM AI</a></li>
</ul>
</div></div></div></div><div data-location="legal" class="ng-footer_bottom"><div class="container-fluid"><div class="row"><div class="col-lg-7 col-md-6 ng-footer_bottom-left">



        
        <p>Copyright © 2025 <a href="https://www.massmed.org/" target="_blank" rel="noopener" class="ng-footer_bottom-link"><b>Massachusetts Medical Society</b></a>. All rights reserved, including those for text and data mining, AI training, and similar technologies. Electronic ISSN 1533-4406. Print ISSN 0028-4793.The content of this site is intended for health care professionals.</p>
</div><div class="col-lg-5 col-md-6 ng-footer_bottom-right">



        
        <style>
  #teconsent a {
    color: #666;
    text-decoration: none;
  }
  #teconsent a:hover {
    color: #666;
    text-decoration: underline;
  }
</style>
<ul class="ng-footer_bottom-list">
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/copyright-information.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Copyright</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/terms-of-use.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Terms</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/privacy-policy.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Privacy Policy</a></li>
<li class="ng-footer_bottom-list-item"><span id="teconsent" consent="undefined" aria-label="Open Cookie Preferences Modal" role="complementary"><a role="link" id="icon-id0044761188674738994" tabindex="0" lang="en" aria-haspopup="dialog" aria-label="Cookie Preferences, opens a dedicated popup modal window" class="truste_cursor_pointer">Cookie Preferences</a></span></li>
</ul>
<a href="https://www.nejmgroup.org/" title="NEJM Group" target="_blank" rel="noopener" class="ng-footer_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/logo_group.svg" alt="NEJM Group logo" class="ng-footer_logo" loading="lazy" width="103" height="40"></a>
</div></div></div></div><div data-show-after="400" class="back-to-top back-to-top--align-right  "><button data-snap="footer__top" class="back-to-top__action position-relative p-0 m-0 border-0 d-flex flex-column align-items-center justify-content-center"><svg viewBox="0 0 36 36" class="position-relative"><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" class="back-to-top__action__ring-bg"></path><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" stroke-dasharray="0, 100" class="back-to-top__action__ring"></path></svg><span class="back-to-top__action-icon position-absolute d-flex"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-up"></use></svg></span></span><span class="sr-only">Back to top</span></button></div></footer>

                    
                        



        
        <!-- TrustArc: Banner -->
<div id="consent_blackbar"><style>  #consent_blackbar{    position:relative;    width:100%;    z-index: 999999;  }    #trustarc-banner-overlay {  background-color: rgb(0, 0, 0);   opacity: 0.3;   position: fixed;   z-index: 1000000;   width: 100%;  height: 100%;   top: 0px;   left: 0px;   overflow: hidden;}.truste-title {  /*font-family: "Source Sans Pro", sans-serif;  font-size: 23px;  font-style: normal;  font-stretch: normal;*/  color: #222;  margin-bottom: 20px;  text-align: center;/*  font-weight:bold;*/}.truste-footer {  margin: 0 auto;      }.truste-left {  margin: 0px 0px 15px 15px;/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;    */}.truste-banner { margin: 0 auto; }.truste-messageColumn {/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;*/  color: #666666;  margin: 0px;}#truste-consent-button, #truste-consent-required {    background-color: #FF1E00;    color: #F2F1F1;    padding: 5px 10px;    border: 1px solid #FF1E00;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }      #truste-show-consent {    background-color: #FF1E00;    color: #F2F1F1;    border: 1px solid #FF1E00;    padding: 5px 10px;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }div.truste-consent-track-class {  position: fixed;  z-index:9999999;   background: #666;   border: 1px solid #333;    /*padding: 10px 60px;*/    bottom:0px;    right:0px;    left:0px;    margin: 10px;}.truste-left {  margin: 0;}div.text-content {  display: flex;  flex-direction: column;  align-self: baseline;}#truste-consent-text {    /*font-family: "Source Sans Pro", sans-serif;    font-size: 16px;*/    color: #fff;    margin: 15px 0px;}.truste-footer {  padding-top: 15px;}#truste-consent-content {  margin: 0 auto;    padding: 0 10px;    max-width: 1366px;}.truste-consent-footer {  display: none;}.flex-container {  display: block;  align-items: center;  justify-content: space-between;}#truste-consent-buttons {  float: right;  margin: 10px 5px 10px 0px;}#truste-show-consent { background: #F30 !important;}#truste-consent-button, #truste-consent-required { background: #F30 !important; } /* MEDIA QUERIES */  @media screen and (max-width: 500px) {  #truste-consent-track {    padding: 5px 20px;  }  }@media screen and (max-width: 375px) {  .truste-buttonsColumn {    float: none;    margin: 0;  }  #truste-consent-button, #truste-consent-required, #truste-show-consent {    width: 100%;    margin-bottom: 5px;  }          #truste-consent-buttons {  float: none;  margin: 10px 0px 10px 0px;	}}</style><div id="truste-consent-track" style="display: block; opacity: 1;">  <div id="trustarc-banner-overlay"></div>  <div class="truste-consent-track-class">    <div id="truste-consent-content" class="truste-banner">        <div class="flex-container">          <div class="text-content">            <div id="truste-consent-text" class="truste-messageColumn">This site uses cookies and related technologies, as described in our privacy policy, for purposes that may include site operation, analytics, enhanced user experience, or advertising. You may choose to consent to our use of these technologies, or manage your own preferences.                       </div>          </div>          <div id="truste-consent-buttons" class="truste-buttonsColumn">            <button id="truste-show-consent" aria-haspopup="dialog">Manage Settings</button>      <button id="truste-consent-button">Accept</button>      <!-- <button id="truste-consent-required">Decline All</button> -->          </div>        </div>                <div style="clear:both;"></div>    </div>  </div></div><!--emptycomment--></div>
<!-- /TrustArc: Banner -->

                    
                        



        
        <link rel="stylesheet" href="https://cssjs.nejm.org/mmsWidgets.css"><script nonce="9523b28971f9626e-SJC" type="text/javascript" src="https://cssjs.nejm.org/mmsWidgets.js"></script><script nonce="9523b28971f9626e-SJC" type="text/javascript">var litSSO = {
    "ucid": null,
    "accessToken": null,
    "authState": null
};

var loginUri = '/action/doSsoLogin';
var logoutUri = '/action/doLogout';

displayAuthenticatedMessage();

mmsWidgets.init({
    clientId: 'qsra7g4d6jwdsgn3zbe6udp6r6278mr9',
    origin: 'NEJM',
    xdReceiver: 'http://www.nejm.org/pb-assets/sso/xd.html',
    isFullPageSignIn: isSignInPage(),
    debug: true,

    onReady: function (e) {
        console.log('<<<<<<<<<< client: received onReady event.');
        $("A.litSsoLogin").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0) {
                mmsWidgets.signIn(e);
                return false;
            }
        });
        $("A.litSsoLogout").click(function (e) {
            mmsWidgets.signOut(e);
            return false;
        });
        $("A.litSsoCreate").click(function (e) {
            mmsWidgets.showRegModal(e);
            return false;
        });
        $("A.litSsoSubscribe").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0)
                location.assign(e.currentTarget.href);
            return false;
        });
        if (window.doSSOLogin) {
            window.setTimeout(function () {
                mmsWidgets.signIn();
            }, 500);
        }
        ;
    },
    onLoginSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLoginSuccess event.' + JSON.stringify(e));

        const redirectUrl = getRedirectUri(window.location.search, location.href.replace(window.location.origin, ""));
        document.cookie = "skipSso=; expires=; path=/";
        if (!litSSO.ucid || e.ucid != litSSO.ucid || !litSSO.accessToken || e.accessToken != litSSO.accessToken) {
            location.assign(loginUri + "?ucid=" + e.profile.ucid
                + "&accessToken=" + e.accessToken
                + "&authState=" + e.authState
                + "&email=" + encodeURIComponent(e.profile.email)
                + "&givenNames=" + e.profile.givenName
                + "&surname=" + e.profile.familyName
                + "&redirectUri=" + redirectUrl
                + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                + "&rememberMe=" + e.rememberMe);
        }
    },
    onAuthStateReady: function (e) {
        console.log('<<<<<<<<<< client: received onAuthStateReady event.' + JSON.stringify(e))

        var isMmsSsoAuthenticated = (e.authState && e.authState !== "anonymous" && e.authState !== "lead" && e.ucid && e.accessToken) ? true : false;
        var isLitSsoAuthenticated = (litSSO.ucid && litSSO.accessToken && litSSO.authState) ? true : false;
        console.log('           isMmsSsoAuthenticated=' + isMmsSsoAuthenticated + ', isLitSsoAuthenticated=' + isLitSsoAuthenticated);

        if (isMmsSsoAuthenticated) {
            if (!isLitSsoAuthenticated || litSSO.ucid != e.ucid) {
                if (window.skipSso)
                    document.cookie = "skipSso=" + encodeURIComponent(e.ucid) + "; expires=; path=/";

                if (!window.skipSso && document.cookie.indexOf("skipSso=" + encodeURIComponent(e.ucid)) == -1) {
                    location.assign(loginUri + "?ucid=" + e.profile.ucid
                        + "&accessToken=" + e.accessToken
                        + "&authState=" + e.authState
                        + "&email=" + encodeURIComponent(e.profile.email)
                        + "&givenNames=" + e.profile.givenName
                        + "&surname=" + e.profile.familyName
                        + "&redirectUri=" + location.href.replace(window.location.origin, "")
                        + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                        + "&rememberMe=" + e.rememberMe);
                } else
                    console.log('**** client: Skip SSO ****');
            } else if (e.accessToken !== litSSO.accessToken)
                updateLitSession(e.ucid, e.accessToken);
        } else if (isLitSsoAuthenticated)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));

        if (document.getElementById("ssoerr-ucid"))
            document.getElementById("ssoerr-ucid").innerHTML = e.ucid;

    },
    onRegistrationSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onRegistrationSuccess event.' + JSON.stringify(e))
        document.cookie = "skipSso=; expires=; path=/";
        var uccLastUpdatedDate = '1812-01-01 00:00:00.1 +0000';
        location.assign(loginUri + "?ucid=" + e.profile.ucid
            + "&accessToken=" + e.accessToken
            + "&authState=" + e.authState
            + "&email=" + encodeURIComponent(e.profile.email)
            + "&givenNames=" + e.profile.givenName
            + "&surname=" + e.profile.familyName
            + "&redirectUri=" + location.href.replace(window.location.origin, "")
            + "&uccLastUpdatedDate=" + encodeURIComponent(uccLastUpdatedDate)
            + "&rememberMe=" + e.rememberMe);
    },
    onLogoutSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLogoutSuccess event.' + JSON.stringify(e))

        document.cookie = "skipSso=; expires=; path=/";
        location.assign(logoutUri);
    },
});

function updateLitSession(ucid, accessToken) {
    $.ajax({
        method: "GET",
        url: "/action/doSsoSessionUpdate",
        data: {ucid: ucid, accessToken: accessToken},
        success: function (callData, textStatus) {
            console.log("Session accessToken updated")
            litSSO.accessToken = accessToken
        },
        error: function (jqXHR, textStatus, errorThrown) {
            alert("Your website session has expired and will now be reset.")
            console.log("Session update failed: " + jqXHR.responseText)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));
        }
    });
}

function getRedirectUri(location, fallback) {
    const urlParams = new URLSearchParams(location);
    const uriUrlParam = urlParams.get('uri');
    if (uriUrlParam)
        return encodeURIComponent(uriUrlParam);
    else
        return encodeURIComponent(fallback);
}

function isSignInPage() {
    return document.querySelector('meta[name="pbContext"]').content.indexOf("customPage:string:/sign-in") > -1;
}

function displayAuthenticatedMessage() {
    if (isSignInPage()) {
        var div = document.getElementById('authMsg');
        if ("" === "PersonUser") {
            div.innerHTML += "You are already signed in to " + window.location.origin.replace("https://", "").replace("www.", "") + ". If you would like to sign in with a different email address, please use the form below.";
        } else {
            div.innerHTML = '';
        }
    }
}</script>

                    
                
            </div>
        </div><iframe name="trustarc_notice" id="trustarcNoticeFrame" title="Trustarc Cross-Domain Consent Frame" src="https://consent.trustarc.com/get?name=crossdomain.html&amp;domain=nejm.com" style="display: none;"></iframe>
        


        
        

            <script src="/products/mms-nextgen/mms/releasedAssets/js/build.lazyload.bundle-c8c4e7d20884f81951fb.js" nonce="9523b28971f9626e-SJC"></script>

        <script src="/products/mms-nextgen/mms/releasedAssets/js/main.bundle-3819a02ec7bc2aca01ec.js" nonce="9523b28971f9626e-SJC"></script>
        


<div id="adModal" tabindex="-1" aria-labelledby="exampleModalCenterTitle" class="ng-modal modal" style="display: none;" aria-hidden="true">
    <div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered ad-promoLayer">
        <div class="ng-modal_content modal-content p-0">
            <div class="ng-modal_body modal-body m-0">
                <div class="ng-modal_header modal-header">
                    <button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#close"></use></svg></span></span>
                    </button>
                </div>

            </div>
        </div>
    </div>
</div>
<script type="text/javascript" src="/wro/1125813~product.js" nonce="9523b28971f9626e-SJC"></script>








<input id="showLayers" type="hidden" value="true">

    <!-- placeholder id=null, description=ad-layer-config -->
    <!-- placeholder id=null, description=ad-lauchLayer-1 -->
    <!-- placeholder id=null, description=ad-layer-promo-1 -->

    <input id="firstAd" type="hidden" value="">
    <input id="secondAd" type="hidden" value="">

    
    
    

    
    
    <input id="IsInstitution" type="hidden" value="false">
    <input id="IsSubscriber" type="hidden" value="true">
    <input id="CustomerId" type="hidden" value="">


<script type="text/javascript" nonce="9523b28971f9626e-SJC">
  jQuery.extend(jQuery.mmsLayers.config, {
    rules: [{
      "name": "Launch Layer Ad",
      "frequency": 30,
      "showOnPage": 5,
      "enabled": false,
      "cookieName": "MarketingLaunchLayer",
      "styleClass": "launchLayer"
    },
    {
      "name": "Promo Layer Ad",
      "frequency": 14,
      "enabled": true,
      "cookieName": "PromoLayer",
      "styleClass": "promoLayer"
    },
    {
      "name": "Interstitial Ad",
      "frequency": 7,
      "enabled": false,
      "cookieName": "InterstitialAd"
    },
    {
      "name": "Iperceptions - Ion Layer Ad",
      "showOnPage": 1,
      "enabled": false,
      "test": false,
      "cookieName":"Iperceptions"
    }]
 });
</script>

















    <script type="text/javascript" nonce="9523b28971f9626e-SJC">
        $(document).ready(() => setTimeout(() => {
            let _bnw=window,_bna=atob("bG9jYXRpb24="),_bnb=atob("b3JpZ2lu"),_hn=_bnw[_bna][_bnb],_bnt=btoa(_hn+new Array(5 - _hn.length % 4).join(" "));
            $.get("/resource/lodash?t="+_bnt);
        },4000));
    </script>












    

    
    

    
    
    
    
        
            
                <script type="text/javascript" src="/wro/1125813~article-metrics.js" nonce="9523b28971f9626e-SJC"></script>
            
            
            
        
    




<script type="text/javascript" src="/wro/1125813~full-text-analytics.js" nonce="9523b28971f9626e-SJC"></script>


    


            <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'9523b2895ad6626e',t:'MTc1MDM0MzE0NC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script><iframe height="1" width="1" style="position: absolute; top: 0px; left: 0px; border: none; visibility: hidden;"></iframe><script defer="" src="https://static.cloudflareinsights.com/beacon.min.js/vcd15cbe7772f49c399c6a5babf22c1241717689176015" integrity="sha512-ZpsOmlRQV6y907TI0dKBHq9Md29nnaEIPlkf84rnaERnq6zvWvPUqr2ft8M1aS28oN72PdrCzSjY4U6VaAw1EQ==" data-cf-beacon="{&quot;rayId&quot;:&quot;9523b2895ad6626e&quot;,&quot;serverTiming&quot;:{&quot;name&quot;:{&quot;cfExtPri&quot;:true,&quot;cfEdge&quot;:true,&quot;cfOrigin&quot;:true,&quot;cfL4&quot;:true,&quot;cfSpeedBrain&quot;:true,&quot;cfCacheStatus&quot;:true}},&quot;version&quot;:&quot;2025.6.2&quot;,&quot;token&quot;:&quot;f55e150c7a5f4a4ab9ef82f4a1c9c43c&quot;}" crossorigin="anonymous"></script>

        
        
    

<div style="display:none;" id="signInEmbedded" class="ucc-fullpage-signin ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Sign In</h1>
  </div>    
  <div class="capture_signin">
    {* #signInForm *}
    <div class="ucc-form-inner-wrapper">
      {* signInEmailAddress *}
      {* currentPassword *}
      <div style="padding-top:10px;">
          <div class="capture_form_item capture_form_rememberme">
          <label class="ucc-form-checkbox">                
            <input checked="checked" id="ucc-remember-me-cb-embedded" name="ucc-remember-me-cb-embedded" type="checkbox" value="true">
            <span>Remember Me</span>
          </label>                           
          </div>
          <div class="capture_form_item capture_form_forgotpwd">
            <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
          </div>
      </div>
      <div class="capture_form_item">      
        <button id="ucc-sign-in-submit-embedded" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
      </div>
      <div class="capture_form_item capture_form_footer">
        <div class="ucc-no-acct-msg">Don't have an account?</div>
        <div class="ucc-no-acct-msg-2">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
          <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
        </div>
      </div>
      <div class="capture_form_item capture_form_submit">
        
      </div>      
    </div>
    {* /signInForm *}
  </div>
</div><div style="display:none;" id="forgotPassword" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Forgot Password</h1>
  </div>   
  <div class="ucc-form-inner-wrapper">
  <p style="color:black">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
  </div> 
  <div class="capture_forgotpassword">
    {* #forgotPasswordForm *}      
      <div class="ucc-form-inner-wrapper">
        {* forgotPasswordEmailAddress *}
        {* captcha *}
        <div class="capture_form_item" style="padding-top: 20px;">        
          <input id="ucc-widget-forgotpwd-submit" value="Continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
        </div>
      </div>
    {* /forgotPasswordForm *}
  </div>
  </div><div style="display:none;" id="forgotPasswordSuccess" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Create New Password</h1>
  </div>    
  <div class="capture_forgotpassword">
      <div class="ucc-form-inner-wrapper">
        <p style="padding-top: 30px; padding-bottom: 30px;">We've sent an email with instructions to create a new password. Your existing password has not been changed.</p>        
        <div class="capture_form_item">      
          <button class="capture_btn capture_primary capture-full-width-btn" onclick="janrain.capture.ui.modal.close()">CLOSE</button>
        </div>
      </div>
  </div>
  </div><div style="display:none;" id="resetPassword" class="ucc-widgets-nejm-next">
      <div class="row">      
        <div class="col-md-8 col-md-offset-2 reset-pwd-info"><p>To reset your password, enter a new password twice and click the 'Reset Password' button.</p></div>
      </div>
      <div class="col-md-4 col-md-offset-4">
        {* #changePasswordFormNoAuth *}
          {* newPassword *}
          {* newPasswordConfirm *}     
          <div class="capture_form_item">
            <input value="RESET PASSWORD" type="submit" class="capture_btn capture_primary capture-full-width-btn">
          </div>
          {* /changePasswordFormNoAuth *}
      </div>
    </div><div style="display:none;" id="resetPasswordSuccess">
        <div class="reset-pwd-info">
          <div class="reset-pwd-success-welcome"></div>
          <p class="reset-pwd-success-msg">Your password has been reset. You will need to <a href="/signin" onclick="mmsWidgets.signIn(event)">sign in</a> again using your new password to access site content and features.</p>
          <p class="reset-pwd-success-nav"></p>
        </div>      
    </div><div style="display:none;" id="resetPasswordRequestCode" class="ucc-widgets-nejm-next">
        {* #resetPasswordForm *}
        <div class="capture_form_error">The link that you followed to reset your password has expired.</div>
          <div class="col-md-8 col-md-offset-2">
            <p class="reset-pwd-info">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
          </div>
          <div class="col-md-4 col-md-offset-4">
            {* signInEmailAddress *}
            <div class="capture_form_item">
              <input value="continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
            </div>
          </div>
        {* /resetPasswordForm *}
    </div><div style="display:none;" id="resetPasswordRequestCodeSuccess">
      <div class="reset-pwd-info">
        <p>If the address matches an existing account, you will receive an email with instructions to reset your password.</p>
        <p class="reset-pwd-success-nav"></p>
      </div>
  </div><div id="addtoany" style="position: static;"><div class="a2a_overlay" id="a2a_overlay"></div><div id="a2a_modal" class="a2a_modal a2a_hide" role="dialog" tabindex="-1" aria-label=""><div class="a2a_modal_body a2a_menu a2a_hide" id="a2a_copy_link"><label for="a2a_copy_link_text" id="a2a_copy_link_icon" class="a2a_svg a2a_s_link a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><title>Copy link</title><path fill="#FFF" d="M7.591 21.177c0-.36.126-.665.377-.917l2.804-2.804a1.235 1.235 0 0 1 .913-.378c.377 0 .7.144.97.43-.026.028-.11.11-.255.25-.144.14-.24.236-.29.29a2.82 2.82 0 0 0-.2.256 1.056 1.056 0 0 0-.177.344 1.43 1.43 0 0 0-.046.37c0 .36.126.666.377.918a1.25 1.25 0 0 0 .918.377c.126.001.251-.015.373-.047.125-.037.242-.096.345-.175.09-.06.176-.127.256-.2.1-.094.196-.19.29-.29.14-.142.223-.23.25-.254.297.28.445.607.445.984 0 .36-.126.664-.377.916l-2.778 2.79a1.242 1.242 0 0 1-.917.364c-.36 0-.665-.118-.917-.35l-1.982-1.97a1.223 1.223 0 0 1-.378-.9l-.001-.004Zm9.477-9.504c0-.36.126-.665.377-.917l2.777-2.79a1.235 1.235 0 0 1 .913-.378c.35 0 .656.12.917.364l1.984 1.968c.254.252.38.553.38.903 0 .36-.126.665-.38.917l-2.802 2.804a1.238 1.238 0 0 1-.916.364c-.377 0-.7-.14-.97-.418.026-.027.11-.11.255-.25a7.5 7.5 0 0 0 .29-.29c.072-.08.139-.166.2-.255.08-.103.14-.22.176-.344.032-.12.048-.245.047-.37 0-.36-.126-.662-.377-.914a1.247 1.247 0 0 0-.917-.377c-.136 0-.26.015-.37.046-.114.03-.23.09-.346.175a3.868 3.868 0 0 0-.256.2c-.054.05-.15.148-.29.29-.14.146-.222.23-.25.258-.294-.278-.442-.606-.442-.983v-.003ZM5.003 21.177c0 1.078.382 1.99 1.146 2.736l1.982 1.968c.745.75 1.658 1.12 2.736 1.12 1.087 0 2.004-.38 2.75-1.143l2.777-2.79c.75-.747 1.12-1.66 1.12-2.737 0-1.106-.392-2.046-1.183-2.818l1.186-1.185c.774.79 1.708 1.186 2.805 1.186 1.078 0 1.995-.376 2.75-1.13l2.803-2.81c.751-.754 1.128-1.671 1.128-2.748 0-1.08-.382-1.993-1.146-2.738L23.875 6.12C23.13 5.372 22.218 5 21.139 5c-1.087 0-2.004.382-2.75 1.146l-2.777 2.79c-.75.747-1.12 1.66-1.12 2.737 0 1.105.392 2.045 1.183 2.817l-1.186 1.186c-.774-.79-1.708-1.186-2.805-1.186-1.078 0-1.995.377-2.75 1.132L6.13 18.426c-.754.755-1.13 1.672-1.13 2.75l.003.001Z"></path></svg></label><input id="a2a_copy_link_text" type="text" title="Copy link" readonly=""><div id="a2a_copy_link_copied">✓</div></div><div class="a2a_modal_body a2a_menu a2a_thanks a2a_hide" id="a2a_thanks"><div class="a2a_localize" data-a2a-localize="inner,ThanksForSharing">Thanks for sharing!</div></div></div><div class="a2a_menu a2a_full a2a_localize" id="a2apage_full" role="dialog" tabindex="-1" aria-label="Share" data-a2a-localize="title,Share"><div class="a2a_full_header"><div id="a2apage_find_container" class="a2a_menu_find_container"><label for="a2apage_find" id="a2apage_find_icon" class="a2a_svg a2a_s_find"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" aria-hidden="true"><title>Find any service</title><path fill="#CCC" d="M19.7 18.2l-4.5-4.5c.7-1.1 1.2-2.3 1.2-3.6 0-3.5-2.8-6.3-6.3-6.3s-6.3 2.8-6.3 6.3 2.8 6.3 6.3 6.3c1.4 0 2.6-.4 3.6-1.2l4.5 4.5c.6.6 1.3.7 1.7.2.5-.4.4-1.1-.2-1.7zm-9.6-3.6c-2.5 0-4.5-2.1-4.5-4.5 0-2.5 2.1-4.5 4.5-4.5 2.5 0 4.5 2.1 4.5 4.5s-2 4.5-4.5 4.5z"></path></svg></label><input id="a2apage_find" class="a2a_menu_find a2a_localize" type="text" autocomplete="off" title="Find any service" data-a2a-localize="title,FindAnyServiceToAddTo"></div></div><div class="a2a_full_services" id="a2apage_full_services" role="presentation"></div><div class="a2a_full_footer"><a href="https://www.addtoany.com" title="Share Buttons" rel="noopener" target="_blank"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span>AddToAny</a></div></div><div id="a2apage_dropdown" class="a2a_menu a2a_mini a2a_localize a2a_hide" tabindex="-1" aria-label="Share" data-a2a-localize="label,Share"><div class="a2a_mini_services" id="a2apage_mini_services"></div><div id="a2apage_cols_container" class="a2a_cols_container"><div class="a2a_col1" id="a2apage_col1"></div><div id="a2apage_2_col1" class="a2a_hide"></div><div class="a2a_clear"></div></div><div class="a2apage_wide a2a_wide"><a href="#addtoany" id="a2apage_show_more_less" class="a2a_more a2a_localize" title="Show all" data-a2a-localize="title,ShowAll"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span><span class="a2a_localize" data-a2a-localize="inner,More">More…</span></a></div></div><div style="height: 1px; width: 1px; position: absolute; z-index: 100000; top: 0px; visibility: hidden;"><iframe id="a2a_sm_ifr" title="AddToAny Utility Frame" aria-hidden="true" src="https://static.addtoany.com/menu/sm.25.html#type=core&amp;event=load" style="height: 1px; width: 1px; border: 0px; left: 0px; top: 0px; position: absolute; z-index: 100000; display: none;"></iframe></div></div><script type="text/javascript" src="https://api.altmetric.com/v1/internal-556fdf0f/doi/10.1056/nejmoa2200433?callback=_altmetric.embed_callback&amp;domain=www.nejm.org&amp;cache_until=11-19"></script><div role="status" aria-live="assertive" aria-relevant="additions" class="ui-helper-hidden-accessible"></div><div id="janrainEngageEmbed" style="display: none;"><div class="janrainContent" style="width: 380px !important; height: 156px !important; padding-left: 5px !important; padding-right: 5px !important; box-sizing: content-box !important; background-color: rgb(255, 255, 255) !important; border: 1px solid rgb(192, 192, 192) !important; border-radius: 10px !important; overflow: hidden !important; position: relative !important;"><div id="janrainView"><div class="janrainHeader" style="background-color: rgb(255, 255, 255) !important; font-size: 14px !important; color: rgb(102, 102, 102) !important; position: relative !important; height: 20px !important; left: -5px !important; padding: 5px 5px 0px !important; white-space: nowrap !important; width: 380px !important; z-index: 100 !important; border-radius: 10px 10px 0px 0px !important; text-align: left !important;"><div style="padding-left: 1px !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important;">Sign in using your account with</div></div><div id="janrainProviderPages" style="padding-top: 5px; left: 5px; position: absolute;"><div class="janrainPage" pageindex="0"><ul class="providers" id="janrainProviders_0" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-aol" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="1" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-aol" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-aol" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">AOL</span></a></li><li id="janrain-openid" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="3" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-openid" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-openid" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">OpenID</span></a></li></ul><ul class="providers" id="janrainProviders_1" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-yahoo" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="2" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-yahoo" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-yahoo" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">Yahoo!</span></a></li></ul></div></div><div style="background-color: rgb(255, 255, 255) !important; width: 380px !important; height: 10px !important; position: absolute !important; left: 0px !important; padding-left: 5px !important; padding-right: 5px !important; padding-bottom: 5px !important; bottom: 0px !important; font-size: 10px !important; text-align: left !important; color: rgb(102, 102, 102) !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; border-radius: 0px 0px 10px 10px !important;"><div style="padding-left: 1px !important;"><a href="http://janrain.com/products/engage/social-login?utm_source=mms.rpxnow.com&amp;utm_medium=Partner&amp;utm_campaign=attribution" target="_blank">Social Login by Janrain</a></div></div></div></div></div><iframe name="captureIFrame_sop695hw3aqjtzpm67phkxq8c8b90d0ww02nv1cx" data-transactionid="sop695hw3aqjtzpm67phkxq8c8b90d0ww02nv1cx" id="captureIFrame_sop695hw3aqjtzpm67phkxq8c8b90d0ww02nv1cx" src="about:blank" class="" data-captureiframeloadeventbound="yes" style="display: none;"></iframe><div id="janrainModalOverlay" style="inset: 0px; position: fixed; background-color: rgb(0, 0, 0); opacity: 0.4; display: none; z-index: 1000;"></div><div id="janrainModal" style="width: 380px; height: 131px; position: absolute; z-index: 1000; display: none;"><a href="#" class="janrain_modal_closebutton" style="position: absolute; cursor: pointer; z-index: 1000;">X</a><div style="display: block;" id="signIn" class="ucc-widgets-nejm-next janrain-capture-ui capture-ui-content capture_screen_container" data-capturescreenname="signIn" data-captureventadded="true">
    <div class="capture_header">
      <h1>Sign In</h1>
    </div>    
    <div class="capture_signin">
      <form id="capture_signIn_signInForm" name="signInForm" data-capturefield="signInForm" action="https://mms.us.janraincapture.com/widget/traditional_signin.jsonp" class="capture_form capture_signInForm" method="POST" novalidate="novalidate" data-transactionid="sop695hw3aqjtzpm67phkxq8c8b90d0ww02nv1cx" target="captureIFrame_sop695hw3aqjtzpm67phkxq8c8b90d0ww02nv1cx" accept-charset="UTF-8" next="{&quot;noop&quot;:&quot;&quot;}"><div id="capture_signIn_signInForm_defaultSavedProfileMessage"></div><div id="capture_signIn_signInForm_errorMessages"></div><input id="capture_signIn_utf8" data-capturefield="undefined" value="✓" type="hidden" class="capture_utf8" name="utf8"><input id="capture_signIn_screen_sop695hw3aqjtzpm67phkxq8c8b90d0ww02nv1cx" data-capturefield="undefined" value="signIn" type="hidden" class="capture_screen_sop695hw3aqjtzpm67phkxq8c8b90d0ww02nv1cx" name="capture_screen"><input id="capture_signIn_js_version_sop695hw3aqjtzpm67phkxq8c8b90d0ww02nv1cx" data-capturefield="undefined" value="d445bf4" type="hidden" class="capture_js_version_sop695hw3aqjtzpm67phkxq8c8b90d0ww02nv1cx" name="js_version"><input id="capture_signIn_transactionId_sop695hw3aqjtzpm67phkxq8c8b90d0ww02nv1cx" data-capturefield="undefined" value="sop695hw3aqjtzpm67phkxq8c8b90d0ww02nv1cx" type="hidden" class="capture_transactionId_sop695hw3aqjtzpm67phkxq8c8b90d0ww02nv1cx" name="capture_transactionId"><input id="capture_signIn_form_sop695hw3aqjtzpm67phkxq8c8b90d0ww02nv1cx" data-capturefield="undefined" value="signInForm" type="hidden" class="capture_form_sop695hw3aqjtzpm67phkxq8c8b90d0ww02nv1cx" name="form"><input id="capture_signIn_flow_sop695hw3aqjtzpm67phkxq8c8b90d0ww02nv1cx" data-capturefield="undefined" value="standard" type="hidden" class="capture_flow_sop695hw3aqjtzpm67phkxq8c8b90d0ww02nv1cx" name="flow"><input id="capture_signIn_client_id_sop695hw3aqjtzpm67phkxq8c8b90d0ww02nv1cx" data-capturefield="undefined" value="qsra7g4d6jwdsgn3zbe6udp6r6278mr9" type="hidden" class="capture_client_id_sop695hw3aqjtzpm67phkxq8c8b90d0ww02nv1cx" name="client_id"><input id="capture_signIn_redirect_uri_sop695hw3aqjtzpm67phkxq8c8b90d0ww02nv1cx" data-capturefield="undefined" value="https://www.nejm.org" type="hidden" class="capture_redirect_uri_sop695hw3aqjtzpm67phkxq8c8b90d0ww02nv1cx" name="redirect_uri"><input id="capture_signIn_response_type_sop695hw3aqjtzpm67phkxq8c8b90d0ww02nv1cx" data-capturefield="undefined" value="code" type="hidden" class="capture_response_type_sop695hw3aqjtzpm67phkxq8c8b90d0ww02nv1cx" name="response_type"><input id="capture_signIn_flow_version_sop695hw3aqjtzpm67phkxq8c8b90d0ww02nv1cx" data-capturefield="undefined" value="20240514181256512029" type="hidden" class="capture_flow_version_sop695hw3aqjtzpm67phkxq8c8b90d0ww02nv1cx" name="flow_version"><input id="capture_signIn_settings_version_sop695hw3aqjtzpm67phkxq8c8b90d0ww02nv1cx" data-capturefield="undefined" value="" type="hidden" class="capture_settings_version_sop695hw3aqjtzpm67phkxq8c8b90d0ww02nv1cx" name="settings_version"><input id="capture_signIn_locale_sop695hw3aqjtzpm67phkxq8c8b90d0ww02nv1cx" data-capturefield="undefined" value="en-US" type="hidden" class="capture_locale_sop695hw3aqjtzpm67phkxq8c8b90d0ww02nv1cx" name="locale"><input id="capture_signIn_recaptcha_version_sop695hw3aqjtzpm67phkxq8c8b90d0ww02nv1cx" data-capturefield="undefined" value="2" type="hidden" class="capture_recaptcha_version_sop695hw3aqjtzpm67phkxq8c8b90d0ww02nv1cx" name="recaptchaVersion">
      <div class="ucc-form-inner-wrapper">
        <div id="capture_signIn_form_item_signInEmailAddress" class="capture_form_item capture_email capture_form_item_signInEmailAddress" data-capturefield="undefined"><label for="capture_signIn_signInEmailAddress">Email Address</label><input id="capture_signIn_signInEmailAddress" data-capturefield="signInEmailAddress" value="" type="email" class="capture_signInEmailAddress capture_required capture_text_input" placeholder="Email Address" name="signInEmailAddress"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="signInEmailAddress">Validating</div><div class="capture_tip_error" data-elementname="signInEmailAddress"></div></div>
        <div id="capture_signIn_form_item_currentPassword" class="capture_form_item capture_password capture_form_item_currentPassword" data-capturefield="undefined"><label for="capture_signIn_currentPassword">Password</label><input id="capture_signIn_currentPassword" data-capturefield="currentPassword" value="" type="password" class="capture_currentPassword capture_required capture_text_input" placeholder="Password" name="currentPassword"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="currentPassword">Validating</div><div class="capture_tip_error" data-elementname="currentPassword"></div></div>
        <div style="padding-top:10px;">
            <div class="capture_form_item capture_form_rememberme">
                <label class="ucc-form-checkbox">                
                    <input checked="checked" id="ucc-remember-me-cb" name="ucc-remember-me-cb" type="checkbox" value="true">
                    <span>Remember Me</span>
                </label>          
            </div>
            <div class="capture_form_item capture_form_forgotpwd">
              <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
            </div>
        </div>
        <div class="capture_form_item">
          <button id="ucc-sign-in-submit" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
        </div>
       
        <div class="capture_form_item">
          <div class="ucc-no-acct-msg">Don't have an account?</div>
          <div class="ucc-no-acct-msg-2" id="signInModalCreateAccountLink">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

          <div class="ucc-no-acct-msg-2" id="signInModalCloseLink" style="display:none">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

        </div>
     
        <div class="capture_form_item capture_form_submit">
          
        </div>      
      </div>
      </form>
    </div>
  </div></div></body></html>